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Ureaplasma parvum and Ureaplasma urealyticum are sexually transmitted, 
opportunistic pathogens of the human urogenital tract. There are 14 known serovars of 
the two species. For decades, it has been postulated that virulence is related to serotype 
specificity. Understanding of the role of ureaplasmas in human diseases has been 
thwarted due to two major barriers: (1) lack of suitable diagnostic tests and (2) lack of 
genetic manipulation tools for the creation of mutants to study the role of potential 
pathogenicity factors.  
  
To address the first barrier we developed real-time quantitative PCRs (RT-qPCR) 
for the reliable differentiation of the two species and 14 serovars. We typed 1,061 
ureaplasma clinical isolates and observed about 40% of isolates to be genetic mosaics, 
arising from the recombination of multiple serovars. Furthermore, comparative genome 
analysis of the 14 serovars and 5 clinical isolates showed that the mba gene, used for 
serotyping ureaplasmas was part of a large, phase variable gene system, and some 
serovars shown to express different MBA proteins also encode mba genes associated with 
other serovars. Together these data suggests that differential pathogenicity and clinical 
outcome of an ureaplasmal infection is most likely due to the presence or absence of 
potential pathogenicity factors in individual ureaplasma clinical isolates and/or patient to 
patient differences in terms of autoimmunity and microbiome. 
To address the second barrier we are adapting the traditional molecular biology 
and novel synthetic biology tools to Ureaplasma, such as creation of oriC plasmids, use 
of transposons, and most prominently the engineering bacterial genomes cloned as yeast 
centromeric plasmids followed by genome transplantation to make ureaplasma mutants 
programmed by the genomes manipulated in yeast. This will allow for the creation of 
targeted single or multiple mutants that will greatly increase the understanding of 
ureaplasma pathogenicity. Efforts to transplant the genomes of bacteria, outside the 
mycoides group have been thwarted due to recombination between the donor and 
recipient cell genomes. We are exploring the use of the DNA cross-linking drug, 
Mitomycin C, to inactivate the recipient cell genomes and thus prevent false positive 
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To all the little ones born too soon and fighting for their lives, all the little angels 
gone too soon and their families!  
 
“Sometimes the smallest things take up the most room in your heart!” 
-Winnie the Pooh 
 
Just For By Unknown Author 
Just for this morning, I am going to step over the laundry, 
And pick you up and take you to the park to play. 
Just for this morning, I will leave the dishes in the sink, 
And let you teach me how to put that puzzle. 
Just for this afternoon, I will unplug the telephone and keep the computer off, 
And sit with you in the backyard and blow bubbles. 
Just for this afternoon, I will not yell once, not even a tiny grumble when 
You scream and whine for the ice cream truck, and I will buy you one if he comes by. 
Just for this afternoon, I won't worry about what you are going to be 
When you grow up, or second guess every decision I have made 





Just for this afternoon, I will let you help me bake cookies, 
And I won't stand over you trying to fix them. 
Just for this afternoon, I will take us to McDonald's 
And buy us both a Happy Meal so you can have both toys. 
Just for this evening, I will hold you in my arms and tell you a story 
About how you were born and how much I love you. 
Just for this evening, I will let you splash in the tub and not get angry. 
Just for this evening, I will let you stay up late 
While we sit on the porch and count all the stars. 
Just for this evening, I will snuggle beside you for hours, 
And miss my favorite TV shows. 
Just for this evening when I run my finger through your hair as you pray, 
I will simply be grateful that God has given me the greatest gift ever given. 
I will think about the mothers and fathers, 
Who are searching for their missing children, 
The mothers and fathers who are visiting 
Their children's graves instead of their bedrooms, 
And mothers and fathers who are in hospital rooms 
Watching their children suffer senselessly, 
And screaming inside that they can't handle it anymore. 
And when I kiss you goodnight I will hold you a little tighter, a little longer. 
It is then, that I will thank God for you and ask him for nothing, 
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Chapter 1. Introduction 
1.1 Microbiology of Ureaplasma species 
Ureaplasmas are among the smallest self-replicating organisms capable of 
axenic growth. Shepard provided the first description of ureaplasmas in 1954, initially 
known as “T-strain” mycoplasmas, when he cultivated them in vitro from the urethras 
of men with nongonococcal urethritis (NGU)  [1]. The genus Ureaplasma, was 
established in 1974 [2], comprising those members of the family Mycoplasmataceae 
in the class Mollicutes that hydrolyse urea and use it as a metabolic substrate for 
generation of ATP. There are five species in the class Mollicutes that are human 
pathogens. The best known is Mycoplasma pneumoniae, which is a respiratory 
pathogen that is an agent of “walking pneumonia.” The other four, Mycoplasma 
genitalium, Ureaplasma parvum (UPA), Ureaplasma urealyticum (UUR), and 
Mycoplasma hominis are all urogenital pathogens.  This genus Ureaplasma currently 
has seven recognized species that have been isolated from humans and various 
animals: U. canigenitalium (dogs), U. cati (cats), U. diversum (cattle), U. felinum 
(cats), U. gallorale (chickens), U. parvum  (UPA) (humans), and U. urealyticum 
(UUR) (humans).  Numerous other ureaplasmas of animal origin have been 
described, but they have not been given species designations [3]. Human ureaplasmas 
were considered to belong to a single species, U. urealyticum. Patient isolates and 
corresponding patient sera were collected and each patient isolate was reacted with 
each individual serum sample. These identified 14 groups of reactions, therefore the 




comprised of 14 serovars distributed between two genetically distinct biovars until 
2002 when the two biovars were reclassified as two distinct species, UPA and UUR, 
based on the sequences of 16S rRNA gene, the 16S-23s-rRNA intergenic region, the 
urease gene and DNA-DNA hybridization experiments [7]. UUR comprises 10 
serovars – UUR2, UUR4, UUR5, UUR7-13, and UPA includes 4 serovars – UPA1, 
UPA3, UPA6, UPA14 [7].  
Genomes of UPA and UUR are very small (760-1140 kilobase (kb) pairs), 
have an extremely low GC content of 25.5% and utilize a non-standard genetic code 
[8, 9]. Their limited biosynthetic capacity is responsible for many of the biological 
characteristics and fastidious growth requirements of human Ureaplasma spp. It is 
believed that Ureaplasma spp. have evolved from Gram-positive bacteria by 
degenerative evolution, which included losing the peptidoglycan cell wall [4].  Lack 
of a rigid cell wall prevents them from staining by Gram stain, confers pleomorphic 
cell structure, and makes them very susceptible to dehydration, thereby limiting them 
to a parasitic existence in association with eukaryotic cells of their host. Ureaplasmas 
are coccoid cells approximately 0.2 - 0.3 µm in diameter with a generation time of 
about one hour. The organisms can be cultivated overnight in liquid media such as 
Shepard’s 10 B broth containing a mycoplasma broth base supplemented with 20% 
horse serum, 10% urea, DNA, yeast extract, and L-cysteine [10]. They will produce 
granular brown urease-positive colonies approximately 15 -60 µm in diameter on A8 
agar after 24-48 hours of incubation at 37°C and 5% CO2 due to calcium chloride 





As many as 40% to 80% of healthy adult women may harbor ureaplasmas in 
their cervix or vagina and they are readily transmitted venereally as well as vertically; 
with a transmission rate to  infants born to colonized mothers as high as 90% [11]. As 
more and more studies of ureaplasma prevalence in different countries are being 
performed, it is evident that prevalence of ureaplasma colonization varies based on 
sexual activity status, geographical location and ethnicity, socioeconomic status, and 
hormonal changes (menopause and pregnancy) [11-20]. Iwasaka et al report 
Ureaplasma spp. can be detected in the vaginal flora of 25% post-menopausal 
women, 67% of sexually active women, and 40% of sexually inactive women [14, 21, 
22]. Ureaplasma colonization during pregnancy varies from 35% to as high as 90% 
[14, 23, 24]. Their occurrence is somewhat less in the lower urogenital tract of 
healthy men (approximately 20-29%) [25, 26]. U. parvum is considerably more 
common than U. urealyticum as a colonizer of the male and female urogenital tracts 
and in the neonatal respiratory tract [11].  
1.3 Clinical Importance 
Ureaplasmas are common opportunistic pathogens, as they don’t cause disease 
in some healthy individuals, however they are implicated in a variety of clinical 
outcomes including but not limited to: non-gonococcal urethritis, pelvic inflammatory 
disease, infertility, adverse pregnancy outcomes, chorioamnionitis, and 
bronchopulmonary dysplasia in neonates [11]. Ureaplasmas reside primarily on the 




There are no reports of intracellular ureaplasmas. They are capable of attaching to a 
variety of cell types such as urethral epithelial cells, spermatozoa, and erythrocytes 
[12]. Non-pregnancy related ureaplasma infections are usually easily treated with 
administration of proper antibiotics (discussed later). The greatest burden of 
ureaplasma infections is from adverse pregnancy outcomes and neonatal sequelae. 
Pregnant women colonized with ureaplasma are more likely to deliver preterm infants 
[27-29], requiring prolonged stay in hospital neonatal intensive care units (NICU). If 
a preterm infant is diagnosed with respiratory ureaplasma infection, the chance of it 
developing bronchopulmonary dysplasia is significantly elevated [30-34], requiring 
further medical care and could have long-term health implications [35].  
1.3.1 Ureaplasma and Adverse Pregnancy Outcomes 
Ureaplasma spp. are the micro-organisms most frequently isolated from 
amniotic fluid, and placentae in women who deliver prematurely, either with preterm 
premature rupture of membranes or in preterm labor with intact membranes and from 
the cord blood, respiratory tract and cerebrospinal fluid of infants born prematurely 
who develop bronchopulmonary dysplasia and developmental disabilities [11, 22, 
36]. These organisms have been isolated in the amniotic fluid as early as the 16th 
week, and can result in a clinically silent chronic and progressive infection where 
delivery does not occur for several weeks [37]. Detection of Ureaplasma sp. by the 
PCR assay in second-trimester amniotic fluid from asymptomatic women was highly 
correlated with subsequent preterm labor and preterm delivery [27]. Isolation of 




with histologic chorioamnionitis and this relationship is inversely related to birth 
weight [11]. There are more than 50 studies on the relationship of ureaplasma 
colonization and adverse pregnancy outcomes, including preterm labor, premature 
preterm rupture of membranes, and chorioamnionitis. The essence of these studies 
has been summarised in a review by Capoccia [14]. A direct causal relationship of 
these organisms with adverse pregnancy outcomes has been elusive due to the 
polymicrobial nature of cervicovaginal colonization and most intra-amniotic 
infections [38] and study design. However, there is growing experimental evidence of 
the capacity of ureaplasmas to cause adverse pregnancy outcomes using different 
animal models and in vitro ureaplasma infections. [27, 36, 39]. The strongest 
evidence is the induction of chorioamnionitis, fetal inflammation and preterm labor in 
the Rhesus macaques after intra-amniotic injection of UPA [25].. 
1.3.1.1 Contribution of Ureaplasma species to development of BPD 
BPD is defined as oxygen dependence at 28 days or at 36 weeks 
postmenstrual age [35]. Sung et al observed that ureaplasma respiratory colonization 
was inversely related to gestational age. Sixty-five per cent of infants  delivered 
before 26 weeks gestation were culture or PCR-positive compared to 31% of infants 
delivered at or after 26 weeks gestational age. Their findings also show that UPA 
serovars are the most common [40]. The studies examining the relationship of 
ureaplasma colonization and BPD are controversial. Some studies report that there is 
association [30-34], while other did not find an association [41-44]. This controversy 
may be attributed to different patient populations, divergent ventilator management 




Three meta-analyses were performed with stringent entry criteria in order to analyse 
the relationship of ureaplasma and BPD. The studies were published in 1995 [46], 
and 2014 [47] and observed a significant association between Ureaplasma spp. 
respiratory tract colonization and BPD.  
The major insights into the pathogenesis of ureaplasma-mediated lung injury 
have been contributed by epidemiological studies of human preterm infants and 
experimental intrauterine infection models in mice, sheep and non-human 
primates[35]. Observations from the animal studies have been confirmed by lung 
histological examinations of infants dying with ureaplasma pneumonia sharing 
characteristics of moderate-to-severe fibrosis; increased myofibroblasts; disordered 
elastin accumulation; and increased number of tumour necrosis factor-α (TNF-α) and 
transforming growth factor β1 (TGFβ1) immunoreactive cells [22, 35]. Similar 
findings were observed in the antenatally infected animal models, the baboon, rhesus 
macaques, and sheep with UPA. When the immature, UPA infected baboon was 
exposed postnatally to ventilation and oxygen it developed chronic inflammatory and 
profibrotic immune response that contributes to lung injury, altered developmental 
signaling, and fibrosis [48]. Duration of intrauterine UPA exposure greater than 10 
days leads to lung fibrosis and thickened alveolar walls in the rhesus macaques, thus 
the severity of fetal lung injury, influx of inflammatory cells and epithelial necrosis 
was dependent on the length of intrauterine exposure to the infection [27]. Acute 
intrauterine exposure to either UPA3 or lipopolysaccharide (LPS) alone or combined 
leads to differential expression of TGFβ signalling components and elastin deposition 




ureaplasma exposure and BPD due to its contribution to lung inflammation, altered 
lung development and lung fibrosis, which are characteristic of the BPD phenotype 
[35].  
1.3.1.2 Contribution of Ureaplasma species to development of NEC 
The intestinal barrier development may be altered due to direct exposure of 
the fetal intestinal tract to microbes and amniotic fluid containing inflammatory 
mediators. This may stimulate an inflammatory response and lead to increased 
intestinal permeability and potential bacterial translocation [35]. Okogbule-Wonodi et 
al demonstrated that the risk for NEC was increased 2-fold for infants born before 33 
weeks gestation with respiratory Ureaplasma spp. infection. The risk for NEC 
increased 3.3-fold for infants born before 28 weeks gestation. The same study also 
showed that among infants suffering NEC, those that were ureaplasma positive had 
significantly higher levels of IL-6 and IL-1β in their cord blood compared to those 
that were ureaplasma negative [50]. These observations were confirmed in the sheep 
intrauterine infection model, where fetal intestinal exposure to amniotic UPA3 isolate 
for up to 14 days prior to preterm delivery caused intestinal inflammation, reduced 
enterocyte proliferation and villous atrophy. Improvement of the condition was seen 
by including recombinant interleukin-1 receptor antagonist in the treatment, 
suggesting that IL-1 signalling is likely involved in ureaplasma-mediated intestinal 




1.3.1.3 Ureaplasmal Invasive Disease in the neonate  
Ureaplasma spp. occurrence in blood, cerebrospinal fluid (CSF) and brain 
tissue is at a lower rate than in the lungs with only 12.6%–23.6% [52-54] . 
Nevertheless, this rate suggests the potential of ureaplasmas for invasive disease. 
Viscardi et al found that the risk of severe IVH was 2.5-fold higher in infants whose 
serum was positive for ureaplasma by PCR, than PCR-negative infants [52]. 
Interestingly, ureaplasma detection in CSF was usually asymptomatic and normal 
CSF parameters [22, 52], except in one study where six out of eight infants  with 
ureaplasma positive CSF developed severe IVH, followed by posthaemorrhagic 
hydrocephalus or death [55]. Experimental intrauterine infection models provide 
further evidence for the connection of invasive ureaplasma infections and fetal brain 
injury. In the murine model intrauterine UPA3 infection lead to microglia activation, 
delayed myelination and disturbed neuronal development in fetal and neonatal 
brains[56]. In the rhesus macaque model an antenatal UPA infection resulted in 
culture positive CSF and fetal brains for 20% of the animals, confirming the invasive 
capability of ureaplasmas  [27]. A potential link between invasive ureaplasma, 
cytokinemia, and neonatal brain injury has been suggested based on the observation 
that when serum IL-1β is elevated in combination with ureaplasma-positive serum the 
risk of IVH increases 5-fold. Thus, cytokine activation of the central nervous system 
immune response is likely responsible for the brain injury associated with an 




1.3.1.4  Long-term Outcomes of Perinatal Ureaplasma Exposure 
Isolation of ureaplasmas from the upper respiratory tract in infants and 
children less than 3 years of age has been associated with wheezing [22]. Maternal 
Ureaplasma spp. vaginal colonization during pregnancy was associated with a 2-fold 
increased risk for infants [22]. At 2 years of age, infants born  earlier than 33 weeks 
gestation who were exposed to intrauterine ureaplasma infection had higher rate of 
cerebral palsy and lower psychomotor development index scores on the Bayley 
Scales of Infant Development at 2 years adjusted age compared with non-exposed 
infants [57]. As of today there are not enough studies on the long-term outcomes of 
perinatal ureaplasma exposure. Viscardi brings up the need to include long-term 
pulmonary and neurodevelopmental assessments in studies of potential therapeutic 
interventions for perinatal ureaplasma exposure [35]. 
1.3.2 Infertility and other genitourinary tract diseases 
UPA and UUR are most often found in the genitourinary tract of sexually 
active adults as common opportunistic pathogens that can cause many different 
infections. There is no doubt that they can cause non-gonococcal urethritis (NGU) 
[58] in both men and women. An association of ureaplasma colonization and bacterial 
vaginosis (BV)[3, 59], cervicitis [3], and endometritis[3]  has been reported; however 
it is not clear yet if ureaplasma itself is causing the pathology due to the 
multibacterial nature of such diseases. Infection can spread to the upper female 
genital tract and it can lead to pelvic inflammatory disease (PID) [60], or if it happens 




outlined above. Furthermore, PID is a common cause of infertility, chronic pain and 
ectopic pregnancy [61]. The possible influence of ureaplasmas on human fertility is 
still not clear. However, more studies are emerging reporting association between 
ureaplasma colonization and subpar fertility parameters or infertility as the 
development of diagnostic procedures, especially more common use of PCR methods, 
expands. Major contributors to infertility in patients colonized with ureaplasma are 
low sperm quality and recurrent miscarriage [62-70]. 
1.3.3 Ureaplasmal extragenital diseases  
Ureaplasma has been reported to cause arthritis in persons with 
hypogammaglobulinemia [11]. There are case reports of Ureaplasma spp. as a cause 
of meningitis, aortic graft infection, and intrarenal abscess in adults [71-73]. There 
have been few reports of Ureaplasma spp. as a cause of sternal wound infection, a 
life-threatening complication after cardiac surgery associated with high morbidity and 
mortality [74-77].  
1.4 Diagnostic Methods 
1.4.1 Conventional techniques  
Culture is considered the reference standard for detection of Ureaplasma spp. 
in clinical specimens and remains the most widely used method for laboratory 
diagnosis. Some laboratories prefer to prepare their own liquid and solid media to 
reduce costs, but commercial sources are available in many countries [78]. If 




particular care must be taken to ensure the organisms remain viable, which means the 
specimen must be inoculated into an appropriate transport medium and shipped 
frozen on dry ice. Detailed methods and quality control procedures  for culture-based 
detection of ureaplasmas are available in reference texts [10, 79]. Due to their 
relatively rapid growth rates, confirmed culture results for human ureaplasmas are 
usually available within 2 to 5 days, exclusive of specimen transport time and 
shipment if an offsite reference laboratory is used. Human ureaplasmas can be 
positively identified to genus level by their colonial morphology and urease 
production on A8 agar, but genotypic or serologic procedures are necessary for 
species designation. For routine diagnostic and patient management purposes it is not 
necessary to determine which species is present in a clinical specimen.  A single 
culture procedure utilizing 10 B broth and A8 agar can detect Ureaplasma spp. as 
well as Mycoplasma hominis, which is also a pathogen of the human urogenital tract 
but it uses arginine as an energy source istead of urea. Culture has an additional 
advantage in that it provides an isolate that can be studied further, and on which 
antimicrobial testing can be performed if needed. Up to 50% of Ureaplasma  isolates 
in the United States may contain tetM and exhibit tetracycline resistance [11]. 
While serology has been an important tool in diagnosis of Mycoplasma 
pneumoniae infections for many years, it has not proven useful for ureaplasmal 
infections, largely because of ubiquity of these organisms in healthy persons makes 
interpretation of antibody titers difficult and the mere existence of antibodies alone 
cannot reliably distinguish among colonization, current or prior infection [10]. Even 




have been applied in research settings, such assays have never been standardized and 
are not generally practical for diagnostic purposes. 
1.4.2 Molecular techniques   
The advances in molecular biology over the past 25 years have greatly 
improved diagnostic methods for infectious diseases. As a result fast, sensitive, and 
specific techniques for their detection and in some instances, further characterization 
have been developed. Turnaround time has significantly reduced. However, the 
expense has increased due to the requirement for having complex molecular biology 
laboratory equipment and personnel with sufficient education and training to employ 
these techniques correctly. The most important molecular-based methods for 
ureaplasma detection and characterization are described in subsequent sections. 
1.4.2.1 Nucleic acid amplification methods  
1.4.2.1.1 PCR  
PCR was first described in its modern form in 1988 [80]. By the end of the 
decade the widespread use of PCR was bringing about a revolution in clinical 
diagnostics. No area of diagnostic medicine was more enabled by PCR than clinical 
microbiology. Shortly after the publication of the U. urealyticum urease gene 
sequences in 1990 [81] and 1991, Willoughby and colleagues reported the first use 
of PCR to detect ureaplasmas [82]. 
As PCR evolved as a molecular biology technique, numerous variations of 




formats, such as reverse-transcription PCR, real-time PCR, and multiplex PCR. 
Real-time PCR is capable of amplifying and simultaneously detecting and 
quantifying the target DNA molecule as it accumulates during the reaction in real 
time after each amplification cycle. Real-time PCR is frequently combined with 
reverse transcription to quantify messenger RNA (mRNA). Multiplex-PCR uses 
several pairs of primers annealing to different target sequences and allows the 
simultaneous analysis of multiple targets in a single sample. According to the 
detection strategy, all PCR methods can be classified into conventional PCR and 
real-time PCR. Conventional PCR measures the end stage PCR products using gels 
or other methods while real-time PCR detects and quantifies the products 
simultaneously with amplification.   
Various PCR methods as well as their respective gene targets have been 
reported to detect Ureaplasma spp. The earlier gel-based conventional PCR assays 
targeted sequences of 16S rRNA gene and 16S rRNA -23S rRNA intergenic spacer 
regions [83-87], the ure gene subunits [81, 88], and the mba genes [86, 89-92]. 
Published real-time PCR assays have targeted primarily the ure gene [93-95] and the 
mba gene [96, 97]. A summary of published PCR assays and gene targets used for 
Ureaplasma PCR assays for detection, speciation, and serotyping of the organisms is 
provided in [3].  
Published PCR assays to characterize the Ureaplasma spp. at the serovar 
level have mainly focused on primers based on the mba gene and its 5′-end upstream 
regions. In combination with direct sequencing or restriction enzyme analysis, these 




10 serovars of U. urealyticum into different subgroups [89-91, 96, 98]. Because of 
limited sequence variation in the mba genes, earlier PCR-based methods lacked the 
capacity for complete separation of all 14 serovars. Moreover, whole genome 
sequencing of all 14 serovars presented in chapter 2  has shown mba to be part of a 
large gene family present in many variations in different serovars and the gene is 
phase variable [99]. Thus, while the mba gene is a valid target for serovar-specific 
PCRs, attention must be paid to make certain that targets do not span sites at which 
chromosome rearrangements occur during phase variation.   
In Chapter 3 we describe the development of a real-time PCR assay for 
Ureaplasma speciation and serotyping. We evaluated the complete genome 
sequences for all 14 serovars and designed primers and probes targeting new specific 
regions for Ureaplasma speciation and serotyping by real-time PCR. One multiplex 
species-specific PCR assay and 14 serovar-specific monoplex PCRs were developed 
and shown to accurately distinguish between the two species and among all 14 
serovars without cross-reactivities [97]. The UU063 gene (NP_077893), which 
encodes a conserved hypothetical protein that is identical in all 4 U. parvum 
serovars, was used as target for U. parvum; a 15,072 bp open reading frame (ORF), 
UUR10_0554,  that is almost perfectly (>99.97%) conserved in all 10 U. urealyticum 
serovars (serovar 10, GenBank ID ACI59931.1), was selected as target for U. 
urealyticum. Serovar-specific PCR assays to study large numbers of clinical 





At least one molecular-based assay that includes detection of Ureaplasma 
spp. in clinical specimens is commercially available in some countries, but not in the 
United States. STD6 ACE Detection by Seegene, Inc. (Rockville, MD, USA, 
http://www.seegene.com) simultaneously detects Trichomonas vaginalis, 
Mycoplasma hominis, Mycoplasma genitalium, Chlamydia trachomatis, Neisseria 
gonorrhoeae, and U. urealyticum in endocervical/urethral swabs. The novel feature 
of the Seegene technology is a dual priming oligonucleotide system that contains two 
separate priming regions linked by a polydeoxyinosine spacer. The polydeoxyinosine 
has no binding specificity or priming, but instead forms a bubble or tiny D-loop that 
results in more stable priming. The Seegene STD6 ACE kit should work with any 
thermocycler, and the post PCR assay is designed for either manual or automated gel 
electrophoresis [100]. The ureaplasma assay is not species specific. It amplifies a 
130 bp region of the ureD gene cassette [101]. Seegene now offers a new version of 
their kit for detecting urogenital pathogens that differentiates U. urealyticum from U. 
parvum based on the U. urealyticum ureD and U. parvum ureC genes called 
AnyplexTM II STI-7 Detection Kit. A recent study compared the 3 assays available 
for detection of Ureaplasma spp: Anyplex II, Seeplex, and Mycoplasma IST. 
Anyplex II and Seeplex are PCR based assays, while Mycoplasma IST is a culture 
based assay. The PCR assays were significantly more accurate than the culture based 
assay, and Seeplex was more accurate than Anyplex II, however it cannot 
differentiate between UPA and UUR [102]. 
A high-resolution melt (HRM) PCR assay for the differentiation of the four 




recently [103]. In HRM PCR, UPA strains are separated into four serovars using the 
conserved coding region of the multiple-banded antigen (MBA) gene by PCR 
amplification and HRM analysis to generate reproducible and distinct melt profiles 
that distinguish clonal representatives of the four UPA serovars. Furthermore, this 
HRM PCR assay could classify DNA extracted directly from 16 clinical swabs. An 
important limitation of this assay is that it cannot identify the composition of mixed 
serovar samples. In the presence of a clinical sample containing multiple serovars, 
this assay can only tell if the sample contains more than one UPA serovar. This is an 
important limitation, because our genotyping study of 1061 clinical isolates of 
ureaplasmas showed that 40% of samples contained more than one serovar and 30% 
contained more than two serovars. Furthermore, many mixed clinical samples 
contained mixtures of UPA+UUR serovars [104], in which case this assay will show 
only the UPA constituent of the sample, thus requiring that this assay is run along an 
additional assay capable of detecting UUR.  As the connection between ureaplasma 
infection and development of disease gets better established, we can expect to see 
more diagnostic assays developed to include detection of ureaplasmas. A multiplex 
PCR assay capable of detecting four venereal pathogens simultaneously, one of them 
UUR/UPA, was recently developed by Yao et al [105].   
1.4.2.1.2  Novel PCR –based nucleic acid-based detection systems. 
Molecular-based testing used in clinical laboratories relies primarily on PCR; 
however PCR can be used in combination with other nucleic acid based detection 
(NABD) techniques. NABD techniques are advantageous because of their speed, 




is difficult to culture. NABD techniques used in combination with PCR  for 
Ureaplasma detection and species identification include reverse line hybridization 
blotting combined with multiplex PCR (mPCR/RLB) [106] and microarrays [107]. 
These methods require a visualization step based on specific interaction between 
biotin and conjugated-streptavidin. The mPCR/RLB technique integrates multiplex 
PCR (mPCR) using biotin-labeled primer pairs or biotin-dNTPs to generate labeled 
PCR products that hybridize with highly specific, membrane-bound, amine-labeled 
oligonucleotide probes by reverse line blot hybridization [108]. To visualize the 
hybridized PCR products, the membrane is incubated with peroxidase-labeled 
streptavidin and chemiluminescent substrate, e.g. electrochemiluminescence (ECL) 
detection liquid. Chemiluminescence results can be detected by a light sensitive film 
or a lumino-imager [108]. 
The microarray used for the detection of ureaplasma and some other 
microorganisms is based on immobilizing probes on a glass surface that hybridize to 
their complimentary biotin labeled-DNA targets produced by previous PCR 
procedure. The microarray is then incubated with gold-conjugated streptavidin. The 
interaction of biotin and streptavidin leads to silver precipitation onto the steptavidin-
bound nanogold particles. This is visualized as black spots on the microarray [107]. 
1.4.2.1.3 Non-PCR-based nucleic acid-based detection systems 
There are other nucleic acid amplification based techniques that do not use 
PCR and have been used for detection of pathogenic organisms like loop-mediated 




acid sequence-based amplification (NASBA)[111-113], strand displacement 
amplification (SDA)[114] and in-situ hybridization (ISH)[115]. In some cases their 
chief attribute is that their technology is not subject to patents surrounding PCR. 
Loop-mediated isothermal amplification (LAMP) allows amplification of 
target DNA to the magnitude of 109 copies in less than an hour. The technique uses 
DNA polymerase and four specific primers that recognize six distinct sequences on 
the target. An internal primer is designed to include sense and anti-sense strand 
sequence of the target DNA. The annealing of this primer to target DNA initiates the 
LAMP reaction. In the following step an outer primer is used to begin strand 
displacement DNA synthesis, as a result of which a single-stranded DNA molecule is 
released. This molecule serves as a template, primed by a second inner primer 
annealing to the other end of the target DNA. The newly synthesized DNA strand is 
displaced by a second outer primer, and forms a stem-loop DNA structure. The 
subsequent hybridization of one inner primer to the loop initiates cycling 
displacement DNA synthesis resulting in the production of new stem-loop DNA 
structures.  The final products of LAMP are stem-loop DNAs with multiple loops 
between alternately inverted repeats of the target DNA[109, 116].  
Ligase chain reaction (LCR) is based on the ligation of two adjacent synthetic 
oligonucleotides by thermostable ligase. The reaction uses total of four 
oligonucleotides. Two are designed to be complementary to the sense strand of the 
DNA target and the other two to the anti-sense strand. The reaction is heated to 95°C 




and ligation. The ligated oligonucleotides serve as template DNA in subsequent 
cycles to amplify the target DNA[110].  
Nucleic acid sequence-based amplification (NASBA) is an isothermal 
(~40°C) amplification technique primarily used for amplification and detection of 
mRNA. The technology has been used also on DNA templates. The process involves 
two primers and the enzymes avian myeloblastosis virus reverse transcriptase 
(AMV-RT), Escherishia coli RNase H and T7 RNA polymerase. The method can 
amplify the target sequence more than 1012-fold in 90 minutes. The first primer binds 
to the RNA template and initiates the synthesis of a DNA:RNA hybrid molecule by 
AMV-RT. The RNA strand of the hybrid is hydrolysed by RNase H and the second 
primer can anneal to the single DNA strand and is elongated by AMV-RT to produce 
double stranded DNA molecule (cDNA). The first primer contains target specific 
sequence and a T7 RNA polymerase promoter site. Thus a new now anti-sense RNA 
copy can be produced to start a cycle in which now the second primer initiates the 
production of the DNA:RNA hybrid molecule. NASBA can be used in a real-time 
and multiplex format. The real-time format of NASBA involves the use of a 
molecular beacon, which is a hairpin-shaped oligonucleotide. One end of the beacon 
has a fluorescent group and the other a quencher. When the beacon anneals to the 
target sequence the quencher is situated farther away from the fluorophore, therefore 
light emission can be detected.[111-113, 117, 118]  
Strand displacement amplification (SDA) is another isothermal (~40°C) 
technique, which can amplify a target sequence 108-fold in a 2 hour incubation 




technique: Two forward and two reverse primers. The inner forward and reverse 
primers include 5′ restriction enzyme site. The outer forward and reverse primers do 
not contain restriction enzyme sites. After heat-denaturation of the template the 
reaction is cooled down to ~40°C and primers anneal to the target sequences; follows 
addition of restriction enzyme and exonuclease deficient DNA polymerase. All four 
primed regions are extended, which causes the displacement of the strands 
synthesized by the extension of the internal pair of primers. The displaced primers 
serve as templates. Eventually, fragments with restriction enzyme sites are generated. 
The restriction enzyme nicks the DNA at those sites and the 3′-end at the nick is 
extended by DNA Polymerase, displacing the stand. Primers hybridize to the 
displaced strand to repeat the process, which leads to exponential amplification of 
the target sequence. SDA has been used in multiplex and real-time formats as 
weel.[119, 120].  
In situ hybridization allows visualization of the localized gene expression 
within the context of tissue morphology. ISH was shown to be useful in detection of 
Ureaplasma in lung tissue samples collected from intranasally inoculated newborn 
mice. After fixation of the tissue samples, the slides were incubated with biotinylated 
DNA probes specific for an internal nucleotide sequence within the urease gene. The 
hybridization signal was amplified by binding of peroxidase-conjugated streptavidin 
to biotin and byotinyl tyramide incubations. A chromogenic dye producing a brown 
precipitate at the hybridization sites was used to visualize the hybridization signal 




1.4.3 Choosing culture versus molecular-based tests for UU detection 
While there is no question that molecular-based tests have been extremely 
important for research studies, investigating Ureaplasma pathogenesis, 
epidemiology, and disease over the past two decades, culture still plays a significant 
role in routine diagnostic testing of clinical specimens obtained from patients in 
whom a clinically significant Ureaplasma infection is suspected. The discussion 
above makes a strong and clear-cut case for the many advantages of real-time PCR 
over conventional PCR for detection and speciating ureaplasmas. Real-time PCR is 
more expensive than conventional PCR in terms of cost of reagents and materials 
necessary to perform the assay; however the one-day turnaround time compared to 2-
3 days for conventional PCR offsets these costs when considering the personnel time 
involved. Thus, the decision is quite straightforward in selecting real-time PCR over 
conventional PCR if financial resources permit. It is somewhat more complex 
deciding whether PCR or culture-based detection should be employed on a routine 
basis. It is impossible to state that one method or the other is always preferred in 
every circumstance. Even though real-time PCR is theoretically more sensitive than 
culture and can provide same day results, it may not be a practical methodology for 
daily runs in a laboratory that receives only an occasional specimen submitted for 
Ureaplasma detection or which does not have suitable physical facilities, molecular 
diagnostic equipment or personnel with the necessary education and training to 
perform NABD techniques. Each PCR assay requires reagents for positive and 
negative and internal controls as well as the specimen to be tested, so the cost per test 




has a throughput of 32 samples per run, including the necessary controls.  The cost of 
culture is essentially the same whether one specimen or multiple specimens are 
processed at the same time. The reagent cost of running a single real-time PCR assay 
for Ureaplasma detection and speciation is approximately 4-fold greater than the 
costs for liquid and solid media for culture-based diagnosis, assuming the media is 
prepared on site. If purchased commercially, the cost of media is greater but is still 
considerably less than the cost of running a single PCR assay. 
The first culture methods developed for human ureaplasmas in 1950s were 
further refined over the next several years so that basic and clinical studies could be 
performed to investigate their pathogenic role in disease.  Commercial marketing of 
agar and broth media based on the original formulations described by researchers 
facilitated adoption of ureaplasma cultures for diagnostic purposes by larger hospital 
laboratories and reference laboratories, so now it is a reasonably commonly 
performed procedure in the United States. Widespread availability of diagnostic kits 
in several European and Asian countries has also contributed to more broad use of 
culture-based diagnosis for ureaplasmal infections. The development of PCR-based 
detection systems have been obligatory for species such as Mycoplasma genitalium 
and are now the tests of choice for M. pneumoniae. However, need for PCR-based 
detection of Ureaplasma spp. has not been as critical because of their relative ease of 
in vitro cultivation and rather rapid growth. PCR-based studies have been necessary 
to provide data to support the separation of U. parvum and U. urealyticum as 
individual species and to enable complete characterization of all 14 serovars in a 




two human Ureaplasma species and their respective serotypes has not been answered 
conclusively, there are no current recommendations for identification of ureaplasmas 
to the species or serovar level for diagnostic purposes. We anticipate that molecular-
based technology is likely to become much more widely available and simplified in 
the future, making it appeal to a broad range of clinical laboratories. If more 
diagnostic companies choose to include gene targets for Ureaplasma spp. in 
commercial PCR kits, especially if such products can be used to detect other 
pathogens in the same assay, their use is bound to increase. Availability of the 
complete genomic sequence data for all 14 serovars will surely facilitate 
development of such additional assays. 
1.5 Pathogenicity: Reasons for differential clinical outcome  
1.5.1 Serovars 
It has been proposed that differential pathogenicity may be dependent on the 
specific serovar colonizing the individual. Studies focusing on correlating serovars to 
specific diseases and disease severity have failed to make specific connections of 
serovars to disease.  We genotyped 1061 clinical isolates to analyze the potential 
relationship of specific serovars to specific clinical outcomes; however to our surprise 
we found extensive horizontal gene transfer and high occurrence of samples 
containing more than one serovars, making it impossible to establish such 




1.5.2 Host immune response 
There is increasingly more evidence that the severity and type of disease is 
greatly influenced by the immune response of the patient. An intact humoral immune 
response appears to be important in limiting invasion and dissemination of 
ureaplasma beyond mucosal surfaces.  This is demonstrated by their tendency to 
cause chronic respiratory infections in persons with hypogammaglobulinemia, and to 
cause invasive disease in preterm neonates [7]. A recent study [121], demonstrated 
that mice deficient the innate host defense molecule, surfactant protein A (SP-A) had 
delayed clearance of ureaplasma from their lungs, increase in inflammatory cells and 
pro-inflammatory cytokine expression, compared to wild type mice. SP-A is deficient 
in preterm infants, and may at least partially explain the vulnerability of this 
population to more severe outcomes of an ureaplasma infection.  
Ureaplasma infection induces the stimulation of inflammatory cytokines, 
which is believed to be a causative link between intrauterine infection and organ 
injury [35]. The release of TNF-α, IL-1β, IL-8, monocytechemoattractant-1, TGFβ1 
and other mediators has been demonstrated by various cell types in vitro. Increased 
concentration of these cytokines in tracheal aspirates of infants during their first week 
of life is associated with ureaplasma colonization and development of BPD [122]. 
The activation of these networks leads to inflammatory cell recruitment and 
activation and subsequent local tissue injury, leading to alterations in normal 




Toll-like receptors (TLRs) can mediate microbial recognition by the host 
innate immune system. UPA lipoproteins, including the MBA, have been shown to 
activate NF-κB in reporter cell lines through TLR1, 2 and 6 signaling [123]. A study 
by Peltier et al. showed this signaling to be mediated through TLR2 or TLR4 
receptors [124]. SNPs in these TLR6 have been reported to make the host less 
susceptible to ureaplasma colonization and development of diseases [125]. This 
confirms that differences in the host immune system response and genetic makeup 
play roles in the difference observed in clinical outcome among different patients. It 
is interesting to note that chronic intra-amniotic colonization by ureaplasmas 
profoundly diminished responses to intra-amniotic lipopolysaccharide in the preterm 
fetal sheep [126]. Such endotoxin tolerance can be beneficial to the host due to 
decreased inflammation and thus decreased organ injury [45].   
Although we are gaining much better knowledge of the molecular mechanism 
in the host leading to specific diseases in the presence of ureaplasma infections, still 
little is known of the molecular mechanism of this opportunistic pathogen leading to 
these host responses.    
1.5.3 Potential Virulence Factors of Ureaplasma Species 
Ureaplasmas are capable of attaching to a variety of cell types such as 
urethral epithelial cells, spermatozoa, and erythrocytes [12]. The adhesins of 
ureaplasmas have not been characterized completely, but current evidence suggests 
the receptors are sialyl residues and/or sulphated compounds [7]. As described 




may be dependent on the presence of specific virulence factors in the ureaplasma 
strain colonizing the individual. One of the major goals of our comparative genome 
analysis of 19 ureaplasma strains, described in Chapter 2, was to find genes that may 
potentially be involved in virulence and pathogenicity. Although there is no evidence 
that ureaplasmas produce toxins, they do possess several potential virulence factors. 
A major family of phase-variable, surface proteins, the multiple banded 
antigens (MBA), is immunogenic during ureaplasmal infections.  The MBA is a 
surface lipoprotein consisting of an N-terminal conserved domain including a signal 
peptide, lipoprotein attachment site, and transmembrane domain and a C-terminal 
variable domain which usually consists of tandem repeating units. MBAs have been 
used as a basis for the development of reagents for diagnostic purposes and for 
serotyping [62-65]. Furthermore, the variability of the number of tandem repeats of 
the variable domain requires interaction with the host immune system as 
demonstrated in the sheep intrauterine infection model. Only chronic infections (69 
days) elicited variability of the number of tandem repeats of the MBA TRU [127, 
128]. The MBA family contains at least 22 different TRUs. The variable number of 
tandem repeats of the TRU of the mba and the potential capacity of the organism to 
switch the TRUs has been suggested as a mechanism to evade the host immune 
system response. It is possible that the different types of TRUs may lead to or 
contribute to differential pathogenicity. Furthermore, the mba is one of the genes we 
saw to be exchanged via HGT among two ureaplasma strains, co-infecting a patient.  
Immunoglobulin A (IgA) protease activity has been demonstrated in all 




[66, 67]. IgA protease has been considered as one of the major factors contributing to 
the pathogenic potential of ureaplasmas [66, 67]. It is expressed in bacterial 
pathogens especially if they colonize a mucosal surface [68]. This can provide them 
with an advantage in evasion of the host-defenses. It is interesting to note that the 
Neisseriae commensal species do not express this enzyme [69]. Our computational 
analysis of all ureaplasma sequenced genomes could not identify an IgA protease 
gene, suggesting that this may be a novel type of IgA protease (see Chapter 2).  
Ureaplasmas have also been reported to have phospholipase A1, A2 and C 
activities [70-73]. Such activity when the infection reaches the amnion or placenta 
can lead to production of free arachidonic acid, which may activate the synthesis of 
prostaglandins, thus inducing labor prematurely. Our computational analysis of the 
19 sequenced ureaplasma genomes could not identify any of these phospholipases. 
Our attempts to replicate the results of the studies reporting these activities were 
unsuccessful. During our attempts we carefully analyzed the design of the original 
radioactivity assay and the commercial Amplex Red PLC detection assay 
(Invitrogen). We determined that both assays would measure the activity of both 
PLC and PLD, thus are not specific for PLC. The Amplex Red PLC assay can be 
modified to measure PLD activity only by omitting the first step in the assay. The 
PLD activity can then be subtracted as background from the PLC+PLD activity 
measured by the assay. Using this strategy we were unable to detect PLC activity in 
ureaplasmas infecting humans.  Recently, PLC activity was reported in Ureaplasma 
diversum, however, the Amplex Red assay was used to detect it. The authors did not 




did identify a phospolipade D domain containing gene in the sequenced UUR and 
UPA genomes, which may be present in U. diversum. Therefore, further experiments 
are needed to confirm if the phospholipase activity observed in U. diversum is PLC, 
PLD or maybe both. A detailed discussion of additional potential pathogenicity 
factors, as well as the ones listed above is provided in Chapter 2. 
1.6  Antimicrobial Susceptibility of Ureaplasma 
Ureaplasmas are naturally resistant to β-lactams as they lack peptidoglycan. 
The absence of folic acid synthesis makes sulfonamides inefficient against them to 
[14]. However, ureaplasmas are generally sensitive to tetracyclines, fluoroquinolons, 
macrolides and clindamycin, although resistance to some of these has been reported. 
Table 1-1 summarizes the susceptibility of ureaplasma isolates collected during 
pregnancy and compiled from different studies[14]. Recent studies in animal models 
have evaluated novel treatment plans during pregnancy to prevent premature birth 
and neonatal complications. Grigsby et al showed that azithromycin maternal therapy 
can eradicate ureaplasmas from amniotic fluid, placenta and fetus, prolonging the 
pregnancy and reducing the severity of neonatal complications [129, 130]. Keelan at 
al explored the use of solitromycin for maternal administration in the pregnant sheep 
model [131]. They found that its rate of transplacental passage is relatively high and 
its efficiency of transfer was greater than existing macrolides. This may be one of the 
reasons they observed that a single maternal dose is sufficient to establish therapeutic 













Table 1-1. Antimicrobial Susceptibilities of Ureaplasmas 







1.7  Major Barriers to Understanding Pathogenicity  
Understanding of the role of ureaplasmas in human diseases has been 
thwarted thus far due to two major barriers: 1) Lack of suitable diagnostic tests that 
can identify and characterize the two species and their respective serotypes that could 
account for differential pathogenicity; 2) Lack of genetic manipulation tools for the 
creation of deletion mutants and their complementation to study the role of potential 
pathogenicity factors.   
A major effort in the field of ureaplasma research over the past 20 years has 
been focused on overcoming the first barrier. Since 1990, nearly 300 peer-reviewed 
publications have described basic and clinical investigations involving ureaplasmas 
using PCR and various other nucleic acid-based techniques. Based on the genome 
sequences of the 14 ATCC type strains of each ureaplasma serovar, our group has 
developed species and serovar specific real-time PCR assays to detect ureaplasmas in 
patient isolates [132], which were applied to a collection of 1,061 clinical isolates 
[133]. The results of this large scale serotyping study are discussed in detail in 
Chapter 3 of this dissertation. Briefly our study showed 39% of clinical isolates 
contained more than one serovar, and 28% of the evaluated mixed isolates were 
chimeric organisms containing markers from up to 4 serovars (Figure 4-1 and Table 
4-4). This suggested that ureaplasmas are subject to extensive horizontal gene 
transfer. Therefore it is possible that ureaplasmas do not exist as stable serovars in 
their hosts, but rather as a dynamic population exchanging genes, most likely not only 




findings, the long sought after serotyping assays are of limited value, and there is no 
utility in trying to associate individual serovars with specific disease. The differential 
clinical outcome of ureaplasmal infection may be due primarily to presence or 
absence of potential pathogenicity factors in the colonizing ureaplasma strain [134] 
and/or patient to patient differences in terms of autoimmunity and microbiome. 
The second major barrier to the understanding of ureaplasma pathogenicity is 
the lack of molecular tools for creation of deletion to study the role of potential 
pathogenicity factors. This problem has not been explored nearly as exhaustively as 
the development of serotyping assays. The capacity to create deletion mutants has 
been a prerequisite in understanding host-pathogen interaction and factors involved in 
pathogenicity in many well studied pathogens.  
Approximately twenty years ago efforts to develop genetic manipulation 
systems for ureaplasma were unsuccessful (personal communication with Kevin 
Dybvig). This is one reason little use was made of the first ureaplasma genome 
sequence, which was published early in the genomic era. New technologies such as 
TN4001, OriC plasmids, expression of E. coli RecA via a suicide plasmid, and the 
technology developed for synthetic biology offer new possibilities for development of 
genetic tools for ureaplasma. The development of tools for genetic manipulation of 
Ureaplasma spp. will tremendously facilitate the study and understanding of factors 
leading to differential pathogenicity of Ureaplasma strains. Mutants can be extremely 
valuable for study in existing animal models for ureaplasmal infections in humans. 
Furthermore, the increased understanding of pathogenicity factors can aid in 




morbidity associated with ureaplasmal infections.  The results of this effort are 





Chapter 2. Comparative Genome Analysis of 19 Ureaplasma 
urealyticum and Ureaplasma parvum strains 
2.1 Abstract 
Ureaplasma urealyticum (UUR) and Ureaplasma parvum (UPA) are sexually 
transmitted bacteria among humans implicated in a variety of disease states including 
but not limited to: nongonococcal urethritis, infertility, adverse pregnancy outcomes, 
chorioamnionitis, and bronchopulmonary dysplasia in neonates. There are 10 distinct 
serotypes of UUR and 4 of UPA [5, 7, 83, 86, 87, 135, 136]. Efforts to determine 
whether difference in pathogenic potential exists at the ureaplasma serovar level have 
been hampered by limitations of antibody-based typing methods, multiple cross-
reactions and poor discriminating capacity in clinical samples containing two or more 
serovars.  
We determined the genome sequences of the American Type Culture Collection 
(ATCC) type strains of all UUR and UPA serovars as well as four clinical isolates of 
UUR for which we were not able to determine serovar designation. UPA serovars had 
0.75-0.78 Mbp genomes and UUR serovars were 0.84-0.95 Mbp. The original 
classification of ureaplasma isolates into distinct serovars was largely based on 
differences in the major ureaplasma surface antigen called the multiple banded 
antigen (MBA) and reactions of human and animal sera to the organisms. Whole 
genome analysis of the 14 serovars and the 4 clinical isolates showed the mba gene 
was part of a large superfamily, which is a phase variable gene system, and that some 




hypothetical genes, and in general the two species and 14 serovars are extremely 
similar at the genome level.  
Comparative genome analysis suggests UUR is more capable of acquiring 
genes horizontally, which may contribute to its greater virulence for some conditions. 
The overwhelming evidence of extensive horizontal gene transfer among these 
organisms from our previous studies combined with our comparative analysis 
indicates that ureaplasmas exist as quasi-species rather than as stable serovars in their 
native environment. Therefore, differential pathogenicity and clinical outcome of a 
ureaplasmal infection is most likely not on the serovar level, but rather may be due to 
the presence or absence of potential pathogenicity factors in an individual ureaplasma 
clinical isolate and/or patient to patient differences in terms of autoimmunity and 
microbiome. 
2.2 Introduction 
We sequenced the 14 ATCC UPA and UUR serovars as an effort to aid the 
development of serotyping methods and to enhance the study of the suggested 
differential pathogenicity [10] and ureaplasma biology. Based on these sequences 
real-time PCR genotyping assays were developed that detect the 14 ATCC serovars 
without cross-reactions [12]. Surprisingly, the application of these assays to 1,061 
clinical isolates failed to correlate specific serovars with different clinical outcomes. 
Our inability to correlate patient disease outcomes with specific serovars was at least 
in part because a large fraction of these patient samples were classified as genetic 




of dome of the hybrid genomes showed that serotype specific markers were 
transferred horizontally among ureaplasmas [24]. Combining these findings with the 
comparative genome analysis of the 14 ureaplasma ATCC serovars has allowed us to 
better understand the potential mechanisms and reasons for these observations among 
clinical isolates. We report on genes that may contribute to the virulence of 
ureaplasmas, including the MBA and its putative mechanism of phase variation. 
2.3 Materials and Methods 
2.3.1 Sequencing methods for ATCC and 4 clinical isolates  
Ureaplasmas were grown in 10B medium and phenol chloroform extracted as 
described previously [8]. We randomly fragmented through shearing the purified 
genomic DNA from the 14 ATCC type strains and generated 1–2 kbp and 4–6 kbp 
fragment libraries. Using Sanger chemistry and ABI 3730 DNA sequencers, each 
serovar was sequenced to 8-12X redundancy. In order to obtain data to complete the 
genome sequence of Serovar 2, the Sanger data were supplemented with 454 
pyrrosequencing (Roche) data. We sequenced the 4 clinical isolates only using 454 
chemistry. Genome sequences produced with Sanger chemistry were assembled using 
the Celera Assembler. The 454 data were assembled using the Newbler Software 
Package for de novo genome assembly. 
2.3.2 Annotation 
All 14 ureaplasma strains were annotated using the JCVI Prokaryotic 




enhance the quality of annotation before being submitted to NCBI. Annotation was 
done on various levels, the individual protein level, the pathways and the multiple 
genome comparisons. The annotation pipeline has two distinct modules: one for 
structural annotation and the other for functional annotation. The structural annotation 
module predicts an extensive range of genomic features in the genome. Glimmer3 
[137] was used to predict the protein coding sequences whereas, tRNAs, rRNAs, 
cDNAs, tRNA and ribozymes are predicted based on matches to Ram libraries, a 
database of non-coding RNA families [138]. The programs tRNA scan [139] and 
ARAGORN [140], which is a program that detects tRNA and tmRNA genes.  
For functional annotation, JCVI uses a combination of evidence types which 
provides consistent and complete annotation with high confidence to all genomes. 
The automated annotation pipeline has a functional annotation module 
(AutoAnnotate), which assigns the function to a protein based on multiple evidences. 
It uses precedence-based rules that favor highly trusted annotation sources based on 
their rank. These sources (in rank order) are TIGRFAM HMMs [141] and Pfam 
HMMs, best protein BLAST match from the JCVI internal PANDA database and 
computationally derived assertions (TMHMM and lipoprotein motifs). Based on the 
evidences, the automatic pipeline assigns a functional name, a gene symbol, an EC 
number and Gene Ontology domains [142], which cover cellular component, 
molecular function and biological process(es). The assigned domains are related to 
evidence codes for each protein coding sequence with as much specificity as the 
underlying evidence supports. The pipeline also predicts the metabolic pathway using 




genomes for the presence or absence of biochemical pathways. Genome properties 
incorporate both calculated and human-curated assertions of biological processes and 
properties of sequenced genomes. A collection of properties represents metabolic 
pathways and other biological systems and these are accurately detected 
computationally, generally by the presence/absence of TIGRFAMs and Pfam HMMs. 
This is the basis for the automatic assertions made for the presence of the whole 
pathway/system in any genome. Finally a curator checked for consistency and quality 
of annotation, deleting spurious assertions and inserting any missed ones. This 
resulted in the manual merging of some genes, primarily the MBA genes, which were 
problematic for the automated pipeline due to the nature of their repeats. JCVI’s 
internal Manual Annotation tool (MANATEE) was used extensively to annotate these 
genomes. Manatee is a freely available, open-source, web-based annotation and 
analysis tool for display and editing of genomic data. The genome comparisons and 
annotation transfer were done using the Multi Genome Annotation Tool (MGAT) 
which is an internally developed tool integrated within MANATEE to transfer 
annotations from one gene to other closely related genes. The clusters are generated 
based on reciprocal best BLASTP hits determined by Jaccard-clustering algorithm 
with a BLASTP identity >= 80%, a P value <= 1e-5 and a Jaccard coefficient 
threshold of 0.6. The clusters are composed of genes both within the genome and 
across different ureaplasma genomes. The same clusters are used in the genome 
comparisons generated by SYBIL (http://sybil.sourceforge.net/), which is also an 




2.3.3 Comparative genomics 
The 19 genomes were compared using a variety of bioinformatics tools. Sybil 
[144] was used to generate clusters of orthologous genes (COGs), Jaccard clusters 
(paralogous gene clusters) and identify genes specific for each strain (singletons). The 
information generated with Sybil was used to deduce the pan genome for all 19 
sequenced ureaplasma strains and different subsets of strains. PanSeq version 2.0 
[145] was used to identify unique areas in the clinical UUR isolates that could not be 
serotyped. The functional annotation of genes in those areas was examined using 
Manatee [146] . The percent difference table between pairs of genomes was generated 
by mapping pairs of ureaplasma genomes to each other using BLASTN; that is, 
contigs in genome 1 were searched against the sequences in genome 2. The BLASTN 
results were processed to compute the mean identity and fraction (of contig) covered 
for each contig in genome 1. These values were totaled to give the final value of 
mean identity and fraction covered when mapping genome 1 to genome 2. All 182 
comparisons were carried out. In the mapping process, no attempt was made to 
compute a one-to-one mapping between genome 1 and genome 2, and thus, multiple 
regions in genome 1 can map to a region in genome 2. The mean percent difference 
was calculated from the generated data and reported in Table 3. 
2.3.4 MBA locus 
The nucleotide sequence of all genomes was uploaded to the Tandem Repeats 
Database (TRDB)  and the Inverted Repeats Database (IRDB) [147] and was 




Genomes were analyzed one at a time and the main tandem repeating unit of the 
MBA of the serovar was located and the genomic area around it was inspected for 
other tandem repeats. This approach identified the presence of tandem repeats in the 
close vicinity to the MBA, that when compared through the Basic Local Alignment 
Search Tool (BLAST) [148] against the rest of the serovars’ genomes matched the 
MBA’s tandem repeating units of other serovars. The putative recombinase 
recognition sequence was identified by analyzing inverted repeats detected with the 
IRDB tools and close examination of the MBA loci of serovars 4, 12, and 13, which 
have the same set of tandem repeating units in different rearrangements. Dotplots 
were generated for these serovars using Dotter [149] and BLASTn [148] to help 
identify the conserved sequence that may serve as a recombinase recognition site. To 
identify other genes of the MBA phase variable system all COGs generated by the 
Sybil [144] computes that had participating genes annotated as MBA were examined 
and organized into Table 2-7. 
2.3.5 PLC, PLA, and IgA protease genes 
Tools used to search the genomes were BLAST [148, 150] and Hidden 
Markov Models (HMMs) [151] deposited in PFAM [152]. We set up databases of all 
human ureaplasma open reading frames, proteins and full genome sequences. 
BLASTn and BLASTp [148, 150] were used initially to search the open reading 
frames and protein databases with known PLC, PLA1, and PLA2 genes and protein 




make sure that the gene was not missed by the gene predicting software, we used 
tBLASTn [150] to search the ureaplasma full genomes translated nucleotide database. 
2.3.6 PLC assay 
Amplex® Red Phosphatidylcholine-Specific Phospholipase C Assay Kit 
(Invitrogen Cat.No.A12218) was used to detect activity of the enzyme in whole cell 
lysates, membrane, cytosolic, and media fractions of exponential and stationary phase 
cultures. The Amplex® Red Assay provides lecithin as substrate for PLC that when 
cleaved forms phosphocholine. Phosphocholine is modified to choline by alkaline 
phosphatase, which in the presence of choline oxidase produces betaine and H2O2. 
The Amplex red reagent in turn reacts in the presence of H2O2 and horseradish 
peroxidase to produce the red fluorescent compound resorufin. However, if the test 
sample contains PLD, PLD will cleave lecithin to produce choline, which bypasses 
the alkaline phosphatase step of the assay’s cascade; therefore, this assay would give 
a combined readout of PLC and PLD. Due to the potential presence of a PLD gene in 
ureaplasmas, to make the assay PLC specific we modified the assay by repeating it 
for each test sample, but omitting alkaline phosphatase from the reaction, in order to 
be able to subtract any activity by the putative PLD enzyme in the ureaplasma 
genomes. Everything else followed the manufacturer’s assay protocol. ATCC UPA3 
and UUR8 cultures were grown in 10B or Trypticase Soy Broth to exponential phase. 
Cells were harvested through centrifugation and subjected to osmotic lysis. Cell 




the cell membranes were tested for PLC activity with the Amplex Red assay and with 
the previously published assay by DeSilva and Quinn [153-155]. 
2.3.7 Phylogenetic trees 
Multiple sequence alignments (MSA) and phylogenetic tree constructions 
were performed using ClustalX 2.1 [85]. [156]. Phylogenetic trees were visualized 
with Dendroscope [157]. Multi-gene phylogenetic trees were generated by aligning 
the nucleotide sequences of 82 genes: the 7 genes encoding the urease subunits 
(ureA-G), 47 genes encoding ribosomal proteins, 12 genes encoding RNA and DNA 
polymerase subunits, and 16 genes encoding tRNA ligases. The MSAs of all genes 
were concatenated and edited with Jalview 2.6.1 [158] to remove the non-informative 
positions (100% conserved in all 19 genomes) from the alignment. This was needed 
because the extreme similarity among the strains generated multiple sequence 
alignments containing approximately 5% informative positions. Although these 
informative positions were enough to separate the two species, they were not enough 
to resolve the relationship among serovars/strains within each species. The removal of 
the non-informative positions increased the bootstrap values but did not affect the 
structure of the clades. The phylogenetic tree was generated with ClustalX 2.1 
neighbor-joining bootstrap option. The gene content tree was generated using the 
information from the formed clusters of orthologous genes (COG) to generate a table 
with a serovar on each row and a COG in each column. The presence of a gene in a 
serovar for each COG was marked with the number 0–6 (0 = none, 1–6 = number of 




informative data. The core genome COGs (genes conserved in all 19 genomes) were 
removed from the dataset, since they are non-informative. To be able to use ClustalX 
2.1 to generate the tree the numbers were turned to letters: (0 =C, 1 = S, 2=T, 3=P, 
4=A, G=5, N=6). The table was turned into a multifasta formatted file and loaded into 
ClustalX 2.1. The sequences did not need to be aligned with ClustalX 2.1, since they 
were already aligned. The tree was constructed using the bootstrap, neighbor joining 
method. The root for all trees is a poly-A sequence of similar size, since only the 
relationship within ureaplasmas was of interest. 
2.4 Results and Discussion 
2.4.1 Genome sequencing of 19 U. urealyticum and U. parvum strains  
Subsequent to the publication and annotation of the complete genome of a 
clinical isolate of UPA3 by Glass and colleagues [8], sequencing of all 14 serovar 
type strains deposited in the ATCC was begun to study differences among them and 
examine them for virulence factors. The intent was to completely sequence the ATCC 
UPA3, which is the reference strain for UPA, and UUR8, which is the reference 
strain for UUR. The genomes of those serovars were completed along with UUR2 
and UUR10. The sequencing coverage for each genome varied between 7X to 14.5X 


















































































1 27813 NZ_ABES00000000 760 753,674 8 604 212 25% 14.6X 
3 27815 NC_010503 760 751,679 1 609 219 25% 10.2X 
3 700970 NC_002162 
Patient 
Isolate  751,719 1 614 154 25% - 
6 27818 NZ_AAZQ00000000 760 772,971 5 619 221 25% 11.4X 
14 33697 NZ_ABER00000000 760 749,965 7 594 199 25% 14.5X 
2 27814 NZ_ABFL00000000 880 861,061 1 664 248 26% 10.7X 
4 27816 NZ_AAYO00000000 910 835,413 4 654 206 26% 7.0X 
5 27817 NZ_AAZR00000000 1140 884,046 18 677 252 26% 8.5X 
7 27819 NZ_AAYP00000000 880 875,530 4 660 246 26% 8.3X 
8 27618 NZ_AAYN00000000 890 874,381 1 673 232 26% 9.9X 
9 33175 NZ_AAYQ00000000 950 947,165 10 711 244 26% 8.6X 
10 33699 NC_011374 890 874,478 1 657 232 26% 12.1X 
11 33695 NZ_AAZS00000000 840 876,474 6 644 236 27% 10.0X 
12 33696 NZ_AAZT00000000 870 873,466 2 650 234 25% 9.0X 
























Genome sizes of UPA serovars were between 0.75-0.78 Mbp and of UUR 
serovars between 0.84-0.95 Mbp. We sequenced the genomes of four UUR clinical 
isolates that were negative for all of our serovar genotyping real-time PCR assays 
[104]. All of the isolates’ genomes had some minor genome rearrangements, regions 
that were deleted, and some regions that were inserted and are new for the 
urealyticum group when compared to the ATCC reference strains. Whether we can 
assign new serovar numbers to any of the unidentifiable isolates is a matter of 
clarifying the requirements for an ureaplasma to be considered a specific serovar. 
2.4.2 Genome Analysis of UU clinical isolates that could not be 
genotyped to the serovar level 
There were 67 (6%) isolates that were negative for all serovar-specific assays 
from the collection of 1061 clinical isolates of human ureaplasmas from diverse 
patient populations that we typed using our species and serovar specific real-time 
PCR assay. These serovars could not be assigned to any of the 14 known serovars by 
PCR [104]. Initial analysis of dotplots comparing each isolate’s genome to each 
ATCC serovar showed that isolates 2033 and 2608 were most closely related to 
serovars 12 and 4, which are the closest related serovars among the urealyticums 
(data not shown). Isolate 4155 was most similar to serovar 11, whereas isolate 4318 
was most similar to serovar 2. All of the isolates’ genomes had some minor genome 
rearrangements, areas that were deleted, and some areas that were inserted and are 
new for the urealyticum group when compared to the ATCC reference strains. The 




that the targets were either missing completely or some of the target was missing or 
modified so that one of the primers would not bind. However, it is clear that these 
isolates have changes in other areas of the genome as well. Whether we can assign 
new serovar numbers to any of the unidentifiable isolates is a matter of clarifying the 
requirements for a ureaplasma to be considered a specific serovar. The genomes of 
the four isolates were examined for regions that were not present in any of the ATCC 
serovars using  PanSeq [145]. Such areas were identified in isolates 2608 (3217nt 
long; genomic region coordinates: 4318-7534), 2033 (989nt long; genomic region 
coordinates: 585519-586507), and 4318 (3217nt long; genomic region coordinates: 
21576-24792), but not in 4155. Isolates 2608 and 4318 had a 99% identical region 
that was novel for ureaplasmas. All of these areas encoded hypothetical proteins of 
unknown function. The unique region of isolate 2033 contained one 825 nt long gene 
(ORF00459). The gene encoded a signal peptide which suggests that it may be 
secreted. The unique area of isolate 2608 unique area contains 3 genes: ORF00004 
(840nt), ORF00005 (561nt), and ORF00006 (1125nt). The unique area of isolate 
4318 also contains 3 genes: ORF01501, ORF01502, and ORF01503. 
2.4.3 Gene content analysis of all 19 Ureaplasma genomes 
All strains had the expected two rRNA operons and tRNA coding genes (Table 
2-2). UPA serovars have an average of 608 genes, of which 201 encode hypothetical 
proteins on average, and UUR serovars have an average of 664 genes, of which 230 








Table 2-2. Anticodon Table of tRNAs Showing count of tRNAs used by Human 
Ureaplasmas.  
The number next to each anticodon sequence represents the number of tRNA gene 
copies in ureaplasmas. Green marks the start anticodon and red marks the 2 stops. 
The UGA codon (a stop codon in the standard genetic code) codes for tryptophan  




































based on all 19 sequenced ureaplasma genomes contains 1020 protein coding genes 
of which 758 genes have orthologs in at least one other ureaplasma strain, and 515 
genes are universally conserved among all 19 strains (ureaplasma core genome). The 
number of genes identified only in the genome of single serovars (singletons) is 262. 
The average number of singletons per genome is 14, however the range is wide (0 
singletons in ATCC UPA3 and 68 in ATCC UUR9). Table 2-4 compares the pan 
genomes of different sets of ureaplasma species.  
Table 2-4. Pan genome of different Ureaplasma species sets 
 
It has been suggested that genes that are not affected by the selective pressure 
on mycoplasmas gradually mutate at a faster rate than genes whose sequences are 
highly conserved to a higher AT content and eventually are lost [8]. Therefore, the 
%GC content may point out which genes are important for ureaplasmas or have 
recently been acquired horizontally. We evaluated the percent GC content of all genes 
across the 19 sequenced strains. Genes encoding hypothetical surface proteins 
conserved across all ureaplasma strains with high GC content may play an important 
role for ureaplasmas in processes like adherence to mammalian cells and 
colonization. A histogram of the distribution of %GC values of the ureaplasma pan 




GC content than hypothetical genes (Figure 2-1). The median for the core genome 
was 27%GC, therefore genes with %GC higher than 27 are likely to be essential 
and/or acquired. The median for the hypothetical proteins was 24%GC. Considering 
that the ureaplasma genomes have an overall 25%GC content, it is likely that genes 
with GC content below 25% may be non-essential and on their way to be lost. The 
lowest GC content is of a hypothetical protein with only 13%GC content.  
 
Figure 2-1. Percent GC Distribution Among Genes of The Ureaplasma Pan Genome 
(19 Strains).  
For genes that are present in two or more genomes the average %GC of the orthologs 
was used. Values were grouped in bins (example: bin 20 contains genes with %GC 





The genomes of the 14 sequenced ATCC ureaplasma serovar strains showed 
extreme similarity between the two species and 14 serovars. The comparison of the 
finished genomes shows synteny on the gene level and not many rearrangements. We 
obtained percent difference values by whole genome comparison on the nucleotide 
level. The average intra-species percent difference was 0.62% with the least 
difference between UUR4 and UUR12 of only 0.06%, and the greatest difference 
between UUR9 and UUR13 of 1.27%. On the inter-species level the average percent 
difference was 9.5%, with the greatest difference between UPA1 and UUR9 of 10.2% 
(Table 2-5). Figure 2-2 shows the minor differences between the genomes of serovars 
4 and 12.  
Table 2-5. Serovar to Serovar Difference Expressed in Percent  








Figure 2-2. Dotplot of the genomes of UUR4 and UUR12.  
Boxes a, b, and c are enlarged views of the 3 areas with minor rearrangements or 






As mentioned earlier, UUR serovars have about 118 Kbp (13.5%) larger 
genomes than UPA serovars. As a result UUR serovars have on average 58 genes 
more than UPA serovars. Fifty percent of these extra genes encode hypothetical 
proteins, the rest are spread among different functional categories (Table 2-3). 
Table 2-6 shows the predicted genes present only in UUR serovars or only in 
UPA serovars. As it is seen in Table 2-3, UUR had more genes encoding cell surface 
proteins, DNA restriction modification enzyme genes and remnants of transposons 
(truncated genes or genes with unverified frameshifts). Furthermore, there are subtle 
differences in the predicted activities of proteins encoded by various reductase genes 
among serovars, which may facilitate unequal resistance of different ureaplasmas to 





Table 2-6. Number of Clusters of Orthologous Genes (COGs) per functional category 





2.4.4 Ureaplasma phylogenetic tree 
Constructing an accurate phylogenetic tree that resolves the relationship of 
ureaplasma serovars has been difficult due to the extreme similarity of these 
organisms on the genome level. Several methodologies exist for the construction of 
phylogenetic trees: single gene trees, trees based on concatenated gene sequences, 
gene content trees, and gene order trees.  Phylogenetic trees based on single genes are 
unlikely to provide an accurate lineage of the serovars because of horizontal gene 
transfer among ureaplasmas. We find extensive horizontal gene transfer among 
clinical isolates relative to the 14 ATCC type strains [104]. Another challenge of 
building intra-species phylogenetic trees based on a single gene is that the primary 
nucleotide sequences of the genes conserved among all ureaplasma serovars/strains 
have such a high percentage of identity that there are not enough informative 
positions in the multiple sequence alignment to provide a resolution capability with 
high confidence. A gene content tree is based on a multiple sequence alignment in 
which each sequence (line) represents the genome of a strain and each position 
(column) in the multiple sequence alignment signifies the presence or absence of a 
gene in the strain. Therefore, such a tree has a binary nature (presence=1, absence=0). 
The pan genome of ureaplasmas generates a relatively short multiple sequence 
alignment: 1020 positions for 1020 genes in the pan genome. Therefore, a gene 
content tree of ureaplasma strains does not have the fine resolution capability of a 
phylogenetic tree based on nucleotide sequences. This can be noted in the low 
bootstrap values of the deep nodes of the gene content tree based on the pan genome 




because the majority of the genomes are in multiple pieces, thus making it hard to 
judge the gene order in these genomes.  
 
 






Phylogenetic trees of ureaplasmas have been published previously, showing 
clear separation of the parvum and urealyticum species [159, 160]. The conserved 
domain of the mba genes has been used to generate a phylogenetic tree to resolve the 
relationship of serovars [98, 135]. We reconstructed the mba conserved domain tree 
using the first 430 nucleotides of the mba gene of all 19 strains (Figure 2-4).  
 
Figure 2-4. MBA Based Phylogenetic Tree of 19 Ureaplasmas.  
The tree is based on the nucleotide sequence of the conserved domain of the mba (1-




We also present a phylogenetic tree (Figure 2-5) based on the information of 
the nucleotide sequence of 82 housekeeping genes forming four groups: 1) 16 tRNA 
ligase genes 2) 12 RNA and DNA polymerase genes, 3) 47 ribosomal protein genes, 
and 4) 7 ureases. The clades of the multigene tree are very similar to the clades of the 
previously published mba based tree; however, the deep nodes of the two trees show 
some differences. These differences may be due to differences in the gene acquisition 
events that are averaged in a phylogenetic tree based on multiple genes versus a 
single gene tree. Similar differences in the deep tree nodes can be seen in the 
phylogenetic trees resulting from the concatenated alignments of the genes of each of 
the four groups and the trees resulting from different combinations of the groups 
(Figure 2-6, Figure 2-7, and Figure 2-8). However, as more genes are used to 







Figure 2-5. Phylogenetic tree of 19 ureaplasma strains based on 82 housekeeping 
genes.  
ATCC type strains are labeled with tree letters (species) followed by a number 
(serovar). UUR=Ureaplasma urealyticum; UPA=Ureaplasma parvum; ntUPA3= 
clinical isolate sequenced in 2000; 2033, 2608, 4155, and 4318 are clinical isolates of 
Ureaplasma urealyticum that cannot be serotyped. The tree is based on the 
concatenated alignment of 82 housekeeping genes (16 tRNA ligase genes, 12 DNA 
and RNA polymerase genes, 47 ribosomal protein genes, and 7 urease genes). The 
non-informative positions were removed from the alignments. The removal of the 







Figure 2-6. Phylogenetic trees based on the nucleotide sequence of multiple 
concatenated genes: 
 a. 7 urease genes; b. 47 ribosomal protein genes; c. 12 RNA and DNA polymerase 





Figure 2-7. Phylogenetic trees based on the combination of two of the four groups of 
concatenated genes.  
The nucleotide sequence of the genes was used; a. tree based on 7 usease genes and 
12 RNA and DNA polymerase genes; b. tree based on 7 usease genes and 16 tRNA 
ligase genes; c. tree based on 7 urease genes and 47 ribosomal protein genes; d. tree 
based on 16tRNA ligase genes and 12 RNA and DNA polymerase genes; e. tree 
based on 16 tRNA ligase genes and 47 ribosomal protein genes; f. tree based on 12 






Figure 2-8. Phylogenetic trees based on the combination of tree of the four groups of 
concatenated genes.  
The nucleotide sequence of the genes was used; a. tree based on 7 usease genes, 12 
RNA and DNA polymerase genes and 16 tRNA ligase genes; b. tree based on 7 
usease genes and 16 tRNA ligase genes, and 47 Ribosomal protein genes; c. tree 
based on 7 urease genes, 12 RNA and DNA polymerase genes, and 47 ribosomal 
protein genes; d. tree based on 16tRNA ligase genes, 12 RNA and DNA polymerase 




2.4.5 Recombination and Integration of DNA 
All ureaplasma serovars contained one or more integrase-recombinase genes 
and some serovars contained transposases, or remnants of transposases, and some 
phage related proteins. Most of the recombinases were site-specific tyrosine 
recombinases, which are present also in other mycoplasmas and firmicutes. The 
highest number and variety of such genes was observed in serovar 2, and in general, 
UUR serovars had higher number of these genes than UPA serovars. However, 
insertion events represented only a small portion of the average 118 Kbp difference 
between the two species. A site-specific integrase-recombinase was adjacent to the 
phase variable locus of the MBA in 12 of the 14 serovars. This recombinase was 
likely involved in the rearrangements of the mba locus resulting in the variation of the 
C-terminal of this surface antigen. The presence of transposases suggested that 
foreign mobile DNA elements have been inserted in the genomes of ureaplasma 
serovars. Some of the transposases have truncations or unverified frameshifts 
indicating that the mobile element that they were part of was most likely no longer 
mobile. It was no surprise to find transposon related genes in serovar 9, which had 
acquired tetracycline resistance. The tetM gene was identified as part of a Tn916 
transposon, based on the genes around it.  Although tetracycline-resistant ureaplasma 
were probably less frequent when serovar 9 was isolated, now they comprise 25-35% 
of all patient isolates. A report covering the years 2000-2004 from several states in 
the USA showed that 45% of unique clinical isolates of Ureaplasma spp. contain 
tetM and are tetracycline-resistant [11]. Further evidence of genome integrated 




TnpX, required for the excision of Tn4451 [11] and TndX, which was the first 
member of the large-resolvase subgroup of the resolvase/invertase family of site-
specific recombinase shown to be able to mediate the insertion and excision of a 
conjugative transposon, more specifically Tn5397 [161].  
A TraG/D family protein was recognized in serovars 9 and 13 (UUR9_0186 
[GenBank: ZP_03079565] and UUR13_0031 [GenBank: ZP_02932006]). The 
TraG/D (transport) family genes aid the transfer of DNA from the plasmid into the 
host bacterial chromosome [162, 163], mediate the interactions between the DNA 
processing (Dtr) and mating pair formation (Mpf) systems during conjugation.  
Another suggestion for the capacity of horizontal gene transfer in at least some 
serovars is the presence of relaxases/mobilization proteins (UUR9_0148 [GenBank: 
ZP_03079581] and UUR13_0045 [GenBank: ZP_02696018]). Such proteins are 
required for the horizontal transfer of genetic information contained on plasmids that 
occurs during bacterial conjugation [164]. Aligning the genomes of the 14 ATCC 
ureaplasma genomes made evident two major insertion events. The first one was 
consistent with a transposon insertion, due to the repeat of some host sequence on 
both sides of the inserted region. At the time of insertion a short part of the 3’ end of 
the ruvB was duplicated, so that the insertion was located between the full length 
ruvB gene and its short duplication. The insertion has been inherited by UPA1, 3, and 
14 from a common ancestor. Some of the genes present in this insertion had orthologs 
in UUR serovars. The inserted DNA fragment was 11,822 bp long in UPA3 and 14, 
and 12293 bp in UPA1. It contained 8 genes, which encoded 6 hypothetical proteins, 




subunit restriction protein. The second insertion was present in 9 of the 14 serovars 
(UPA3, and 6, UUR4, 5, 7, 8, 10, 11, and 12) and had a size of about 20 Kb.  
Based on the fact that there were three phage genes in the insert, we believe 
that this event is due to a phage insertion into the genomes. The first gene of the 
insertion encodes an integrase-recombinase protein that contains a phage integrase 
domain (UPA3_0153 [GenBank: YP_001752228]). A phage recombination protein 
Bet (UPA3_0162 [GenBank: YP_001752237] is encoded further downstream of the 
integrase and the final gene in the insert encodes a phage terminase, large subunit, of 
the pbsx family (UPA3_0176 [GenBank: YP_001752251]. The rest of the genes are 
hypothetical proteins, however some of them encode one or more transmembrane 
domains and/or signal peptides, suggesting that they may play a role on the surface of 
the ureaplasma cell. It is important to note that the same exact insertion regions have 
been identified through a comparative genomic microarray analysis of 10 UPA 
clinical strains [134]. In this comparative genome microarray study these two 
insertions were present in some isolates of the same serovar and absent in other 
isolates of the same serovar. The authors suggest the phage insertion might be a 
putative pathogenicity island. Although the C+G content of the insertion is less than 
1% higher than the rest of the genome, Momynaliev and colleagues [134] found that 
GCGC and CGCG tetranucleotides, that are present in ureaplasma DNA fragments, 
were missing in the inserted DNA fragment, thus providing another clue of the 
foreign character of the inserted DNA fragment.  
Examining the putative restriction-modification (RM) genes in the 14 serovars 




systems are incomplete. Serovars 3, 5, 7, 8, 10, and 11 may have a complete type III 
RM system, serovar 9 may have a complete type I and type II RM system, whereas 
serovars 1, 14, 2, 12, and 13 appear to have only remnants of RM systems. RM 
systems are used in general by organisms to protect themselves from foreign DNA 
like viruses. Although phages that infect ureaplasmas have not been reported, the 
existence of these RM systems, as well as the presence of either intact or remnants of 
RM systems in the other urogenital mycoplasmas M. genitalium and M. hominis 
suggests that there are phages that infect these obligate parasites. In organisms like 
Chlamydia spp., which are obligate intracellular parasites and have no identifiable 
infecting viruses, there are no functional RM systems [165].  
2.4.6 Potential pathogenicity genes 
2.4.6.1 Phospholipase C, A1, A2 
Phospholipase C, A1, and A2 (PLC, PLA1, PLA2) activity was reported in 
Ureaplasma serovars 3, 4, and 8 by DeSilva and Quinn [153-155]. It is important to 
note that the assay used by DeSilva measures combined activity of PLC and 
phospholipase D (PLD) because both cleavage products are in the soluble fraction 
and the radioactively labeled hydrogen would be found in both cleavage products 
[166]. PLC activity has been reported in Ureaplasma diversum cells as well, and has 
been suggested to play a role in ureaplasma invasion in mammalian cells [167]. 
However, the detection method used the artificial substrate p-
nitrophenylphosphorylcholine (p-NPPC), which can be hydrolyzed by several other 




ureaplasma serovar genomes and the genome of the previously sequenced clinical 
isolate of UPA3 were extensively evaluated for the presence of PLC, PLA1, and 
PLA2 genes.  No genes showed significant similarity to known sequences of PLC, 
PLA1, or PLA2 in any of the genomes. HMMs developed for known PLC, PLA1, and 
PLA2 did not detect any ureaplasma genes with significant similarity. This suggested 
that ureaplasma may encode phospholipases that are either very degenerate or have 
evolved separately from known phospholipases as previously suggested by Glass et al 
[8], or that no phospholipase genes are present in Ureaplasma spp. It is interesting to 
note that a PLD domain containing protein was easily identified. In all serovars this 
protein is annotated as cardiolipin synthase (UPA3_0627 [GenBank 
YP_001752673]). 
We used two PLC assays to test ureaplasmas for PLC activity: Invitrogen’s 
Amplex® Red Phosphatidylcholine-Specific Phospholipase C Assay Kit, which 
detects also PLD activity, and the original PLC assay published by DeSilva and 
Quinn. We were not able to detect PLC or PLD activity in ureaplasma cultures of 
serovars 3 and 8. Our attempts to repeat De Silva and Quinn’s PLC assay using L-a-
dipalmitoylphosphatidylcholine – (choline-methyl-3H) with UPA3 and UUR8 
cultures grown to exponential phase and processed to collect the cell membranes and 
cleared cell lysates as described in their original publications [153-155]  failed to 
replicate the specific activity levels they reported in ureaplasma cultures. Because we 
were not able to find PLC, either computationally or experimentally, we believe that 
this gene is not present in ureaplasmas. However, a study done by Park et al. suggests 




production of prostaglandins and initiation of labor [169]. Since all ureaplasma 
serovars and the four sequenced clinical isolates contain a gene with PLD domains, a 
future functional characterization of this gene would be of interest. We have not been 
able to find computationally the genes encoding PLA1 and PLA2 in ureaplasmas.  
2.4.6.2 IgA Protease 
In the mammalian immune system, a primary defense mechanism at mucosal 
surfaces is the secretion of immunoglobulin A (IgA) antibodies. Destruction of IgA 
antibodies by IgA specific protease allows evasion of the host defense mechanism. In 
Neisseria gonorrhoeae the IgA protease doubles as a LAMP-1 protease to allow it to 
prevent fusion of the phagosome with the lysosome [170]. IgA protease activity was 
demonstrated in ureaplasma serovars [171, 172]. All sequenced human ureaplasma 
genomes were evaluated for IgA protease genes with the same methods as the 
phospholipases gene search. We could not computationally identify an IgA protease 
gene. It is possible that the IgA protease activity detected in all ATCC serovars could 
be due to the expression of a protease capable of cleaving the IgA antibody, as a its 
secondary function. Therefore, this protease does not have the typical IgA protease 
amino acid sequence and conserved domain architecture and has another primary 
protease function. We obtained the complete lest of Pfam families from the Pfam 
database, which holds a large collection of protein families, each represented by 
multiple sequence alignments and HMMs [173]. We used this list to create a new list 
containing all Pfam families that described any proteases or peptidases. This resulted 
in 166 pfam families at the time of our search in 2011. We used this list to search our 




genomes which sequences matched these pfam families. We found a total of 236 
ORFs which sequences matched at least one of these pfam families. We used our 
comparative genome analysis and BLAST to organize the 236 genes in COGs. Since 
all UU serovars showed IgA protease activity we filtered out all ORFs that were not 
present in all 14 serovars. This filter narrowed our result to 10 potential ORFs that 
may be genes encoding a protease with potentially secondary function as an IgA 
protease. These genes could be cloned and expressed in E. coli or another bacteria 
that does not express an enzyme capable of cleaving IgA antibodies and the potential 
capability of these proteases to also cleave IgA antibodies could be explored. 
Ureaplasmas, utilize a non-standard genetic code in which the UGA codon codes for 
the amino acid tryptophan. When this codon is present in the candidate gene it will 
need to be changed to UGG through site directed mutagenesis in order to be 
translated properly in bacteria that utilize the standard genetic code. Table 2-7 




Table 2-7. Proteases Conserved in All 14 ATCC Serovars.  
These genes could be further investigated for IgA protease activity. The UGA codon 
in ureaplasmas codes for tryptophan instead of a stop codon and would need to be 
corrected for proper expression in E. coli or other bacteria with standard genetic code.  
Ureaplasma urealyticum 
serovar 8                       






UUR8_0075 Oligoendopeptidase  10 broad specificity   
UUR8_0116 ATP-dependent Metalloprotease FtsH  3 
transmembrane 
domain  
UUR8_0251 Methionine Aminopeptidase  3   
UUR8_0282 Glutamyl Aminopeptidase  1 
annotated as 
cellulase in some 
UU serovars 
UUR8_0321 Glycoprotease family protein  0    
UUR8_0361 ATP-dependent Lon protease  2 
Serine protease 
region  









UUR8_0614 Oligoendopeptidase F  9   





Nucleases have been reported as potential pathogenicity factors in other 
organisms as well [174]. Ureaplasmas belong to a group of organisms that import 
nucleotides for DNA and RNA synthesis. Therefore it is likely that they have secreted 
or surface bound nucleases that may also play a role in pathogenicity. We identified 
15 potential nucleases, of which two had a predicted signal peptide, and thus are 
likely to be secreted or surface bound. These nucleases may be an interesting target 
for further studies of their potential involvement in pathogenicity.  
2.4.6.4 Putative O-sialoglycoprotein peptidase 
All 14 ureaplasma serovars contained a gene annotated as an O-
sialoglycoprotein endopeptidase (UPA3_0428 [GenBank: ACA33260]). This enzyme 
has been shown to cleave human erythrocyte glycophorin A in other bacteria [175]. 
The same study showed that the specificity of this peptidase is limited to O-
glycosylated membrane glycoproteins, and it cannot cleave N-glycosylated proteins. 
Abdullah et al. [175] suggest that the potential targets of this enzyme in the host are 
sialoglycoproteins of the mucosal epithelial cells or on the cell surfaces of 
macrophages. In fact the O-sialoglycoprotein peptidase of Mannheimia haemolytica 
cleaves from the surface of the human cell line KGla the CD43-leukosialin and other 
human O-sialoprotein antigens like the progenitor cell-restricted antigen CD34, the 
hyaluronate receptor CD44, and the leukocyte common antigen tyrosine phosphatase 
CD45 class of molecules [175]. If the ureaplasma putative O-sialoglycoprotein 




of the host immune system, colonization of the host, and eventually establishment of 
an infection. In M. haemolytica isolates the presence of this gene is associated with 
the capacity of the bacteria to cause pneumonia in calves [175]. 
2.4.6.5 Macrophage infection mutant protein, MimD 
UUR2 contained a gene annotated mimD (UUR2_0526 [GenBank: 
ZP_03771352]) standing for macrophage interaction mutant D. Mycobacterium 
marinum is a fish, amphibian, and human pathogen that may be able to survive and 
replicate in macrophages. A study of macrophage infection D. marinum mutants 
identified a mutation in a hypothetical protein that resulted in this phenotype [176]. 
The exact function of this gene in interactions with macrophages is not yet defined; 
however the ureaplasma annotated mimD gene (183 aa) had 40% identity and 68% 
similarity over 179 aa long alignment with the M. marinum mimD gene (731 aa). 
Further characterization of MimD in other systems and possibly ureaplasma would be 
interesting.  
2.4.6.6 Resisting hostile environment 
Bacteria are known to produce substances that give them competitive 
advantages over other bacteria in their environment. Some of these substances are 
bacteriocins (like mutacin produced by Streptococcus mutans) and H2O2 to inhibit 
the growth of other bacteria [177]. UUR13 has two of the three suggested genes 
involved in immunity to mutacin, mutE and mutG [178]. A glutathione peroxidase 
gene [GenBank: ACA33207.1] was found in all UPA serovars. Peroxiredoxin 




play a role in resisting oxidative stresses and bacteriocins produced by the rest of the 
bacteria on the mucosal surfaces they occupy. We detected a thioredoxin reductase 
system in all 19 genomes [GenBank: ACA33034 and NP_078428]. The thioredoxin 
reductase system has been described previously in mycoplasmas and functions as a 
detoxifying system to protect the organism from reactive oxygen compounds [179]. 
The presence or absence of such genes in an individual ureaplasma strain may 
contribute to the difference of pathogenic potential of the strain.    
2.4.6.7 Multiple Banded Antigen (MBA) Superfamily 
The original classification of ureaplasma isolates into distinct serovars was 
largely based on differences in the major ureaplasma surface antigen called the 
multiple banded antigen (MBA) (8-10, 12). MBA consists of an N-terminal 
conserved domain and a C-terminal variable domain. The conserved domain contains 
a signal peptide, lipoprotein attachment site, and one transmembrane domain. While 
the conserved mba domains for all 14 serovars had been sequenced previously, for 
most serovars sequencing of the variable domain, which was thought to be serovar 
specific, was only partial [180-182]. Our whole genome data confirmed that variable 
regions usually consist of tandem repeating sequence/units (TRU). Only in UUR13 is 
the conserved domain attached to a variable domain that does not contain any tandem 
repeats. The same variable domain is found also in UUR12 and UUR4; however it is 
not attached to the conserved domain of the mba in these serovars. The MBA is 
recognized by the Toll-like receptors 1, 2, and 6, and is capable of inducing the 
cytokine, NF-κB and antibody production [123]. It is conceivable that ureaplasmas 




Ureaplasma isolates can vary the number of the tandem repeats of their mba gene in 
response to challenge with antibodies presumably by slipped strand mutagenesis 
[183]. Furthermore, mba can phase vary with neighboring genes, and UPA3 was 
recently shown to produce a chimeric gene though phase variation by fusing the N-
terminal part of an mba paralogous gene (UU172 [GenBank: CBI70486] to its 
neighboring gene (UU171 [GenBank: NP_078003]) [99, 184]. These findings suggest 
that mba and some mba paralogous genes might be involved in strategies for evading 
the host immune system employed by ureaplasmas.  
One of the surprises of our whole genome analysis and comparison of the 14 
ATCC serovars showed the mba genes to be part of a large complex gene superfamily 
comprising 183 UPA and UUR genes and 22 subfamilies (Table 2-8). There were a 




Table 2-8. Clusters of Orthologous Genes Potentially Involved in the MBA Phase 
Variable System of Ureaplasmas.   
This table contains the NCBI locus tags for genes potentially involved in the MBA 
phase variable system . Genes with tandem repeats are highlighted in green. A red 





Table 2-9. Tandem Repeating Units (TRUs) Identifies in the mba locus.  
The name of each TRU consists of the mba gene name followed by the period size 
(bp) of the repeating unit. Different sequences of the same period size are marked by 
“.” and a version number (ex. mba18.1 and mba18.2). Observed minimum and 
maximum copy number of the TRU is shown in the third column. Column 6 shows 
the serovar in which the conserved domain was associated with each TRU. Note that 








We found that all UUR serovars and UPA1 and 6 had more than one tandem 
repeating unit type in their mba locus. Although some of these TRUs have not yet 
been observed to be attached to the conserved domain of the mba, they are 
surrounded by inverted repeats that contain a putative recombinase recognition site. 
This suggested that these TRUs were involved with the mba and contributed to 
surface antigen variation. The UPA serovars had a simpler MBA phase variation 
systems than the UUR serovars: the UPA conserved domain was surrounded by 
inverted single base pair repeats, containing the 25 base pair putative recombinase 
recognition site and a site-specific recombinase gene (UPA3_0388 [GenBank: 
YP_001752455]) was located near the mba locus (Figure 2-9 and Figure 2-10). The 
inverted repeats and the site-specific recombinase were potentially involved in 
inverting the orientation of the transcriptional promoter and conserved domain in 
order for expression to occur with one or the other TRU. It is interesting to note that 
one TRU was short and had a high copy number (18 nt – UPA1, 12 nt – UPA6, 
repeated >30X) and the other one was long and had a low copy number (327 nt –
UPA1, 336 nt – UPA6, repeated <5X). Rearrangements of the mba locus were 


















UPA1 genome sequencing data clearly shows a sub-population in which the 
conserved domain of the mba is attached to the alternative TRU ([GenBank: 
NZ_ABES01000008] – assembly 17, [GenBank: NZ_ABES01000003] – assembly 
20; Figure 2-9 & Table 2-8) and another subpopulation in which another gene is 
present between the two TRUs ([GenBank: NZ_ABES01000002] – assembly 21). 
The high repeat number of the mba TRUs, and the existence of a subpopulation in the 
culture being sequenced that has a rearrangement of the mba locus, represent an 
ambiguity for the assembly software, resulting in the generation of smaller alternative 
contigs that cannot be assembled into the chromosome. The alternative 327 nt mba 
TRU of UPA1 is on a 1399 nt long contig [GenBank: NZ_ABES01000008] that 
contains only this gene, and it ends truncating the 327 nt TRU at only 2.3 repeats 
compared to 4 repeats on the main contig. Furthermore, comparing the two variations 
of the mba locus makes evident the break-points where the flip of the conserved 
domain occurred. This coincides with the sites of the inverted repeats suspected to be 
part of the mechanism for MBA phase-variation. This represents sequencing evidence 
that this serovar could express both variations of the MBA at different times.  
All UUR serovars have more than two TRUs in close proximity to each other. 
Serovars UUR7 and UUR11 have only 2 TRUs each, whereas UUR2 and UUR5 have 
6 TRUs each, which is the maximum number of TRUs observed. The largest mba loci 
are around 10 KB and have 6 TRUs and some non-TRU mba genes. Each mba locus 
contains only one conserved domain. The loci are always located adjacent to the 
DNA pol III alpha subunit (except UPA14) and on the other side of the loci there is a 




recombinase recognition sequence 
[ACTTT(T/C)TCT(G/C)TTTGATAATT(C/A)AAAT]. The same recognition site is 
located next to some non-TRU genes in the loci, therefore making them likely to be 
involved in this phase variable superfamily. Furthermore, serovar 13 has a non-TRU 
variable domain fused to the conserved domain of the mba, confirming that the 
variable unit does not necessarily require tandem repeats. An interesting observation 
is that UUR4, 12 and 13 have the same mba locus composition in 3 different 
rearrangements (Figure 2-11).  
 
  
Figure 2-11. The MBA Locus in UUR4, UUR12, and UUR13. 
Genes in each genome are represented as directional blue or green boxes. 
Orthologous gene clusters (COGs) are represented by gray or pink bands spanning 
across the tree genomes. The COG with a pink band represents the first mba gene in 
the MBA locus. The locus includes the next 4 genes following the gene in the pink 
labeled COG (all tree genome have 5 mba genes each). The conserved domain of the 
mba is marked by a red box. Rearrangements of the genes are visible by following the 





Most TRUs were found to be present in more than one serovar. By carefully 
analyzing small contigs in unfinished ureaplasma genomes, we identified variations 
of the mba loci. For example, on a small contig of UUR8 [GenBank: 
NZ_AAYN02000001] we saw a partial mba locus arranged alternatively by 
duplicating one of the TRUs in the locus. Examining the sequencing and assembly 
data of such contigs confirms that these contigs are not misassembled, but rather 
represent a subpopulation of the sequenced culture. The proposed mechanism for 
variation of the ureaplasma mba locus resembles the previously reported variable loci 
of Mycoplasma bovis: vis, Mycoplasma pulmonis: vrs and Mycoplasma agalactiae: 
vis-like [185] in that a site-specific Xer-1 recombinase and inverted repeats are likely 
to be involved and a putative recombinase recognition site has been determined. The 
mba locus resembles the M. pulmonis vrs locus in that it has only one promoter and 
one conserved domain per mba locus, which needs to be moved in front of a variable 
domain to make a functional surface MBA. 
Examination of the mba loci of the four sequenced UUR clinical isolates that 
cannot be assigned to a serovar shows that the mba conserved domain is UUR 
specific. Due to the repetitive nature of the mba TRUs the loci are broken into 
multiple contigs, making it impossible to determine the exact order of the genes in the 
mba loci without further sequencing. Isolate 2033 had 4 identifiable TRUs 
(mba333bp, mba213bp.1, mba30bp and the non-tandemly repeating unit of UUR13; 
see Table 2-9). Of these, mba30bp was found attached to the conserved domain of the 
MBA and is the equivalent of the active TRU in UUR4. The same TRU was also 




TRUs (mba24bp.1, mba267bp, and mba330bp). The conserved domain was found 
attached to mba24bp.1, as in UUR5; this TRU was also present in UUR2 and UUR8. 
Clinical isolate 4318 had 3 identifiable TRUs (mba24bp.1, mba276bp, and 
mba333bp). The conserved domain was attached to mba24bp.1. Isolate 4155 had 5 
identifiable TRUs (mba24bp.1, mba45bp, mba213bp.2, mba252bp.1, and mba276bp). 
The conserved domain was attached to mba276bp; this TRU had not been previously 
seen attached to a conserved domain in any of the 14 ATCC type strains, including 
the clinical UPA3 described by Glass et al. [8]. This is a further confirmation that the 
TRUs found in the mba locus are part of this phase variable system, which trough 
recombination should be capable to present on the surface of the ureaplasma cell 
different TRUs at different times. It would be interesting to investigate whether some 
TRUs are more immunogenic than others and therefore may contribute to differential 
pathogenicity. As mentioned earlier the mba variable domain has been used as one of 
the determinants of serovar classification. It is interesting to note that serovars 4 and 
12, which have an identical set of MBA genes, have a percent difference at the 
nucleotide level in a whole genome comparison (Table 2-5) of only 0.06 or 0.07% 
(value depends on which genome is used as reference sequence). In addition, we 
observed two chimeric U. parvum strains in a clinical isolate that had exchanged 
through horizontal gene transfer their mba genes [104]. Taken together, these 
observation suggest that the mba locus is dynamic and can comprise of a different set 
of variable domains at different times, therefore making this gene an unsuitable target 
for serovar differentiation unless serovar designation is solely based on the currently 





Ureaplasmas have been associated with many different clinical outcomes; 
however, they have been detected also in healthy individuals. Due to their differential 
pathogenicity, effort has gone into assignment of patient isolates into serovars and 
attempting to correlate specific serovars with specific clinical outcomes. Analysis of 
ureaplasma samples obtained from patients in the 1970s identified 14 different 
serovars based on patient and animal antiserum reactions. The expanded serotyping 
scheme developed by Robertson and Stemke in 1979 is based on antiserum generated 
by injecting rabbits with emulsified preparations of cell suspensions of each strain 
separately [186]. Studies were not done at this time to determine the antigen that the 
sera antibodies were recognizing. In a later study, Watson et al. (1990) reported the 
finding of an antigen recognized by infected humans that contains serovar-specific 
and cross-reactive epitopes. This antigen presented a multiple banded pattern on 
immunoblots, wherefore, it was named multiple banded antigen (MBA). The same 
study tested only 4 patient sera in blocking experiments with monoclonal antibodies; 
therefore, it is not possible to deduce the exact antigens for all serovars involved in 
the serotyping of the 14 serovars. Because of the suggested serovar-specific epitopes 
of the MBA, this protein has been used in attempts to develop better serotyping 
techniques. However, the cross-reactivity between serovars still could not be 
eliminated. Comparing the 14 genomes of the ATCC type serovars enabled us to 
better understand why there is cross-reactivity when attempting to use anti-MBA 
antibodies for serotyping. This is due to the fact that all ATCC serovars have more 




gene system. There was a limited number of unique variable domains, however, it 
was showed that one such unique variable domain unit was exchanged/acquired by 
horizontal gene transfer [104], suggesting that the mba locus is dynamic and can 
acquire or lose variable domains. Therefore the MBA genes are not suitable for a 
serotyping tool.  
Ureaplasmas have been shown to adhere to different eukaryotic cells although 
their adhesins have not been identified. Experiments done to gain a better 
understanding of the adhesion properties of ureaplasma showed that cytadherence 
involves N-acetylneuraminic acid (NANA) as a ligand receptor molecule. The same 
study showed that ureaplasma adherence was significantly lower, but not inhibited by 
neuraminidase treatment, therefore, there are additional receptors that do not involve 
NANA [187]. Our comparative genome analysis of the 14 ATCC serovars showed 
that ureaplasmas have a great variety of genes coding for surface proteins and 
lipoproteins, however the majority of these genes could not be assigned a function, 
since they were orthologous of genes coding for proteins of unknown function or the 
predicted gene did not have an ortholog outside of the Ureaplasma genus. It is 
possible that such genes will have a higher GC content, due to their importance for 
the organism, in which case the %GC table could be used together with signal peptide 
and transmembrane domain prediction to identify candidate genes to study for 
adherence properties. The MBAs are part of the surface proteome of the ureaplasmas 
and have been shown to be recognized by the toll like receptors (TLR) and induce 
NF-κB production [123]. Recognition by the TLR can elicit the release of 




in the amnion, chorion, deciduas and myometrium, leading to uterine contractions and 
eventually may lead to pre-term labor. The variety of MBA variable domains and the 
capacity of the organism to vary their sizes and switch between variable domains 
could mean that different MBAs, when recognized by the TLRs, may have a different 
capacity to activate the innate immune system [36]. The fact that the MBA variable 
domain is recognized by patient antibodies and antibody pressure leads to phase 
variable switch in their size or the variable domain [183] suggests that the different 
variable domains could be used for host immune system evasion.   
Although we expected to find evidence of differential pathogenicity on the 
serovar level, the majority of the differences among the two species and the serovars 
are in genes encoding proteins for which we could not assign functions. There are a 
limited number of potential pathogenicity factors that could be recognized 
computationally. The previously shown activity of IgA protease in all 13 tested 
serovars [171, 172, 188] can be an important tool for host immune system evasion in 
the mucosal surfaces, however we could not identify the gene responsible for this 
enzyme activity computationally. The ureaplasmal IgA protease may be a novel IgA 
protease. We believe that one of the predicted genes, which contain a protease 
functional domain in their sequence may be responsible for the observed protease 
activity.  
PLC, PLA1 and PLA2 activity was also demonstrated previously [153-155] 
and has been thought to be a potential pathogenicity factor and contributor in adverse 




ureaplasma genomes computationally. Our attempts to detect PLC activity with a 
PLC commercial assay and by repeating the original experiments were unsuccessful.  
Studies involving clinical isolates of ureaplasma have revealed hyper-variable DNA 
regions that may potentially harbor genes aiding the pathogenicity of ureaplasmas 
[134] and chimeric ureaplasma isolates revealing overwhelming evidence of 
extensive horizontal gene transfer in these organisms [104], which can explain the 
cross-reactivity of sera. Taken together these findings suggest that there might be 
innumerable serovars or strains based on different combinations of horizontally 
transferred genes. Our comparative genome study has identified genes that could 
support horizontal gene transfer. These genes combined with the observed chimeric 
clinical isolates of ureaplasma suggest that these organisms possess active 
recombination mechanisms. Therefore, it is possible that ureaplasmas do not exist as 
stable serovars in their host, but rather as a dynamic population.  
We do know that UUR causes non-gonococcal urethritis in males and pelvic 
inflammatory disease (PID) and/or endometritis in pregnant women more frequently 
than UPA; however no other clinical outcome is significantly more associated with 
either species or a particular serovar [104, 189-194]. We cannot identify any clear 
gene or constellation of genes that might account for greater UUR virulence in some 
situations; although we do note a difference in the genes whose products are 
associated with resistance to H2O2, a known microbial pathogenicity factor. The 
widely different clinical outcomes of ureaplasmal infection could be the result of the 
presence or absence of potential pathogenicity factors in the colonizing ureaplasma 




either all or in part the result of patient to patient differences in terms of 
autoimmunity and microbiome. 
Future studies of ureaplasma biology should concentrate on the development of 
molecular tools for the generation of ureaplasma gene knock-out mutants for 
example, in order to study genes potentially involved in pathogenicity. The sequenced 
genomes can aid in the development of such tools, by identifying transposons, 
integrated phage genomes, and genes involved in horizontal gene transfer. To aid the 
identification of potential pathogenicity factors, the large collection of clinical 
isolates should be explored for presence/absence of candidate genes. Considering the 
low cost of sequencing nowadays, the genomes of isolates from patients with 
different conditions should be sequenced and their comparison should further aid the 
identification of genes involved in differential pathogenicity.  
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Chapter 3. Detection and Characterization of Human Ureaplasma 
Species and Serovars by Real-time PCR 
3.1 Abstract 
We designed primers and probes for detection and discrimination of Upa and 
UUR and their 14 serovars by real-time PCR. Analytical sensitivity and specificity 
for the multiplex species-specific PCR were determined by testing corresponding 
American Type Culture Collection (ATCC) type strains, 47 other microbial species, 
and human genomic DNA. The limits of the multiplex PCR were 2.8x10-2 CFU/µl 
PCR mixture for detecting U. parvum and 4.1x10-2 CFU/µl PCR mixture for detecting 
U. urealyticum. Clinical specificity and sensitivity were proven by comparison with 
culture and traditional PCR. For detection of any Ureaplasma species, the clinical 
sensitivity and specificity of real-time PCR were 96.9% and 79.0%, respectively, 
using culture as reference. Multiplex real-time PCR was more sensitive than 
traditional PCR in discriminating the two Ureaplasma species in culture-positive 
subcultures. Each of the 14 monoplex serovar-specific PCR assays was specific for 
the corresponding ATCC type strain serovar. The serovar-specific PCRs were 
compared with previous immunoblotting results using  monoclonal antibodies and 
results were in complete or partial agreement with serological methods for 35 (70%) 
of 50 isolates tested.  This new speciation PCR is specific and sensitive in detection 
of ureaplasma species in clinical specimens and the serovar-specific PCR assays are 




serovars. These assays provide quick and reliable means for investigating the 
epidemiology and pathogenicity of ureaplasmas at the serovar level.  
3.2 Introduction 
Shepard provided the first descriptions of T-strain mycoplasmas, now known 
as ureaplasmas,  in 1954 when he cultivated them in vitro from the urethras of men 
with nongonococcal urethritis [1], but the genus Ureaplasma was not formally 
designated until 1974 [195]. Ureaplasma urealyticum, eventually shown to be 
comprised of two biovars, was considered to be the only species of this genus known 
to infect humans until 2002 when its two biovars were reclassified as two distinct 
species, U. parvum and U.  urealyticum, based on genome size,  sequences of the 16S 
rRNA gene, the 16S-23S rRNA intergenic region, enzyme polymorphisms, DNA-
DNA hybridization, differential growth response to manganese, and differences in the 
multiple-banded antigen (mba) genes [7]. At least 14 serovars have been identified in 
human ureaplasmas; U. parvum contains serovars 1, 3, 6, and 14, while U. 
urealyticum contains the remaining 10 serovars 2, 4, 5, 7, 8, 9, 10, 11, 12, and 13 [7].  
The two Ureaplasma species can be isolated singularly or simultaneously 
from clinical specimens [11]. They are common opportunistic pathogens colonizing 
the urogenital tract in healthy persons, yet they are also implicated in invasive 
diseases, such as urethritis, post-partum endometritis, chorioamnionitis, spontaneous 
abortion, as well as premature birth, and low birthweight, pneumonia, bacteremia, 
meningitis, and chronic lung disease in prematurely born infants [11]. The reasons 




do not in others are still unknown although an intact functional humoral immune 
system appears to be very important as evidenced by the frequent occurrence of 
systemic ureaplasmal infections such as septic arthritis in adults and children with 
antibody deficiencies [11]. Speculations about the association of particular 
Ureaplasma species or serovars with certain diseases have provided incentive for 
investigations to develop accurate methods for determining the serovars of clinical 
isolates [11].  
Typing methods for Ureaplasma serovar designation using polyclonal or 
monoclonal antibodies (MAbs) directed against whole cells or purfied antigens have 
included growth inhibition tests [196, 197], metabolic inhibition tests [186], 
immunofluorescence of colonies on agar [198-200],  immunoperoxidase [201], 
enzyme-linked immunosorbent assay (ELISA) [6], and immunoblots [180, 202]. 
These antibody-based techniques are time-consuming, cumbersome assays that often 
yield results that are not reproducible, difficult to interpret and inconclusive because 
of multiple cross-reactions and poor discriminating capacity in clinical samples 
containing two or more serovars. Lack of commercial availability and standardization 
generally limited serotyping to those laboratories that developed the serological 
reagents. 
New rapid molecular methods based on genotypic instead of phenotypic 
markers are logical choices to replace the conventional antibody-based serotyping 
methods. PCR-based methods are also becoming an important alternative to 
conventional culture for initial detection of ureaplasmas in clinical specimens and 




[83]. The earlier gel-based traditional PCR assays for detection and speciation of 
human ureaplasmas targeted sequences of the 16S rRNA gene and 16S-23S rRNA 
intergenic spacer regions [83, 84, 86, 87], the urease gene subunit [81, 88], or the 
multiple-banded antigen (mba) genes [86, 89-92]. Major issues remaining to be 
resolved for traditional PCR are its specificity and analytic sensitivity, as well as 
potential for contamination. Real-time PCR assays targeting the urease gene [94-96], 
mba gene [93] and 16S rRNA [203]  have recently been developed to distinguish the 
two Ureaplasma species. Compared to traditional PCR and culture, real-time PCR 
speciation assays are quantitative, as well as more rapid, specific, sensitive and less 
subject to contamination [96]. However, some of  previously published real-time PCR 
assays available for ureaplasma speciation require two separate tests [95, 96] or do 
not have satisfactory sensitivity in one combined test [94]. 
To characterize the Ureaplasma species at the serovar level by PCR, 
genotyping primers based on the mba gene and its 5′end upstream regions have been 
designed previously and partial serovar identification was achieved.  In combination 
with direct sequencing or restriction enzyme analysis, these assays were capable of 
distinguishing the 4 serovars of U. parvum and divided the 10 serovars of U. 
urealyticum into different subgroups [89, 90, 96, 98, 204, 205]. Among these PCR 
serotyping methods, only one was real-time based [96].  Because of limited sequence 
variation in the mba genes, all PCR-based methods reported so far have lacked the 
capacity for complete separation of all 14 serovars. Moreover, our personal 
experience with whole genome sequencing of all 14 serovars has shown mba to be 




gene is phase variable [99]. Thus, while the mba gene is still in some cases a valid 
and in fact necessary target for serovar specific PCRs, attention must be given to the 
locations of phase variable forms of these genes so that PCR amplicons do not span 
recombination sites within these genomes. We evaluated the complete genome 
sequences for all 14 Ureaplasma serovars and designed primers and probes targeting 
new specific regions for speciation and serotyping by real-time PCR assays. One 
species-specific multiplex PCR and 14 serovar-specific monoplex PCRs were 
developed and assessed for analytical and clinical specificity and sensitivity.  
3.3 Material and Methods 
3.3.1 Bacterial strains and clinical specimens.  
Fourteen type strains for the Ureaplasma serovars designated in Table 3-1 
were obtained from the American Type Culture Collection (ATCC) and used to 
evaluate specificity and sensitivity of the multiplex speciation and monoplex 
serotyping assays. Twenty-one Mycoplasma and Acholeplasma species, 21 other 
bacterial species, 1 Candida species, 4 viruses, as well as human gDNA were tested 
by real-time PCR to determine specificity of the multiplex UU speciation assay. 
These organisms were selected based on probability to be in human samples and 
availability in our laboratory. Most of these microorganisms were from ATCC (live 
strains or DNA only), but some were clinical isolates. Mycoplasma amphoriforme 
was obtained from M.F. Balish (Miami University, Oxford, OH, USA). Viral DNA 
was obtained from Dr. Fred Lakeman (Department of Pediatrics, UAB). Human 










Ureaplasma species  Mycoplasma muris ATCC 33757 
U. parvum serovar 1 ATCC 27813 Mycoplasma neurolyticum ATCC 15049 
U. parvum serovar 3 ATCC 27815 Mycoplasma primatum ATCC 15497 
U. parvum serovar 6 ATCC 27818 Mycoplasma pulmonis A ATCC 19612 
U. paruvm serovar 14 ATCC 33697   
U. urealyticum serovar 2 ATCC 27814 Other Bacterial species  
U. urealyticum serovar 4 ATCC 27816 Bordetella pertussis ATCC BAA-589D 
U. urealyticum serovar 5 ATCC 27817 Burkholderia cepacia   ATCC 25416 
U.urealyticum serovar 7 ATCC 27819 Chlamydophila pneumoniae  clinical isolate 
U. urealyticum serovar 8 ATCC 27618 Corynebacterium diphtheriae  ATCC 10701 
U. urealyticum serovar 9 ATCC 33175 Enterobacter cloacae  clinical isolate 
U. urealyticum serovar 10 ATCC 33699 Enterococcus faecalis  ATCC 29212 
U. urealyticum serovar 11 ATCC 33695 Escherichia coli  ATCC 25922 
U. urealyticum serovar 12 ATCC 33696 Haemophilus influenzae  ATCC 23533 
U. urealyticum serovar 13 ATCC 33698 Haemophilus parainfluenzae  ATCC 7901 
  Helicobacter pylori  clinical isolate 
Human Mycoplasma species  Klebsiella pneumoniae  ATCC 33495 
Acholeplasma laidlawii PG 8 ATCC 23206 Legionella pneumophila  ATCC 33152 
Acholeplasma occuli ATCC 27350 Moraxella catarrhalis  ATCC 25240D 
Mycoplasma amphoriforme clinical isolate Neisseria gonorrhoeae  ATCC 49226 
Mycoplasma buccale ATCC 23636 Proteus mirabilis  ATCC 2798 
Mycoplasma faucium ATCC 25293 Pseudomonas aeruginosa  ATCC 27853 
Mycoplasma fermentans PG 18 ATCC 19989 Staphylococcus aureus  ATCC 29213 
Mycoplasma genitaliumPG37 ATCC 33530 Streptococcus agalactiae  ATCC 13813 
Mycoplasma hominis PG21 ATCC 23114 Streptococcus pneumoniae  ATCC 49619 
Mycoplasma lipophilum ATCC 27790 Streptococcus pyogenes  ATCC 19615 
Mycoplasma orale ATCC 23714 Streptococcus salivarius  ATCC 13419 
Mycoplasma penetrans  ATCC 55252 Candida species clinical isolate 
Mycoplasma pirum BER p9 clinical isolate   
Mycoplasma salivarium PG 20 ATCC 23064 Viruses  
Mycoplasma spermatophilum ATCC 49695 Adenovirus  clinical isolate  
  Buffalopox virus BP4 clinical isolate 
Non-human Mycoplasma 
species  Herpes simplex virus type 1 clinical isolate 
Mycoplasma arthritidis PG 27 ATCC 23192 Herpes simplex virus type 2  clinical isolate  
Mycoplasma collis ATCC 35278   






Three groups of clinical specimens or microorganisms maintained in the 
culture collection of the UAB Diagnostic Mycoplasma Laboratory were used in this 
investigation. They consisted of:  (1) 132  neonatal nasal or endotracheal aspirate 
specimens obtained between 2004 and 2007; (2) 194 low passage (< 3) Ureaplasma-
positive broth subcultures of neonatal nasal or endotracheal aspirates obtained 
between 1994 and 2003; and (3) 50 low passage (< 3) Ureaplasma-positive broth 
subcultures of placental specimens obtained between 1987 and 1991 and serotyped by 
immunoblotting using serotype-specific MAbs described previously [202]. Bacterial 
subcultures, clinical specimens, and ureaplasmal serological reagents were kept 
frozen at -80oC until processed for speciation and serotyping PCR assays. Cultures 
were performed as described by Waites, et al [206]. 
3.3.2 DNA preparation for PCR.   
Genomic DNA was extracted by the proteinase K method as described 
previously [207]. Briefly, 200 µl of broth subculture or 1 ml of clinical specimens 
was centrifuged at 14,000 g for 20 minutes at 4oC; pellet was digested with 200 µl 
proteinase K (1 mg/ml) lysis buffer for 1 hour at 60o C. Proteinase K was then 
inactivated by incubation at 95° C for 5 minutes. In case of inhibition, proteinase K 
digested samples were purified using QIAamp® DNA Blood Mini Kit (Qiagen, 
Valencia, CA). Genomic DNAs of 14 Ureaplasma serovar ATCC type strains were 





3.3.3 PCR Primers and Probes.  
Primer/probe sets were designed using Roche LightCycler Probe Design 
Software 2.0.  A multiplex real-time PCR was designed to differentiate the two 
Ureaplasma species simultaneously. The primers anneal to genes present only in U. 
parvum or U. urealyticum (Table 3-2). The U. parvum primer/probe set anneals to the 
477 bp UP063 gene (NP_077893), which encodes a conserved hypothetical protein 
that is identical in all 4 U. parvum serovars. The U. urealyticum primer/probe set 
anneals to a 15,072 bp open reading frame (ORF) that is almost perfectly (>99.97%) 
conserved in all 10 U. urealyticum serovars (serovar 10 Genbank ID ACI59931.1). 
The amplicon size of the two species was the same (152 bp).   
Table 3-2. Primers and probes for UU species-specific multiplex PCR assays 
 













UP063#1 Probe 1 tggtttaacgtgtttttgaagtgctacaaaat-FL 



















UU127#1 Probe 1 gataataacacttggacaatttttaaccaaagcga-FL 




To design the serovar-specific primers/probes, all 14 genomes were 
computationally searched to identify 25-35 base pair candidate regions that were 
unique to each genome. Each of the candidate region/loci sequences in a genome was 
then searched against all the other genomes and only those that had <80% identity 
matches were kept. The subsequent number of the primer loci to test varied in the 
different serovars, from 12 (serovar 12) to 1887 (serovar 9). Unique regions of the 
genomes comprised of mobile genetic elements, such as the transposon containing a 
tetracycline resistance marker in serovar 9, were not used as targets. We used the 
Roche LightCycler Probe Design Software 2.0 to analyze the regions around some of 
the unique 30 base pair regions and primers and probes were generated. Each possible 
primer was checked against all 14 UUgenomes using BLAST and less than 1 in 20 of 
the unique small regions yielded acceptable serovar-specific primers based on 
computational analysis. The resulting primers and probes shown in Table 3-3 were 
tested with the LightCycler using the 14 ATCC type stains. Most serovar-specific 
primers or primer/probe sets annealed to conserved hypothetical genes. The 
specificity of 8 serovars (serovars 2, 3, 6, 7, 8, 9, 13, and 14) came from the 2 primers 
while the other 6 were from probes, either Simple Probe Chemistry (SPC) probes 
(serovars 1, 5, 10, and 11) or fluorescence resonance energy transfer (FRET) probes 
(serovars 4 and 12).  Serovar 5 primers may also amplify the other 9 U. urealyticum 
serovars, however, the amplicon is much larger (668 bp versus 121 bp in serovar 5) 
and the probe has a large unmatched loop (547 bp) so this should not affect 
specificity. A short extension time that only allows complete amplification of serovar 




also be able to tell the differences of the products if unexpected amplification 
occurred. Urease-based primers and 32P-labled probes for Ureaplasma speciation by 
traditional PCR were described previously [208]. All primers were synthesized by 
Invitrogen (Carlsbad, CA) and probes were manufactured by Roche Diagnostics. 
Table 3-3. Primers and probes for UU serovar-specific monoplex PCR assays 
Primer names contain serovar number (ex. UP1- U. parvum serovar 1); MBA: 
Multiple Banded Antigen; CHP: Conserved Hypothetical Protein; 
Primer 
Name Sequence (5' to 3') Description 
UP1F1-2 GATAATTTGAATTATCAAACAGAAAAAGTG 
MBA 
UPA1_G0002                 
gcontig:11065013678
51 







UU2_F_1 CTTGTTGATAAGCAAAAGGATTAC putative lipoprotein UUR2_0261  
(gcontig_1118448734
166) 
Amplicon: 76 bp 
UU2_R_1 GTTTTGGTTCTGGATTGTTTGAC 
UP3F1-2  AATAATGCAAATTATGATGTTAAATTAACC CHP 
UPA3_0391/UU376 
(NC_010503) 
















Uu05-3F ATTATGAAAAATTAAACTCTCATTACTCG ATP-dependent RNA 
helicase   
UUR5_G0006   
(gcontig_1105469453
572) 











UP6R1 CCTGGTTCTTTACCTGGTTCTTTA   
(gcontig_1105428157
138) 






Amplicon: 58 bp 
UU7_R_1 TTATTAACTTCTTCCTTTGTTGTAAGTGTAGC 
UU8_F_1 AGTTTTAATTATTTCGTTGTTTAAGTAGC Intergenic   (gcontig_1118436613
429) 




UUR9_0160   
(gcontig_1105462525
206) 
Amplicon: 51 bp 
UU9_R_1  TATTGCCACACCAGCCAGCA 
UU10_F_4 TGCATCAACATCGCTAAATTCA 
MBA 
UUR10_0418       
(NC_011374) 















UUR12_A0390   
(gcontig_1105428175
482) 
Amplicon: 167 bp 
Uu12_1R ATTTAACACGATTAACATCTTCACGTTTA 
Uu12_1 







F_1: CHP                                                         




Amplicon: 90 bp 
13_R_1 AGAAAACGAGGAGGAATAAATAATGGATT 
UP14F1 TCCACACTACGGTAAGTAGTTT 
Intergenic   
gcontig_11064383280
52 





3.3.4 PCR conditions. 
Real-time PCR assays were performed on a Roche LightCycler 2.0 
instrument. An asymmetric PCR condition was used for the multiplex speciation 
PCR: PCR master mix contained less forward primers (0.3 µM of UP063#1F and 0.2 
µM of UU127#1F) than reverse primers (0.5 µM). Other components were: 0.15 µM 
of each UP probe, 0.2 µM of each UU probe, 0.5U of uracil-DNA glycosylase 
(UNG), 3mM of MgCl2, and 4 µl of 5X Multiplex DNA Master HybProbe buffer 
(Roche Diagnostics). A volume of 2 µl of the specimen was added to the master mix 
to reach a total reaction volume of 20 µl. PCR program was: 10 min pre-incubation at 
40°C and 95°C, then followed by 45 cycles of amplification: 95°C, 15s; 55°C, 10s, 
with single measurement; 72°C, 9s. Melting curves were generated by 95°C, 0s; 
65°C, 30s; 95°C, with slope rate 0.1°C/s and continuous acquisition mode. Finally the 
machine was cooled down to 40°C for 30s. PCR conditions for 14 monoplex serovar-
specific PCRs are summarized in Table 3-4 and Table 3-5. All 20 µl reaction volumes 
contained 0.5U of uracil-DNA-glycosylase (UNG) and 2 µl of specimen. Serovars 1, 
10, and 11 PCRs were asymmetric (Table 3-4). Every PCR program included a pre-
incubation procedure and final cooling procedure described above. Touchdown 
programs were designed for serovars 3, 5, and 8 to ensure specificity (Table 3-5). All 
PCR runs included a positive control that was the designated species or serovar being 
evaluated and a negative control (water). For speciation PCR assays, external 




each run. Urease gene-based traditional PCR conditions have been described 
previously [207].  
 




















Serovar 1 0.3 0.5 0.2  2  0.5 
Serovar 2 0.5 0.5   1 3.0 0.5 
Serovar 3 0.25 0.25   1 3.0 0.5 
Serovar 4 0.5 0.5 0.2 0.2 2  0.5 
Serovar 5 0.4 0.5 0.2  2  0.5 
Serovar 6 0.4 0.4   1 3.0 0.5 
Serovar 7 0.25 0.25   1 3.0 0.5 
Serovar 8 0.25 0.25   1 3.0 0.5 
Serovar 9 0.25 0.25   1 3.0 0.5 
Serovar 10 0.3 0.5 0.15  2  0.5 
Serovar 11 0.2 0.5 0.2  2  0.5 
Serovar 12 0.5 0.5 0.2 0.2 2  0.5 
Serovar 13 0.4 0.4   1 3.0 0.5 
Serovar 14 0.5 0.5     1 3.0 0.5 
a1 = LightCycler® FastStart DNA Master SYBR Green I, 2 µl  
a2 = LightCycler® FastStart DNA MasterPLUS HybProbe, 4 µl 
b Addition MgCl2 added   





Table 3-5. Amplification program of monoplex serovar-specific PCR assays 
Serovar Amplification Program Melting Range 
1 95°C, 1"; 55°C, 10", "Single” acquisition; 72°C, 4". 45 cycles. 50°C - 70°C 
2 95°C, 0"; 57°C, 4"; 72°C, 2", “Single” acquisition. 45 cycles. 65°C - 95°C 
3 
Amplification I: 95°C, 0"; 57°C, 5". 15 cycles. Amplification II: 
95°C, 0"; 57°C, 3"; 2nd target 53°C, 1°C/step, delay 1 cycle; 
"Single” acquisition. 45 cycles. 
65°C - 85°C 
4 95°C, 10"; 55°C, 6",  “Single” acquisition; 72°C, 5". 45 cycles. 50°C - 80°C 
5 
Amplification I: 95°C, 2"; 57°C, 6"; 72°C, 2". 10 cycles. 
Amplification II: 95°C, 5"; 57°C, 8"; Ramp rate=5°C/s; 2nd 
target 54°C, 1°C/step, delay 1 cycle; “Single” acquisition; 72°C, 
3 ". 45 cycles. 
50°C - 70°C 
6 95°C, 0"; 58°C, 2"; 72°C, 1",  “Single” acquisition. 40 cycles. 63°C - 90°C 
7 95°C, 0"; 55°C, 1",  “Single” acquisition. 40 cycles. 65°C - 95°C 
8 
Amplification I: 95°C, 0"; 66°C, 5". 15 cycles. Amplification II: 
95°C, 0"; 66°C, 2"; 2nd target 58°C, 1°C/step, delay 1 cycle; 
72°C, 1",  “Single” acquisition. 40 cycles. 
66°C - 95°C 
9 95°C, 0"; 62°C, 1",  “Single” acquisition. 33 cycles. 70°C - 95°C 
10 95°C, 2"; 56°C, 5",  “Single” acquisition; 72°C, 2". 45 cycles. 55°C - 75°C 
11 95°C, 2"; 53°C, 10", Ramp rate=5°C/s, “Single” acquisition; 
72°C, 4". 50 cycles. 54°C - 75°C 
12 95°C, 10"; 59°C, 5",  “Single” acquisition; 72°C, 6". 45 cycles. 50°C - 80°C 
13 95°C, 0"; 57°C, 2"; 72°C, 2",  “Single” acquisition. 40 cycles. 63°C - 90°C 







3.4.1 Analytical specificity and sensitivity of Ureaplasma species-specific 
multiplex PCR.  
Using genomic DNA of each of 14 ATCC Ureaplasma serovar type strains as 
template, our multiplex real-time PCR run on a LightCycler 2.0 instrument 
differentiated U. parvum and U. urealyticum in two different channels without any 
cross reactions. All serovars within the two respective species were recognized 
(Figure 2-1). Species-specific amplification was successful in the presence of high 
copy numbers of the other Ureaplasma species (1:100 ratio, data not shown).  No 
cross reactivity was detected in any other microorganisms listed in Table 3-1. 
To test the detection limits of the assay, genomic DNA was prepared from 
1:10 serial dilutions of broth cultures for U. parvum and U. urealyticum, using U. 
parvum serovar 3 and U. urealyticum serovar 10 as representatives, respectively. The 
detection limits for the U. parvum assay were 2.8 x 10-2 CFU/µl PCR mixture; for U. 






Figure 3-1. Ureaplasma species-specific multiplex real-time PCR assays 
Amplification curves for Ureaplasma species-specific multiplex real-time PCR assays 
tested against 14 ATCC serovar type strains demonstrating simultaneous distinction 






3.4.2 Comparison of species-specific multiplex PCR with traditional PCR 
and culture. 
The species-specific multiplex PCR assay was evaluated in two groups of 
archived clinical specimens/subcultures in order to include comparison with both 
culture and traditional PCR. Among 132 clinical specimens in group 1, there were 32 
(24.2%) culture-positive for Ureaplasma spp. and 100 (75.8%) culture-negative. The 
multiplex speciation PCR detected 52 (39.4%) UU-positive samples and designated 
80 (60.6%) as negative. Thus, PCR detected 20 (15.2%) more positive samples than 
culture. There was only one culture-positive specimen that was negative by real-time 
PCR and the numbers of organisms in that specimen were < 10 CFUs/ml. Using 
culture as the reference standard, real-time PCR had a sensitivity of 96.9% and a 
specificity of 79.0%. Among 194 UU-positive subcultures from clinical specimens, 
traditional PCR detected 176 positives and 18 negatives, whereas the multiplex real-
time PCR detected 188 positives and 6 negatives. Thus, the multiplex real-time PCR 
reduced the false-negative rate compared to traditional PCR from 9.3% to 3.1%. The 
specimens’ DNA used for this study was originally isolated in 2004, so it is possible 
that degradation occurred over time to account for the fact that some culture-positive 
specimens were PCR-negative when retested for the present evaluation. Among the 
175 subcultures positive by both PCR methods, 116 (66.3%) contained only UPA 54 
(30.9%) contained only UUR, and 5 (2.9%) contained both species by traditional 
PCR; for multiplex speciation PCR, 115 (65.7%) contained only UPA, 48 (27.4%) 
contained only UUR, and 12 (6.9%) contained both species.  Overall, real-time PCR 




3.4.3 Analytical specificity and sensitivity of serovar-specific real-time 
PCR assays.  
Real-time PCR assays specific for 14 UU serovars were developed for the 
ATCC type strains and the specificity of each PCR was tested against the 13 other 
serovar type strains. Each individual PCR assay amplified the designated serovar but 
none of the other 13 serovars (Figure 3-2). For PCRs with primers only (serovars 2, 3, 
6, 7, 8, 9, 13, and 14), the primer concentrations were between 0.25-0.5 µM; for 
PCRs that required a combination of primers and probes, asymmetric PCR conditions 
were used (except for serovars 4 and 12). The annealing time of all programs was 
kept as short as possible, especially for the 8 primers only programs, which could be 
as short as 1 second (serovars 7 and 9). The annealing temperatures were kept as high 
as possible to ensure the specificity of each PCR. Touch-down programs containing a 
short amplification step at stringent conditions prior to the major amplification 
program were developed for serovars 3, 5 and 8 to improve the specificity.  After 
amplification, a melting curve analysis was performed for each PCR providing 
additional proof of differentiation power.  The detection limits of the serovar-specific 
PCR assays ranged from 15 (serovar 6) to 3,461 (serovar 9) DNA molecules/μl of 
PCR mixture. No evaluation was performed directly on broth subcultures to 
determine the limit of CFU detection as was done for the species specific multiplex 
PCR assay, and these assays were not tested directly for specificity against other 
microbial species since their utility is primarily in the testing of isolates or clinical 





Figure 3-2. Monoplex serovar-specific PCR assays 
Amplification curves for monoplex serovar-specific PCR assays tested individually 
with all 14 Ureaplasma sp. serovar (Sero) type strains demonstrating specific 







Taking advantage of the genomic sequence data now available for all 14 
Ureaplasma serovars, our multiplex real-time PCR assay, for simultaneous detection 
and discrimination of the two UU species, targets two conserved hypothetical protein 
gene sequences (UU063 in UPA strains and UUR10_00554 in UUR strains), each 
present only in UPA or UUR. This differs from previously reported assays for 
Ureaplasma speciation that target small differences within genes conserved in both 
species. The specificity of this assay was ensured computationally and experimentally 
verified by BLAST analysis and running the assay against a broad range of other 
microorganisms.  
Compared to culture and traditional PCR, our findings using a single step 
multiplex assay format agreed with those of Cao et al. [93] who found the real-time 
PCR to be the most sensitive in detection of UU species. The detection threshold of 
our assays is well below the level necessary to detect ureaplasmas in clinical 
specimens and our multiplex PCR detected UU spp. in 15.2 %  more clinical 
specimens than culture in a direct comparison using optimum cultivation methods 
developed and validated in our laboratory over several  years [206]. Even though 
culture is often considered the reference method for detection of ureaplasmas in 
clinical specimens, improved PCR assays may be inherently more sensitive and 
capable of detecting the organisms in very low numbers. Thus, the PCR-positive and 
culture-negative specimens we encountered may in fact be true positives rather than 




ureaplasmas in clinical specimens depends on the PCR target, assay conditions, and 
the method of culture used. Numerous studies have shown clearly that PCR assays 
can be superior to culture [11, 207, 209-211]. However, even though PCR has the 
added potential advantages of providing UU species identification and same-day 
turnaround without the necessity of maintaining organism viability, culture is 
relatively simple and can often provide results in 24 to 48 hours. Compared to 
traditional PCR, the new multiplex real-time PCR greatly reduced the false negative 
rate in detection of UU species as defined by culture positivity, making this assay 
even more attractive than traditional PCR in this setting. 
Yi et al. [94] developed a real-time PCR assay to simultaneously detect and 
discriminate the two UU species in a single test with one pair of common primers for 
both species and two species-specific TaqMan probes. This assay, however, lacked 
analytical sensitivity and the clinical sensitivity was lower than traditional PCR. In 
contrast, our multiplex real-time PCR found a total of 6 more UPA alone or in 
combination than with our traditional PCR, and 1 additional UUR. No other studies 
have provided a quantitative comparison of species differentiation using real-time 
PCR versus traditional PCR. 
Molecular genotyping methods based on the mba gene and its 5′-end have 
been explored as a replacement of the antibody-based phenotyping methods [86, 89, 
90, 96, 98, 212, 213] that have been in use for more almost three decades since the 
original description of the 14-member serotyping scheme by Robertson and Stemke 
in 1982 [5]. However, using the sequence data available for previous genotyping 




parvum were readily differentiated from each other, by traditional PCR with different 
sets of primers [89] or by two multiplex real-time PCRs [96]. However, to distinguish 
the 10 serovars of U. urealyticum is still challenging. Using single-stranded 
conformation polymorphism (SSCP) analysis, the 10 serovars were divided into 2 
groups: A (serovars 2, 5, 8, and 9) and B (serovars 4, 7, 10, 11, 12, and 13) [213]. By 
PCR and sequencing, Kong et al. [86] classified the 10 serovars into 3 subgroups: 1 
(serovars 2, 5, 8, and 9), 2 (serovars 4, 10, 12, and 13), and 3 (serovars 7 and 11). The 
same investigators then provided a better discrimination by dividing the 10 serovars 
into 5 MBA genotypes with the added individual separation of serovars 9 and 10: A 
(serovars 2, 5, and 8), B (serovar 10), C (serovars 4, 12, and 13), D (serovar 9) and E 
(serovars 7 and 11) [89].  This approach using just the sequence of an mba gene 
specific to each serovar should be reconsidered in light of the whole genome 
sequences that show all UU serovars encode multiple members of the phase variable 
mba gene family.  
In designing our serovar-specific real time PCR assays, we sought to avoid the 
mba gene family because of its ubiquity within the ureaplasmas and because of its 
phase variability. This intent was thwarted by the high inter-serovar identity among 
the 14 serovars. The average difference among the 4 UPA genomes is 0.56%, and 
among the 10 UUR genomes the average is 0.63%. While it is straightforward to 
design PCRs for discrimination of any pair of serovars, discrimination of one serovar 
from the other 13 is often very challenging. We sought to have all assays employ 
primers and probes; however in many cases this was not possible. We were even 




paralogous gene family genes as shown in Table 3. In those instances, we made sure 
our PCR targets did not span sites at which chromosome rearrangements took place 
during phase variation. Those sites could be identified by analyzing whole genome 
shotgun sequencing assemblies. By computationally searching thousands of unique 
loci in each serovar and testing with 14 ATCC type stains, we created PCRs specific 
to all 14 serovars without any cross reactions. Many PCRs predicted to be serovar-
specific failed when tested and were abandoned. Ultimately, each serovar 
primer/probe set shown in Table 3 contains at least one serovar specific primer or 
probe. In the cases where the set could cross-react, leading to significantly larger 
amplicon, the PCR conditions were adjusted to prevent it. The PCRs are sensitive in 
detecting each specific serovar with detection limit of 15-3,500 molecules/PCR 
mixture. The strategy to multiplex the 14 PCR assays which should be more efficient 
was not used because each PCR condition was unique and combination with another 
assay compromised specificity and sensitivity of one or both assays (data not shown). 
The real-time PCR-based typing results were in partial or full agreement with 
antibody-based results from immunoblotting for 35 of 50 (70%) clinical isolates 
analyzed by both methods. Discrepant results could be classified into four major 
groups: Group 1 included 6 isolates showing PCR-positive serovars but immunoblots 
were negative or non-typeable. The PCR serovars all belonged to their corresponding 
species determined by the multiplex speciation PCR suggesting that PCR typing is 
more sensitive than serological typing. Group 2 discrepant results involved those 
serovars determined by the two methods to belong to different species. One isolate 




PCR. PCR speciation showed it was U. urealyticum. Another isolate was pure serovar 
6 (UPA) by immunoblot but contained PCR serovars 4 and 8. PCR speciation also 
indicated it was UUR. The reasons for this complete non-agreement could not be 
explained other than the possibility that several years of storage could have 
influenced PCR assays performed at a later time. In these cases, our new real-time 
multiplex PCR speciation and real-time monoplex PCR typing still agreed with each 
other, indicating the reliability of our real-time PCR methods. Group 3 discrepant 
results involved detection of different, non-overlapping serovars within the same 
species.  Six isolates (3 UPA and 3 UUR), showed such differences. Group 4 
discrepant results were those found in 9 isolates  in which both methods partially 
agreed with each other, i.e., isolates containing multiple serovars had at least one 
common serovar detected by two methods, but the rest were different. These findings 
might be explained by the changes of relative bacterial populations in mixed cultures 
stored for long periods or differences in the specificity and sensitivity of the PCR 
versus antibody-based methodologies [213].   
Considering the discrepancy between the typing methods, it is important to 
point out that the reference strains used to develop MAbs and PCR primers/probes 
were different. The MAbs were produced against reference strain collections that 
were different from the type strains used for PCR development that were purchased 
directly from ATCC in 2006. The original whole genome sequences of serovar 3 from 
a representative UAB strain [8] and ATCC serovar 3 type strain 27815 were slightly 
different. Genetic variations of clinical isolates from reference strains might be 




previously developed MAbs to serotype the 50 placental isolates against the 14 
ATCC serovar type strains. For example, the UAB strain serovar 1-specific MAb,  
cross reacted with ATCC serovars 3 and 10 (ATCC 37815 and ATCC 33699), (data 
not shown). The complexity of variations in nucleotide sequences of a certain gene or 
region, which were the bases of molecular genotyping methods, is not the same as 
that of antigen-antibody reactions, which were the bases of serological typing 
methods. Thus, a complete correlation between the two methods could not be 
expected. This was also the same in PCR-single strand conformation polymorphism 
analysis typing [213]. 
A single clinical isolate of UUR that was determined by multiplex speciation 
PCR was not typeable by either method, possibly representing a new serotype. The 
old 14-member-serotyping scheme may need to be revised if additional unknown 
subtypes are found by the new 14-PCR-based genotyping method when larger 
numbers of clinical isolates are analyzed. Sequence analysis may provide more 
information about such untypeable isolates. 
In conclusion, our new multiplex real-time PCR for detection and 
discrimination of UU species is robust, ready to replace the traditional PCR for 
clinical diagnostic purposes, and is a suitable alternative to culture.  We have shown 
for the first time that all 14 serovars of UU can be clearly differentiated from each 
other using real-time PCR technology. This should greatly facilitate future 
investigations of differential pathogenicity of ureaplasmas at the species and serovar 
level in clinical conditions when studying clinical isolates of UU species. Our data 




sensitivity and specificity using type strains and clinical isolates. We did not evaluate 
clinical specimens directly. Ideally, a serotyping method should be sufficiently 
sensitive to use in this manner. The analytical sensitivities we obtained suggest our 
assay should meet the requirements for direct testing of clinical specimens that may 
contain serovars alone or in combination. Proof of this will require additional clinical 
studies. 
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Chapter 4. Extensive horizontal gene transfer in UU questions the 
utility of serotyping for diagnostic purposes 
4.1 Abstract 
UPA and UUR are sexually transmitted, opportunistic pathogens of the human 
urogenital tract. There are 14 known serovars distributed between the two species. 
For decades it has been postulated based upon limited data that virulence is related to 
serotype specificity. Results were often inconclusive due to small sample size and 
extensive cross reactivity between certain serovars. We developed real-time 
quantitative PCRs that allow reliable differentiation of the type strains of each of the 
14 serovars.  To investigate species and serovar distribution, we typed 1,061 clinical 
isolates of human ureaplasmas from diverse patient populations. There was only a 
tenuous association between individual Ureaplasma serovars and certain patient 
populations. This may in part be explained by the fact that almost 40% of the isolates 
were genetic mosaics, apparently arising from recombination of multiple serovars. 
This explains the extensive cross-reactivity based upon serotyping and the lack of 
consistent association of given serotypes with disease.  
4.2 Introduction 
It has been speculated for many years that individual Ureaplasma species or 
serovars might be associated with certain diseases more than others, as is the case for 




Although several studies reported that U. urealyticum is more pathogenic than U. 
parvum [84, 216-220], conflicting results have been found by others [208, 221], so it 
is possible that differential pathogenicity might exist at the serovar level rather than at 
the species level. Inconsistent results implicating specific serovars (or serovar groups) 
with various clinical conditions [4, 196, 205, 222-225] coupled with frequent 
detection of Ureaplasma isolates comprised of more than one serovar have also been 
frequently reported [222-224, 226, 227]. Differing results among investigations could 
also be related to inadequate or imprecise typing methods. The possibility that 
individual Ureaplasma isolates may express multiple serovar specificities has been 
suggested, but never investigated in a systematic manner due to the technical 
difficulty of separating all of the 14 serovars [222, 227]. 
Two major methodologies to classify Ureaplasma isolates to the species and 
serovar levels have been described. Antibody-based phenotyping methods included 
growth/metabolism inhibition tests [186, 196, 197] antibody-linked epi-
immunofluorescence or color reaction assays[199, 201, 228, 229]. These methods 
yielded inconclusive results because of multiple cross-reactions and poor 
discriminating capacity. Cross-reactions have been observed even in certain serovar 
reference strains [5]. Molecular genotyping methods were more rapid and accurate, 
readily separating the two Ureaplasma species [83, 88, 93-95]. However, due to 
limited sequence variation in the PCR targets, only partial separation of serovars was 
achieved [86, 89, 90, 96, 98]. Recently we developed a set of Ureaplasma species- 
and serovar-specific real-time PCR assays that separate completely all 14 ATCC 




The improved specificity of real-time PCR compared to conventional PCR is 
mainly due to the use of a third oligonucleotide called a probe that binds to the target 
sequence. Usually, the probe is designed to correspond to a sequence located between 
the forward and reverse primers. Generally, the probe is labeled with a fluorophore 
and a quencher. When the quencher is in close proximity to the fluorophore, the 
fluorescence is inhibited or emitted at a different wavelength. Utilizing a 
fluorescently labeled probe allows a signal to be detected by the instrument only if the 
probe has annealed to its complementary target sequence and the DNA polymerase 
has amplified the target region therefore increasing the distance between the quencher 
and the fluorophore. The use of a labeled probe minimizes the probability of cross-
reaction and detection of undesired amplicons. Such probes are also specifically 
useful when differentiating very closely related organisms is desired, as is the case of 
determining which of the 14 Ureaplasma serovars are present in a clinical specimen. 
Another feature of real-time PCR that contributes to the specificity of the assay is that 
the amplicon melting temperature is determined at the end of the assay, and can be 
used to verify whether the desired PCR product is being detected.  
Analytical sensitivity, can also be improved when using real-time PCR assays.  
PCR sensitivity depends on many factors including DNA extraction method, selection 
of primers, selection of visualization method, and reaction conditions. In addition to 
those factors, real-time PCR diagnostic assays are often designed to produce shorter 
amplicons with an optimal length of under 300bp compared to conventional PCR 
[85]. The smaller the amplicon the more efficient is the PCR reaction and the lower 




primer selection and optimization of reaction conditions, an increased sensitivity of 
real-time PCR may observed compared to assays designed for conventional PCR 
[81]. 
Real-time PCR is faster than conventional PCR mainly because of the 
elimination of post-cycling amplicon handling and more efficient instrumentation. 
The fact that real-time PCR is a closed reaction from beginning to end minimizes the 
risk of errors due to amplicon contamination causing false positive assays. Data 
generated in the real-time PCR assay is analyzed automatically by computer software 
specially designed for the instrument being used such that no gel electrophoresis is 
necessary. These features have contributed to the introduction of real-time PCR into 
clinical laboratories much faster than conventional PCR [84].  Furthermore, the 
current real-time PCR platforms usually have faster temperature ramps (as fast as 
20ºC/sec in the Roche LightCycler) than conventional thermocyclers, which 
additionally shortens the time required for the procedure. Conventional PCR methods 
for detection of Ureaplasma spp. can take between 2-3 days, about the same 
turnaround time as culture, whereas real-time PCR can potentially provide results the 
same day a specimen is received. Since organism viability does not have to be 
maintained for PCR-based detection, specimen collection, handling, and transport for 
Ureaplasma detection by PCR is much simpler than for culture.   
An added bonus of real-time PCR over conventional PCR is that real-time 
PCR can be used to quantitate the starting amount of DNA molecules and therefore 
the pathogen load of the patient can be estimated. This is especially useful when 




be harmful when their load is higher than normal. In such cases a qualitative positive 
result from conventional PCR may not be sufficient to decide whether a person needs 
medical treatment. Theoretically, each commensal organism can have its own 
established cycle threshold (Ct) or cross point (Cp) values range in which it would be 
considered harmless based on accumulated clinical data. The lower the Ct or Cp value 
the higher the load of the organism in the patient.  
Horizontal gene transfer (HGT) plays an important role in microbial 
adaptation, speciation, and evolution [231]. Although mycoplasmas and ureaplasmas 
are characterized by their minimal genomes and are thought to have undergone 
regressive evolution, which usually is not favorable for active DNA acquisition [232], 
evidence has shown that HGT occurs among phylogenetically distinct mycoplasmal 
species sharing the same ecological niche [233] or within the same species [234]. 
Comparative genomic analyses have indicated possible HGT between U. parvum and 
Mycoplasma hominis [235]. Ureaplasma spp. have also been shown to form biofilm 
[236], structures thought to promote DNA exchange among other bacteria. 
Furthermore, recombinases, transposases and putative conjugative transposon 
mobilization proteins have been identified in genomes of the 14 Ureaplasma 
serovars[237]. These findings raise the question of whether HGT occurs among 
Ureaplasma serovars and its potential implications for the hypothesis of differential 
pathogenicity at the serovars level. 
Using Ureaplasma species- and serovar- specific real-time PCR assays that 
we recently developed and validated [230], we analyzed a large number of clinical 




classify them to species and serovar in order to investigate differential pathogenicity 
at these two levels. Initial evaluation of the results suggested the likelihood of HGT 
between species and among serovars, and prompted additional investigations. 
4.3 Materials and Methods 
4.3.1 Bacterial isolates 
Reference strains for the 14 Ureaplasma serovars were obtained from the 
American Type Culture Collection (ATCC) and used as the controls in serovar-
specific PCR assays. The 1061 unique clinical isolates evaluated for species and 
serovar distributions were obtained from cultures collected and stored frozen at -80°C 
or in lyophilized form dating from the late 1970s to 2009. Isolates originated from 
Alabama and various other states within the continental United States and from 
Alberta, Canada in the patient groups described in Table 4-1. Ureaplasmas recovered 
from clinical specimens were initially identified to genus level by standard methods 





Table 4-1. Description of Ureaplasma clinical isolates 
Specimen Type Group Description No. Isolates 
Control groups   
vaginal swabs healthy pregnant females  169 
placental tissue collected at 
cesarean section in women 
with intact fetal membranes 
females without histologic 
chorioamnionitis  42 
catheterized urine male with neurogenic bladder without urethritis  25 
endotracheal aspirate preterm infants without bronchopulmonary dysplasia (BPD)  108 
Diseased groups   
endometrial biopsy tissue 
females with pelvic inflammatory 
disease (PID) and/or post-partum 
endometritis 
85 
placental tissue collected at 
cesarean section in women 
with intact fetal membranes 
females with histologic 
chorioamnionitis 18 
endotracheal aspirate preterm infants with bronchopulmonary dysplasia (BPD) 88 
urethral swab or urine males with non-gonococcal urethritis (NGU) from Canada 421 
urethral swab or urine males with non-gonococcal urethritis (NGU) from USA 81 
blood, cerebrospinal fluid, 
synovial fluid, pleural fluid, 
lung tissue 
invasive isolates from various 
patient groups including adults and 
children 
24 






4.3.2 DNA preparation 
Genomic DNA was extracted from all 1061 clinical isolates by the proteinase 
K method as described previously [207]. Inhibited samples were further purified by 
QIAamp® DNA Blood Mini Kit (Qiagen, Valencia, CA). Prepared DNA samples 
were stored at -80°C unless submitted immediately for PCR assay.  
4.3.3 Genotyping of clinical isolates by PCR 
The clinical isolates were first classified to species level using a multiplex 
species-specific real-time PCR assay for which primers, probes, reagents and PCR 
conditions have been previously described [230]. UPA and UUR  isolates were then 
typed for their corresponding serovars by a series of serovar-specific real-time PCR 
assays [230]. In the event that isolates were negative for any serovars within their 
corresponding species, additional PCR assays for serovars of the other species were 
performed. A designated ATCC type strain control and a negative control (distilled 
water) were included in every PCR run.  Untypable isolates were subjected to a 
secondary PCR assay targeting the urease gene [88]. The species- and serovar-
specific PCR assays were performed using a LightCycler 2.0 (Roche, Indianapolis, 
IN) 
4.3.4 Separation of isolates containing multiple serovars 
Four isolates shown to contain multiple serovars by real-time PCR were 
thawed and incubated in 10B broth overnight. The broth cultures were then filtered 




colonies were readily visible under a stereomicroscope at 126X magnification. At 
least 10 single colonies from each isolate were removed with a sterile needle or 
pipette tip for individual overnight cultures in 10B broth. DNA was then isolated 
from each broth culture and prepared for PCR assay as described above. 
4.3.5 Quantification of each serovar in clinical isolates to distinguish 
mixtures from hybrids 
To quantify each serovar marker in isolates containing multiple serovars, a 
universal control plasmid, pUC19-UU, which carries one copy of each serovar 
marker (except for markers of serovars 4 and 5, which were not able to be stably 
incorporated into the plasmid), was constructed and used to generate an external 
quantification standard curve. Briefly, the RT-PCR assay target for each serovar was 
PCR amplified from extracted gDNA so that the amplicons overlapped each other in 
order to be assembled and cloned into the multi cloning site of pUC19 using the GA 
method. For this each to forward primer  an overhang sequence was added 
complementary to the end of the upstream target, so that the total primer length is 
60nt. Serovar-specific PCRs were performed on 271 randomly selected isolates 
containing multiple serovars (except serovars 4 and 5) and quantities of each serovar 
were calculated. When comparing two serovars, based on the largest calculated 
quantity difference of the pUC19-UU plasmid control between PCR runs, an arbitrary 
differentiation standard was made: an equal or less than 5X difference was considered 




(hyb/mix); any difference greater than 10X was considered to represent a mixed 
culture; if both serovars were in low quantity, it was designated as undetermined. 
4.3.6 DNA Sequencing 
A total of 7 clinical isolates, each containing two serovar markers were 
selected for polymorphic loci analysis by Sanger DNA sequencing. Isolates 10902 
and 97078 contained serovars 1 and 6; isolates 10901 and 8510 contained serovars 3 
and 6; isolates 24318 and 25353 contained serovars 9 and 10. For each pair of 
serovars, 7-10 loci throughout the genome that contained multiple base pair 
polymorphisms between each serovar pair were selected. PCR primers were designed 
to amplify from both serovars across the region containing the polymorphism of 
about 700-800bp. Loci were selected to be gene coding, have at least 90% identity 
and 20 or more mismatched nucleotides by BLASTn analysis (Table S 1).The mba 
gene of UPA3 and UPA6 was sequenced by primers flanking the whole mba gene 
region. Serovar-specific PCR primer regions of serovars 9-12 were also amplified and 
sequenced. PCR was performed using a Veriti 96 well thermal cycler (Applied 
Biosystems, CA). DNA sequencing was performed in the University of Alabama at 
Birmingham Heflin Center Genomics Core Facility. DNA sequences were analyzed 
using CLC DNA workbench 5. 
We sequenced the genomes of four U. urealyticum patient isolates that we 
could not identify on the serovar level using 454 pyrosequencing (454 Life Sciences, 
Branford, CT). The genomes were assembled using the Newbler Assembler (454 Life 




urealyticum genomes by generating dot plots. Sequencing was done at the J. Craig 
Venter Institute.  
4.3.7 Statistical Analysis 
Fisher exact and χ2 test were performed to compare the distributions of UU 
species and serovars in different patient populations. A p value of < 0.05 was 
considered statistically significant. Analyses were conducted using SAS software 
(SAS Institute Inc., Cary, NC) and SPSS 16.0 (SPSS Inc., Chicago, IL). 
4.4 Results and Discussion 
4.4.1 Species and serovar distributions of isolates from different patient 
populations 
Of 1061 unique clinical isolates that were typed, UPA was detected in 508 
(48%) isolates, UUR was detected in 406 (38%) isolates and both species were 
detected in 140 (13%) isolates. The remaining 7 isolates (1%) could not be typed to 
species level by real-time PCR. However, one of them was positive for UUR using a 
PCR targeting the urease gene [88]. The prevalence of UUR was significantly 
increased in isolates from endometrial biopsy tissues from women with pelvic 
inflammatory disease (PID) and/or endometritis (33% vs 14%, p < 0.01) in 
comparison to vaginal swabs from healthy pregnant women. It was also more 
common in American men with NGU when compared to men without urethritis (68% 
vs 48%, p < 0.05). No association of either UU species was found in placentas of 




or without chronic lung disease of prematurity or among the 24 invasive isolates. 
Canadian men with NGU had a significantly higher percentage of mixed species than 
US men (26% vs 6%, p = 0.001); however, the difference might merely reflect 
methodology/isolation procedures.  
The 14 serovars were distributed unevenly in all groups: serovar 3 was most 
common (332) and serovar 5 was least (19) when counting the presence of any 
serovars in all 1061 isolates (Table 4-2). When comparing the prevalence of serovars 
in diseased groups with their corresponding controls, no consistent patterns 
implicating individual serovars were observed. Serovars with significantly increased 
prevalence in diseased groups were: serovars 5, 8 and 11 in the PID/endometritis 
group, serovar 6 in the chorioamnionitis group, serovar 9 in US men with NGU, and 
serovar 10 in neonates in the BPD group. Among the 24 invasive isolates, serovar 3 
was most common, occurring in 7 (29%) isolates. The serovar distribution between 
NGU isolates from US and Canadian men was significantly different, indicating 





Table 4-2. Species and serovar distributions of clinical isolates  
Notes: Numbers in parenthesis are percentage;   a p≤ 0.01; b p<0.05, compared to the 
corresponding controls; c one isolates was U. urealyticum determined by a secondary 
PCR test;  * p=0.001; Up, U. parvum; Uu, U. urealyticum; spp., species; sv, serovar; 
PID, pelvic inflammatory disease; NGU, nongonococcal urethritis; BPD, 





4.4.2 Isolates that were negative for all serovar-specific assays 
There were 67 (6%) isolates that could not be assigned to any of the 14 known 
serovars by PCR.  To ascertain why these isolates were negative in all of our serovar-
specific assays, we did whole genome shotgun sequencing of 4 of these isolates. 
Genome analysis showed isolates 2033 and 2608 are most closely related to serovar 
12 and 4. The ATTC serovars 12 and 4 were the closest related serovars among the 
urealyticum group. Isolate 4155 was most similar to serovar 11, whereas isolate 4318 
was most similar to serovar 2. Relative to the ATCC reference strains, all of the 
isolates’ genomes had some minor genome rearrangements, areas that were deleted, 
and some areas that were inserted and are new for the urealyticum group. Analysis of 
the target areas for the serovars-specific PCR assays showed that the target was either 
missing completely, or some of the target was missing or modified so that one of the 
primers would not bind. However, it is clear that these isolates have changes in other 
areas of the genome as well. Whether we can assign new serovar numbers to any of 
the unidentifiable isolates is a matter of clarifying the requirements for a ureaplasma 
to be considered a specific serovar.  
4.4.3 Isolates containing multiple serovars and conflicting serovars 
Multiple serovar markers were detected in 413 (39%) isolates, predominantly 
U. urealyticum (201) and mixed species (124) (Figure 4-1). Among them, 223 (21%) 
isolates contained 2 serovar markers, 91 (9%) isolates contained 3 serovar markers, 
and 99 isolates (9%) contained 4 or more serovar markers. The maximum number of 




marker numbers per isolate did not show significant differences between control and 
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Figure 4-1. Clinical isolates containing multiple serovars and untypable serovars. 
Clinical isolates containing multiple serovars and untypeable serovars. A total of 
1061 clinical isolates were typed to species and then serovar level by real-time PCR. 
In the event isolates were determined to be negative for any serovars within their 
designated species, additional PCR assays for serovars of the other species were 
performed. Untypeable isolates (0-sv, negative for any serovar; 0-spp, negative for 
any species) were subjected to a secondary PCR assay targeting the urease gene to 




Discordant typing results were observed in 42 isolates. Three isolates typed as 
U. parvum; however their serovar markers belonged to U. urealyticum; on the other 
hand, 15 isolates typed as U. urealyticum but contained U. parvum serovar markers. 
One U. urealyticum isolate showed serovar markers of both species. One isolate 
negative for the species-specific real-time PCR contained 2 different U. urealyticum 
serovar markers; while 22 isolates positive for both species showed serovar markers 
from only one. 
4.4.4 Separation of isolates with multiple serovars 
In an effort to isolate pure serovars from clinical isolates containing multiple 
serovars, we found that the serovars in 4 isolates could not be separated after filtering 
and selecting single colonies for subculture. Two isolates contained serovars 3 and 
14; one isolate contained serovars 1 and 14; and one contained serovars 3 and 6. As a 
control, a mixture of equal amounts of ATCC type strains of serovars 1 and 6 was 
made and the two serovars were completely separated after the same separating 
procedures. We suspected that these isolates and many of the others 
containing multiple serovars might not be true mixtures, but hybrid organisms 
carrying multiple serovar markers. 
4.4.5 Verifying hybrid isolates by sequencing multiple gene-coding, 
polymorphic loci 
 To simplify the test to determine whether the isolates were mixtures or hybrids, we 




DNA sequencing (primers are listed in Table S 1 at the end of this chapter). We chose 
to sequence 7-10 gene-coding loci that are widely distributed around the two genomes 
and contain multiple base-pair polymorphisms. Control mixtures of equimolar 
genomic DNA concentration of ATCC type serovars 3 and 6 had visible double 
nucleotide peaks in the sequencing chromatograms as shown in Table 4-2a. 
Differentiating mixed versus pure isolates was limited when the DNA concentration 
ratio reached 9: 1 and clean single peaks representing the predominant DNA type 
appeared (Figure 4-2a). A hybrid would be expected to show single peaks at 
polymorphic sites representing the sequence of one serovar in some loci and the other 
serovar in the rest of the loci (Figure 4-2b). In all tested loci, ATCC type strains of 




Figure 4-2. DNA sequencing determining Ureaplasma hybrid or mixed isolates. 
DNA sequencing of multiple polymorphic loci throughout the genome. DNA 
sequencing trace files were aligned by using CLC genomic workbench. (a) 
Sequencing of DNA obtained from artificial mixtures of U. parvum serovar 3 and U. 
parvum serovar 6. Reference sequences of gidA orthologous genes of U. parvum 
serovars 3 and 6 are shown on the first two lines. The type of DNA mixture for each 
reaction is provided on the left of the sequences. Polymorphisms are marked with 
shaded boxes. Trace data indicated double peaks in the 1:1 mixture and single peaks 
in 9:1 mixtures, representing the predominant DNA. (b) Sequencing of multiple 
polymorphic loci in isolate 10901. A representative window of three of seven 
sequenced loci is shown. Polymorphic sites are marked with shaded boxes. Isolate 
10901 showed single peaks at the polymorphic loci. Loci 1 and 3 showed 





Seven clinical isolates suspected to contain a hybrid organism of two serovars 
were analyzed. Six isolates (10902, 97078, 10901, 8510, 24318 and 25353) clearly 
showed some polymorphic loci characteristic of one serovar and some characteristic 
of another (Table 4-3). Seven polymorphic loci were examined in two isolates 
containing serovars 1 and 6. Isolate 10902 showed an obvious hybrid pattern: 4 loci 
were from UPA6 and 3 loci were from UPA1. In isolate 97078, 6 out of 7 loci were 
UPA6 specific, and 1 locus was closest to UPA14 (blast showed 99.55% identity to 
UPA14). In order to examine the reason for having serovar-specific real-time PCR 
signal for both UPA1 and UPA6, we proceeded to sequence the two serovars’ real-
time PCR targets. Both PCR assays targeted the mba gene of each serovar. The mba 
sequencing chromatogram depicted only MBA1. Since real-time PCR is more 
sensitive than DNA sequencing, and DNA sequencing failed to recognize mixtures of 
9:1 or lower ratios, we hypothesized that isolate 97078 contained two hybrids in a 
ratio of at least: 90% or more of a UPA6 with a UPA1 specific MBA hybrid, and 10% 
or less of a UPA1 with a UPA6 specific MBA hybrid. Another seven loci were tested 
for serovars 3 and 6 and hybrid patterns were observed in isolates 10901 and 8510. 
Isolates 24318 and 25353 were serial isolates from the same patient. They were 
positive by real-time PCR for serovars 9 and 10 and had ten polymorphic loci from 
UUR10 and two specific loci from UUR9. Sequencing of the real-time PCR targets 
indicated that the two isolates contained serovar markers of both UUR9 and UUR10. 










































































































UPA3_38 UPA3* (UUR2/UPA14?) 
UPA3_39 UPA3 
UPA3_98 UPA6 

























UUR9_ORF01470 (UUR9 only) UUR9  
UUR9_ORF01469 (UUR9 only) UUR9 
UUR9/10_ORF00475 
1 copy of UUR10 and 1 or 























UUR9_ORF01470 (UUR9 only) UUR9 





4.4.6 Prevalence of hybrid ureaplasmas  
To quickly estimate the prevalence of hybrid ureaplasmas in a large number of 
clinical isolates containing multiple serovars, quantitative real-time PCR assays were 
performed using a universal quantification standard, a plasmid pUC19-UU, which 
contained one copy of each serovar-specific PCR target (except for serovars 4 and 5). 
The rationale for this test is based on the observation and hypothesis that mixtures of 
different serovars will still occur as mixtures in different ratios after re-growth 
because of different growth rates of serovars and different mixing ratio at starting 
point. On the other hand, a hybrid, as a single organism will contain the same ratio of 
different serovar markers at the starting point and after re-growth. Thus, by 
quantification of serovar markers in clinical isolates, we should be able to 
differentiate the hybrids and mixtures.   
Among 271 randomly selected isolates out of 413 containing multiple 
serovars (except serovars 4 and 5), 28% were hybrids (Figure 4-3). Among the hybrid 
isolates, 23% were hybrids of two serovars, 4% were hybrids of three serovars, and 
<1% were hybrid of four serovars. Most of the hybrids contained markers of the same 
species (Table 4-4). There were 10 UPA hybrids and 59 UUR hybrids. Interspecies 
hybrids were found in 6 isolates. The most common hybrid types were hybrids of 
serovars 11 and 12. A clinical subculture could be a pure hybrid strain, a mixture of a 
hybrid strain and/or non-hybrid strains, or even a mixture of different hybrid strains, 
like isolate 12599, which was a mixture of two hybrids  a hybrid of serovar 2/11 
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Figure 4-3. Prevalence of hybrid serovars in clinical isolates 
Prevalence of hybrid serovars in clinical isolates. A total of 271 randomly selected 
clinical isolates (except serovars 4 and 5) containing multiple serovars were tested by 
quantitative real-time PCR, and the quantity of each serovar was calculated. To 
determine whether an isolate was a hybrid or mixed culture, an arbitrary standard was 
made based on the largest calculated deviation of the pUC19-UU control between 
PCR runs. A deviation of ≤5-fold among serovars was considered a hybrid strain 
(Hyb; the numbers following the term are the number of serovars detected in one); a 
deviation of 5- to 10-fold was considered a hybrid or mixture (Hyb/Mix); any 
deviation of >10-fold was considered to represent a mixed culture (Mix); and, finally, 
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To address the question whether differential pathogenicity exists at the 
Ureaplasma serovar level, an accurate typing method and a large number of clinical 
isolates are needed. The 14 serovar-specific real-time PCR assays have been proven 
to separate all 14 serovar type strains without cross-reactions [230]. We applied these 
assays to type 1061 clinical isolates from different patient populations. Thus far, this 
is the largest collection of clinical isolates that have been typed to species and serovar 
level by any method. Results indicated that U. urealyticum was significantly 
increased in men with NGU and women with PID and/or endometritis, which agrees 
with previous reports [84, 216-220]. However, no agreement in association of 
particular serovars with diseases was achieved among the different patient groups, 
including the invasive isolates recovered from usually sterile sites. Previous studies 
also showed no consistent data correlating individual serovars and pathogenic 
outcome, even among invasive isolates [4, 180, 196, 205, 222-225]. This suggests 
that serovar designation is not a reliable sub-species marker for determining 
differential pathogenicity of Ureaplasma.  
We utilized the clinical isolates that were available to us for study and we 
acknowledge there are some potential limitations in the study populations and 
comparator groups. One such limitation is comparison of vaginal swabs from healthy 
women to serve as controls for comparison with endometrial tissue in the subjects 
with disease. A second is the relatively small number of control urine specimens (25) 




passage organisms, so it is unlikely that there would be selection of individual 
serovars that grow more rapidly in laboratory culture than others. However, unless 
one tests the original clinical specimens before any in vitro cultivation, it is not 
possible to know with certainty which serovars were there before the specimen is 
subjected to laboratory cultivation conditions. Furthermore, some serovars present in 
mixtures might not have survived prolonged storage and reconstitution. However, 
even with these potential limitations, our conclusions are not likely to be affected in 
the view of our finding hybrid serovars as a result of HGT. Thus, we must question 
the utility of serovar determination in assessment of pathogenicity. 
Multiple serovars were detected in about 40% (413/1061) of the clinical 
isolates, while 6% (67/1061) were not typable and 4% (42/1061) showed conflicting 
species and serovar results. It has been observed since the earliest Ureaplasma typing 
studies that many clinical isolates contain multiple serovars [222-224, 226, 227]. 
Although cross-reactive typing reagents and mixed cultures were generally accepted 
as plausible explanations, it has never been completely clear whether certain strains 
can contain multiple serovar specificities and how this may occur. Failure to separate 
multiple serovars from some clinical isolates suggests the occurrence of hybrids. Our 
studies indicate there are pure organisms carrying multiple serovar markers. DNA 
sequencing of multiple loci with multiple base-pair polymorphisms provided 
evidence of HGT, and explains why some isolates were positive in more than one 
serovar-specific PCR assay. Because serovar-specific markers are exchanged between 
ureaplasmas, some organisms might acquire multiple markers, and some might 




emergence of hybrid ureaplasmas containing multiple serovar markers from one or 
more species, and untypable strains. Alternatively, the untypable strains may also 
represent new serovars that have never been characterized. The 14-serovar 
classification scheme was expected to be expanded at the time it was established [5] 
and several later studies using antibody-based or PCR methods have reported a 
certain number of untypable isolates [205, 222, 238]. To determine whether those 
untypable isolates represent new serovars or loss of markers, additional analysis such 
as whole genome sequencing of such isolates would be instructive. 
HGT between U. parvum and M. hominis which co-localize to the mucosal 
surface of the human urogenital tract was recently reported [235].  Five clusters of 
genes encoding type I and III restriction /modification systems, transposases, and cell 
surface proteins were predicted to undergo HGT between the two phylogenetically 
distinct species.  
In this study, we have reported that HGT occurs within Ureaplasma spp.  
Serovar markers and other sequences throughout the genome were exchanged among 
serovars, including the MBA gene, which was thought to be serovar-specific [202]. 
This finding questions the definition of serovars, because the phenotypic epitopes on 
which the serovars are based may change, combine, or be lost after HGT. The 
mechanisms involved in HGT in ureaplasmas are still not clear. Mobile genetic 
elements, such as conjugative transposons Tn916 and Tn1545, and plasmids have 
been identified in ureaplasmas [239-241]. Ureaplasmas may also form biofilms [236], 
dense structures that enhance gene transfer [242]. Recombination may occur 




hybrid isolates may help to identify possible hotspots of recombination. Furthermore, 
two sets of  major surface antigen proteins MBA & UU376 and UU171 & UU172 of 
serovar 3 are phase variable due to a DNA inversion events [99, 184]. One of those 
phase variants would be undetectable using a serological assay based on the serovar 3 
MBA. On the other hand, different serotyping results have been reported to occur in 
the same strain following  subculturing [222, 243]. 
Genes involved in pathogenicity have not been identified conclusively in 
Ureaplasma spp. and we have shown that individual serovars are unlikely to be 
associated with differential pathogenicity. Therefore, bacterial load and different host 
immune responses may be alternative explanations for varied clinical findings. It has 
been reported that increased bacterial load is associated with NGU [203, 244, 245]. A 
study using an animal model of urinary tract infection showed that complications 
associated with U. parvum infection are primarily dependent on host-specific factors 
[246]. Further studies are needed to elucidate mechanisms of specific host response in 
these and other conditions that may be associated with these organisms.  
In conclusion, this study demonstrates that HGT occurs naturally among 
human Ureaplasma species and serovars and Ureaplasma pathogenicity is unlikely to 
be associated with individual serovars. Our data suggest that “serotyping” is 
impractical and of limited value for assessment of pathogenicity. To clarify the 
mechanisms related to pathogenicity, future studies should focus on the specific 
immune response to Ureaplasma infections, although there is still the possibility that 




ureaplasmas which yet have not been distinguished by examination at the species or 
serovar level.  
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Chapter 5. Expanding the Genetic Toolbox for Ureaplasmas 
5.1 Abstract 
Over 50 years of research have yielded little understanding on why UPA and 
UUR produce invasive diseases in some instances and not in others. Although 
differences in host factors can lead to increased susceptibility to ureaplasmal 
infection, evidence suggests that some strains of UPA and UUR may have a greater 
pathogenic potential than others. Understanding of host-pathogen interactions and 
factors involved in pathogenicity of these organisms has been hampered by the lack 
of molecular tools for modification of their genomes. Such tools have been 
prerequisites for understanding pathogenicity factors and host-pathogen interactions 
for well-studied pathogens. We attempt to apply traditional molecular microbiology 
and synthetic biology methods to develop tools for genetic manipulation of 
Ureaplasma species. Adapting the novel synthetic biology tools to UU, like cloning, 
and engineering bacterial genomes in yeast, and genome transplantation can allow for 
the creation of targeted single or multiple mutants that will greatly increase the 
understanding of ureaplasma pathogenicity. 
5.2 Introduction 
Understanding of the role of ureaplasmas in human diseases has been 
thwarted thus far due to two major barriers: 1) Lack of suitable diagnostic tests that 
can identify and characterize the two species and their respective serotypes that could 




creation of deletion mutants and their complementation to study the role of potential 
pathogenicity factors   
A major effort in the field of ureaplasma research over the past 20 years has 
been focused on overcoming the first barrier. Since 1990, nearly 300 peer-reviewed 
publications have described basic and clinical investigations involving ureaplasmas 
using PCR and various other nucleic acid-based techniques. Based on the genome 
sequences of the 14 ATCC type strains of each ureaplasma serovar, our group has 
developed species and serovar specific real-time PCR assays to detect ureaplasmas in 
patient isolates [132], which were applied to a collection of 1,061 clinical isolates 
[133]. The results of this large scale serotyping study showed 39% of clinical isolates 
contained more than one serovar, and 28% of the evaluated mixed isolates were 
chimeric organisms containing markers from up to 4 serovars (Table 5-1and Figure 
5-1). This suggested that ureaplasmas are subject to extensive horizontal gene 
transfer. Therefore it is possible that ureaplasmas do not  exist as stable serovars in 
their hosts, but rather as a dynamic population exchanging genes, most likely not only 
among themselves, but also with other bacteria in their environment. Based on these 
findings, the long sought after serotyping assays, are of limited value, and there is no 
utility in trying to associate individual serovars with specific disease. The differential 
clinical outcome of ureaplasmal infection may be due primarily to presence or 
absence of potential pathogenicity factors in the colonizing ureaplasma strain [134] 




Table 5-1. Distribution of UU Clinical Isolates 
The table shows the results of the real-time PCR assay (Chapter 4) applied to 1061 
clinical isolates of UU. The results are broken down to number of samples containing 
one, multiple, or unidentifiable serovar/species 
 
Serovars in isolate No. Isolates 








No serovar signal 67 (6.3%) 
No species signal 6 (0.6%) 
Total 1061 
 
Figure 5-1. Distribution of 271 Mixed Ureaplasma Clinical Isolates.  
271 Clinical Isolates with real-time PCR assay singnals for more than one serovar 
were subjected to quantitative real-time PCR to determine the number of chimeric 
organisms compared to co-infections. Data label indicates: group type (chimeric or 
mixture, e.g. co-infection); number of clinical isolates in the group;  percentage of 




The second major barrier to the understanding of ureaplasma pathogenicity is 
the lack of molecular tools for creation of deletion mutants to study the role of 
potential pathogenicity factors. This problem has not been explored nearly as 
exhaustively as the development of serotyping assays. The capacity to create deletion 
mutants has been a prerequisite in understanding host-pathogen interaction and 
factors involved in pathogenicity in many well studied pathogens.  
Approximately twenty years ago efforts to develop genetic manipulation 
systems for ureaplasma were unsuccessful (personal communication with Kevin 
Dybvig). This is one reason little use was made of the first ureaplasma genome 
sequence, which was published early in the genomic era. New technologies such as 
TN4001, EZ-tn5 trnasposomes, OriC plasmids, expression of E. coli RecA via a 
suicide plasmid, and the technology developed for synthetic biology offer new 
possibilities for development of genetic tools for ureaplasma. More recently, Tn4001 
was used to randomly mutagenize an UPA3 clinical isolate; however the methods 
used for that specific ureaplasma clinical isolate have not worked for any other 
ureaplasmas (Brad Spiller, Cardiff University, personal communication; manuscript 
in preparation). Nonetheless, transformation conditions for ureaplasmas have not 
been extensively explored. The development of tools for genome modification of 
Ureaplasma spp. will tremendously facilitate the study and understanding of factors 
leading to differential pathogenicity of Ureaplasma strains. Should transformation 
with a transposon prove successful, transposon mutagenesis studies can be initiated to 
screen for mutations of interest. The search of the ureaplasmal IgA protease gene 




the use of random transposon mutagenesis in a future study.   Mutants can be 
extremely valuable for study in existing animal models for ureaplasmal infections in 
humans [27, 56, 121, 247]. Furthermore, the increased understanding of pathogenicity 
factors can aid in development of better screening methods, drug targets and vaccines 
to decrease the morbidity associated with ureaplasmal infections.  
5.3 Materials and Methods 
5.3.1 Ureaplasma cultures 
U. parvum and U. urealyticum were cultured in 10B growth medium.  This 
growth medium, per 1 L, contains 200 ml Heat-Inactivated horse serum (Gibco Life 
Technologies) or heat-inactivated porcine serum (Life Technologies), 100 ml 25% 
yeast extract (Gibco Life Technologies), 688 g Mycoplasma Broth Base (BD BBL), 1 
ml 1% phenol red, 5 ml IsoVitaleX Enrichment (Gibco Life Technologies), 1 g urea 
(Sigma), and 2.5 ml, 400,000 U/ml penicillin (Sigma). Phenol red was used in the 
10B growth medium as pH indicator to monitor the growth of ureaplasmas.  During 
ureaplasma growth, urea is hydrolyzed to yield ATP, carbon dioxide, and ammonia. 
The ammonia changes the growth medium from acidic to basic and the phenol red 
from yellow to red. 
Ureaplasma growth was monitored through a color changing units (CCUs) 
assay, in which 1:10 serial dilutions of cells up to 10-8 were used. The highest dilution 
to change from yellow to red indicates the approximate number of cells in the starting 




produce granular brown urease-positive colonies approximately 15–60 μm in 
diameter on A8 agar after 24–48 hours of incubation at 37°C and 5% CO2 due to 
calcium chloride incorporated into the media. Alternatively 10B agar can be prepared 
and used to grow ureaplasma colonies. Colonies can be observed after 48-72 hours of 
incubation and appear opaque with light silver tone. Mature colonies exhibit a fried 
egg shape with irregular, wavy colony edge (Figure 5-2). 
 
Figure 5-2. Ureaplasma colonies on 10B Agar.  
The agar plates were incubated at 37°C with 5%CO2 for 3-7 days. At day 3 colonies 
can be detected and have a transparent to silverfish gloss and no “fried egg” center. 
This picture is of 5 day old colonies at 50X magnification. By day 7 the edge of the 
colony becomes irregular and wavy. When cells are too crowded, the colonies don’t 




5.3.2 Extracting intact genomic DNA 
The buffers, enzymes, and agarose in the following procedure are provided 
in the CHEF Mammalian Genomic DNA Plug Kit (BioRad catalog number 170-
3591). Different cell concentrations per one plug were explored. Finally 20ml of 
overnight ureaplasma culture (pH 7.5-8.0) per plug was harvested by centrifugation at 
10 000 x g for 60 min at 10°C. Media was aspirated, leaving about 1ml of it in the 
tube. The pellets (invisible) were re-suspended in the remaining media and all pellets 
were merged together in one 30ml Oakridge Centrifugation tube. Cells were 
harvested by centrifugation at 27 000 x g for 15 min at 10°C and washed in 20 ml of 
PBS then centrifuged at 27 000 x g for 15 min at 10°C. A cell suspension was 
prepared in 50μlper plug of PBS. The 50 well plug mold makes 5 ml of agarose 
plugs. A 2% low melt agarose solution in sterile water was prepared and melted using 
a microwave. The cell suspension solution and the 2% low melt agarose solution were 
equilibrated to 50 °C in a water bath. Next the cell suspension was combined with an 
equal volume of 2% CleanCut agarose and mixed gently but thoroughly. This results 
in a final concentration of 1% agarose. The cell/agarose mixture was kept at 50 °C, 
and transferred to plug molds. The agarose was allowed to solidify. This step can be 
expedited by placing the molds at 4 °C for 10–15 minutes. This also adds strength to 
the agarose for removal from the mold. 25 ml of Proteinase K Reaction Buffer was 
added in a 50 ml conical centrifuge tube. The solidified agarose plugs were pushed 
into the 50 ml centrifuge tube containing the Proteinase K solution by using the snap 
off tool provided on the plug mold. The plugs were incubated overnight at 50 °C 




30 minutes to 1 hour each at room temperature with gentle agitation. 1 mM PMSF 
was added during the second or third wash to inactivate any residual Proteinase K 
activity. The plugs were stored at 4 °C for 3 months to 1 year. The recipes of the 
buffers that come with this kit can be found in the manufacturer’s manual. 
5.3.3  Restriction Digest and CHEF Gel Analysis of gDNA Plugs 
The plugs to be restricted were washed for 30 minutes in 0.1x wash buffer or 
TE. One plug per digest was placed in a sterile 1.5 ml microcentrifuge tube. The plug 
was incubated with 1 ml of the appropriate 1x restriction enzyme buffer for about 1 
hour with gentle agitation at room temperature. The buffer was removed and 0.3 ml 
of fresh 1x restriction enzyme buffer was added. 30-50 U per 100 μl plug restriction 
enzyme, in this case 50U of SmaI or SdaI to linearize the UUR9 genome, and ApaI to 
cut twice the UUR9 genome was added and incubated overnight at the appropriate 
temperature. After overnight digestion, the buffer was removed and 1 ml of wash 
buffer was added. 1⁄4 of a plug per sample was loaded on an agarose gel per well on a 
1% agarose gel along with a lambda DNA ladder. The gel was ran in the CHEF Gel 
III system with the following parameters: Buffer: 0.5x TBE; Temperature: 14 °C; 
Switch Time: 50-90 seconds; Run Time: 22 hours; Angle: 120°; Voltage Gradient: 6 
V/cm. The gel was stained with SybrGold and scanned. 
5.3.4  Minimum Inhibitory Concentration Assay: 
By using the same methods as described in the literature, we found the MIC 




tests were performed in flat bottom 96-well plates by first adding 360 µl of 10B 
growth medium with the antibiotic being tested at its highest tested concentration and 
180 µl of 10B growth medium without antibiotic to the rest of the wells. Next, the 
antibiotics were serially diluted in a 1:2 dilution down the rows, leaving the bottom 
row as a control with no antibiotic. The maximum concentration tested for puromycin 
was 320 µg/ml, and tetracycline 360 μg/ml. Twenty µl of cells were then added to 
each well in the first column and serially diluted in a 1:10 dilution across the 
columns, leaving the right-most column as a control with no cells. The 96-well plates 
were then incubated at 37°C to grow until no further color changes were observed. 
Samples were then placed at room temperature for one hour before observations were 
made as previously described [248]. 
5.3.5 Testing for Nucleases Present on the cell surface of UU cells 
Ureaplasma cells were treated according to the mycoplasma PEG mediated 
transformation protocol and incubated with plasmid DNA under the transformation 
conditions in the protocol. Reactions were stopped with phenol/chloroform at 0, 15, 
30, and 45 minutes and DNA will be precipitated with ethanol. The samples were 
analyzed by gel electrophoresis. A sample without cells was used as a negative 
control. We tested the dependency of the nuclease activity on Ca+2 and Mg+2 ions by 




5.3.6 Preparation of Crude Cellular Extracts 
To prepare cellular extracts 3L overnight culture of UPA3 recipient 
ureaplasmas cells were harvested through centrifugation as described above and re-
suspended in 0.5 ml Lysis Buffer [20mM Tris pH7.5, 10% Glycerol, 150mM NaCl, 
1mM DTT, and 0.1mM EDTA; last two components are added to the buffer 
immediately before the experiment]. The cell suspension was sonicated on ice until 
the solution becomes almost clear. The resulting solution was centrifuged to remove 
cell debris and supernatants were tested for protein concentration [249]. Extracts were 
stored at -80°C.  
5.3.7 Crude Cellular Extract Restriction Enzyme Assay 
To test for restriction enzyme activity of Ureaplasma we were incubated with 
a DNA plasmid in all 4 available restriction enzyme buffers by New England Biolabs 
with the extract at 37°C. The reaction was stopped at different time intervals. The 
DNA was extracted and precipitated with phenol/chloroform and ethanol and the 
DNA was analyzed by gel electrophoresis for digestion patterns [249]. 
5.3.8  Transformation/PEG Concentration Optimization: 
Ureaplasma cells grown at 37°C overnight were transformed by chemical 
mediation of PEG 8,000 (USB) dissolved in 1x phosphate buffered saline solution 
(PBS, Life Technologies). Different concentrations of PEG solution were explored to 
determine the optimal PEG concentration. Once optimal PEG concentration was 




UPA3 cells, (5 ml/experiment) were pelleted in bulk at 10,000 g for 20 
minutes at 4°C in a Beckman Coulter JA 25.50 rotor. The media was pipetted out 
leaving 1 ml. the pellet was resuspended and moved to a 1.5 ml microfuge tube. The 
cell suspension was pelleted at 10000 g for 7 min at 4°C in a Beckman Coulter 
F301.5 Rotor.  Cell pellet was then washed with 1x PBS buffer, and then resuspended 
and treated on ice with 125 µl of 100 mM calcium chloride/sample for 30 minutes.  
During the 30 minute incubation, each experiment was prepared in separate 30 
ml centrifuge tubes (Oakridge) by adding 10 µg of yeast tRNA (Sigma), and 1 µl of 
the plasmid. Then, to one tube at a time, 125 µl of calcium chloride treated cells were 
added, 1 ml PEG 8,000 (varying concentration for optimization experiments and 50% 
subsequent experiments) was added, mixed gently by rolling the tube for one minute, 
and then 5 ml of 10B growth medium without horse serum was added and mixed in 
the same manner. When all samples were mixed with all components, they were 
incubated 4 hours to recover at 37°C. During the recovery, a CCU assay in sets of 
eight tubes per sample was prepared with 900 µl of 10B growth medium with 
selective antibiotic above the determined MIC for experimental samples. For 
tetracycline, 10 µg/ml was used.  
After the 4 hour recovery, samples were centrifuged at 10,000 g for 20 
minutes at 4°C. The supernatant was discarded and samples were re-suspended in 100 
µl of 10B growth medium without selective antibiotic and added to the first tube of 
their corresponding CCU assay set of eight. The sets of eight were then serially 
diluted from tube to tube in 1:10 dilutions, and incubated at 37°C overnight to grow. 




concentration of PEG 8,000 during the PEG optimization. For a successful 
transformation the transformants were expected to grow in the media containing 
tetracycline and growth should be sustained in subsequent cultures of the 
transformant in the presence of tetracycline.   
5.3.9  Plasmids Used and Their Construction 
The EZ-Tn5 transposon (Epibio) containing a puromycin resistance gene, was 
used to transform UUR9 and UPA3. Plasmids containing different Tn5 constructs 
were made. We used the SQFP and SQRP provided by the kit to amplify the 
backbone of the pMOD plasmid. The promoter and antibiotic resistance genes were 
PCR amplified with primers containing overhangs complimentary to the sequence of 
their neighboring assembly DNA pieces. All PCR amplicons were purified and used 
to assemble to plasmid through Gibson Assembly. The final Tn5 transposon insertion 
DNA was PCR amplified using the PCRFP and PCRRP primers (primers were 
provided in the EZ-Tn5™ Custom Transposome™ Construction Kit by Epicenter and 
sequences of the primers can be found in the kit’s manual). The different Tn5 
transposon insertion sequences contained genes conferring resistance to either 
puromycin or tetracycline, and varying promoter regions upstream of the antibiotic 
resistance. These insertion sequences will be referred to as Tn5relevant antibiotic. i.e. 
Tn5Puro, Tn5TetM. The resulting transformed cells are selected by CCU assay 
and/or plated on agar plates for selection and colony analyses. Sanger sequencing 




transposon insertion location [250]. Figure 5-3 depicts the plasmid map of one 
variation of the pMOD-2 plasmid. 
 
Figure 5-3. pMOD-2 custom EZ-tn5 plasmid. 
This is a plasmid map of one variation of the custom design pMOD-2 plasmid 
provided with the EZ-Tn5™ Custom Transposome™ Construction Kitr by Epicenter. 
The backbone of the plasmid contains ampicillin (AmpR) resistance gene and E. coli 
ColE1 Ori origin of replication for plasmid propagation and selection in E. coli. We 
inserted PCR amplicons of the UUR9 tuf promoter area and the UUR9 tetM. To allow 
for GA into the pMOD-2 plasmid the gDNA areas were amplified using the 
UUR9tuf_Fwd_SQFR_pMODhook and UUR9tetM_Rev_SQFP_pMODhook 
primers. The tn5 transposon DNA is PCR amplified using the PCRFP and PCRRP 
primers as described in the materials and methods section. The 19bp repeats of the 
tn5 are labeled. The SQFP and SQRP primers can be used in sequencing reactions to 




According to the manufacturer’s instructions, we produced transposomes by 
combining 2 µl of the Tn5 insertion piece, at a concentration of roughly 100 ng/µl, 
was combined first with 4 µl of EZ-Tn5’s transposase, then 2 µl of glycerol. The 
reaction was then set to incubate at room temperature for 30 minutes. Tn5 
transposomes were then used to transform either UUR9 or UPA3 cells, grown 
overnight with the same transformation procedure described above. Transformation 
experiments were done using 50% PEG 8,000 as described above. No DNA and no 
cells controls were used by substituting the transposomes (no DNA) and cells (no 
cells) with 1 µl and 125 µl of 1x PBS buffer, respectively.  
Similar CCU assays in sets of eight tubes per sample were used to monitor 
ureaplasma growth. However, CCU assay sets also included controls with one set 
grown in 10B growth medium with selective antibiotic and one set grown in 10B 
growth medium without selective antibiotic.  
For puromycin, 100 µg/ml was used, and for tetracycline, 10 µg/ml was used. 
Samples were incubated at 37°C overnight to grow. The next morning, all sets were 
re-titrated and re-titrated one more time 6 hours later. We considered the 
transformation positive if the samples containing the transposon grew in the 
tetracycline containing media to a farther dilution than the no transposon control in 
the tetracycline containing media. Due to the high concentration of the cells used for 
the transformations to compensate for low transformation efficiency, the no 
transposon control usually changes the color of the tetracycline containing media in 




We used a variety of plasmids to attempt ureaplasma transformation. Most 
plasmids were mini tn4001 derivatives with either tetracycline, puromycine, or 
kanamycin resistance genes. We used a pTF20 with tetM to perform PEG 
concentration optimization tests.  
We constructed multiple variations of the EZ-tn5 trasnposon plasmid, pMOD2 
(Epicenter), by varying the antibiotic gene (tetracycline, puromycin) and its source 
and the driving promoter. The tetM was amplified from pTF20 or UUR9; plasmid; the 
putative UUR9 tuf promoter was amplified spanning the intergenic region upstream 
of the tuf and downstream of the gene before tuffrom extracted genomic DNA; the 
backbone of the pMOD2 was amplified to use as a base for the different tn5 
variations. All PCR amplicons were cleaned up using the The Wizard® SV Gel and 
PCR Clean-Up System (Promega) and used in different combination to produce a 
variety of tn5 transposons.  Primers for all the PCRs were designed to have 
appropriate overhangs to allow assembly of the different plasmids using Gibson 
Assembly (GA) [251]. GA reactions were prepared on ice with 25 fmol of each DNA 
component and 10 µl of 2x GA Master-Mix (Invitrogen), brought to a total volume of 
20 µl. Samples were placed in a preheated 50°C PCR machine for 30 minutes.  
GA products were placed on ice until ready to electroporate into DH10B or 
ElectroMax E. coli. One µl of product was combined with 40 µl of defrosted E. coli 
cells in a PCR tube and then transferred into a cuvette on ice. Bubbles were 
minimized by lightly tapping cuvettes on a hard surface. Cuvettes were wiped of any 
external moisture, and then cells were shocked with a setting of 2000 volts, 25 




medium (Invitrogen) by pipetting up and down gently a few times then transferred to 
14 ml round bottom tubes to recover in a shaker for 1 hour at 37°C. After the 
recovery, samples were screened by plating 200 µl of each sample on pre-warmed 
Luria Broth (LB) agar with ampicillin (100 µg/ml) then turned upside-down to grow 
overnight at 37°C. Individual colonies were picked into 2 ml of LB with tetracycline 
(10 µg/ml) and placed at 37°C to grow overnight. Cells were spun down and 
harvested using Qiagen mini-prep kit to extract plasmids. Extracted plasmids were 
then screened by a PCR that amplified the transposon insertion sequence. Transposon 
DNA was obtained through PCR using the PCRFP and PCRRP primers and the 
corresponding pMOD2 customized plasmid as template or through restriction enzyme 
digest followed by gel purification of the transposon DNA using SYBR Gold stain for 
visualization (Life Technologies), and then cleaned-up by using Wizard SV Gel and 
PCR Clean-up System (Promega).  
5.4 Results and Discussion 
5.4.1  Development of traditional tools for genetic manipulation of UU 
genomes 
Considerable progress has been made in the field of Mycoplasma genetics that 
makes some species in this taxon accessible for genetic studies. Such studies are 
facilitated by traditional tools, like transformation of cells with transposons and 
plasmids through electroporation, PEG, and conjugation. Several transposons and 
their derivatives are used in mycoplasmas to disrupt or insert genes. Autonomous 




some of the mycoplasmas that allow targeted disruption of genes. These tools have 
led to better understanding of the biology of some mycoplasmas. We believe that 
these methods and tools can be adapted and used for genetic manipulation of UU 
species. Through personal communication we know that initial attempts to transform 
ureaplasma with Tn916 via PEG-mediated transformation approximately twenty 
years ago were unsuccessful. Tn916 is naturally present in the genome of the ATCC 
UUR9, and it confers tetracycline resistance through the expression of the tetM gene 
it carries. This suggests that Tn916 is a suitable transposon choice. More recently, 
Tn4001 was used to randomly mutagenize an UPA3 clinical isolate; however the 
methods used for that specific ureaplasma clinical isolate have not worked for any 
other ureaplasmas (Brad Spiller, Cardiff University, personal communication; 
manuscript in preparation). Artificial transformation of cells usually involves naked 
DNA. Mycoplasmas produce potent nucleases [252] to scavenge nucleotides from 
their environment, since they cannot synthesize them. Recent experience at the J. 
Craig Venter Institute (JCVI) showed that these nucleases can digest the naked donor 
DNA in genome transplantation experiments. Furthermore, active restriction-
modification systems can digest the donor DNA after it entered the cell and before it 
has been methylated by the recipient cell to make it resistant to those restriction 
enzymes. The comparative analysis of the genome sequences of the 14 ATCC 
serovars shows that all serovars have putative restriction-modification systems and 
putative surface and secreted nucleases [237]. Therefore, initial experiments were 




After these potential issues are addressed we proceed to develop transformation 
protocols as well as vectors to genetically manipulate ureaplasmas. 
5.4.2 Testing UU cells for the presence of surface and restriction 
nucleases 
Our previous experience with Mycoplasma pneumoniae cells shows that they 
have one or more extracellular nucleases capable of digesting plasmid DNA when it 
is incubated with the cells under transplantation conditions. Diluting the cells to slow 
DNA degradation showed that the supercoiled plasmid is cut to a linear molecule 
before it is destroyed, suggesting that there may be both endo- and exo-nuclease 
activity present.  This nuclease activity is dependent on the presence of Ca+2 and 
Mg+2 ions. Removing both these ions abolishes nuclease activity. Pre-incubation of 
the cells with trypsin was enough to allow PEG-mediated transformation in the 
presence of CaCl2 of M. pneumoniae with plasmids. All 14 sequenced UUs contain 
11-14 putative nucleases of different functions. Two of these putative nucleases 
appear to be membrane bound based on the presence of a transmembrane domain and 
a signal peptide. One of them has a lipoprotein attachment site and a calcium binding 
domain. Therefore, before we attempted to transform ureaplasma cells we assayed 
them for extracellular nuclease activity under the conditions of the transformation 
protocol. We did not detect surface nuclease activity under the tested conditions. 
Since there are several formulations of the ureaplasma growth medium in the 
literature, we tested the presence of nuclease activity using three of these 




assay when the growth media was prepared with PPLO or TSB as broth base even in 
the absence of the cells. We did not investigate the reason the plasmid could not be 
recovered.  
All 14 ureaplasma serovars have 6-12 genes annotated with different predicted 
restriction-modification functions. Seven of the serovars may have a functional type 
III RMS, the rest of the serovars appear to have only the type III restriction subunit, 
which would make the system not functional. Only serovar 9 appears to have both 
genes of the type II RMS. In most serovars only the type II restriction enzyme is 
annotated. This system does not require the methylase and nuclease to be in a 
complex to function, however another methylases present in the genomes may be 
utilized to methylate and protect the DNA from the type II restriction enzyme. It is an 
interesting observation that all serovars contain multiple type I specificity proteins, 
which was also observed in M. pneumoniae. Only five serovars (3, 4, 9, 10, 12) have 
annotated type I methylation and restriction subunits. It is possible that the type I 
restriction system in these serovars uses the same restriction enzyme in combination 
with different specificity factors. Because only 3 of the serovars have been 
completely sequenced and assembled into a single contig, and minimal manual 
curration has been provided for all the serovars, it is possible that the missing 
enzymes are in a sequencing gap or have been missed in the automated annotation 
process. This makes it difficult to predict with confidence the potential restriction-
modification activity of these organisms. Therefore, we tested their restriction activity 
through the preparation of crude cellular extracts. We carried out a restriction 




nuclease buffers available through NEB. We did not detect restriction nuclease 
activity under these conditions. These results do not indicate that ureaplasmas don’t 
have surface and restriction nucleases. Rather these results show that under the 
conditions we used the activity of such nucleases was not detectable.  
5.4.3  Minimum Inhibitory Concentration (MIC) Assay:  
We determined the tetracycline MICs for UUR9 and UPA3 to be over 64 
µg/ml and 8 µg/ml, respectively. Our results agreed with previous tetracycline MIC 
tests [248]. The UUR9 tetracycline MIC is higher because the genome contains a 
tetracycline resistance gene. Therefore we used 10 µg/ml tetracycline to select 
transformed cells. Puromycin MIC for both UUR9 and UPA3 were 80 µg/ml, 
therefore, we used 100 µg/ml puromycin for selection of transformed cells. 
5.4.4  Development of a Transformation Protocol for Ureaplasma species 
There are three common methods used to transform mycoplasma species: 
chemical treatment with calcium chloride or polyethylene glycol (PEG), 
electroporation, and liposome encapsulated DNA delivery [142, 143]. We attempted 
to transform ureaplasma first by PEG mediated transformation. We used a vector 
containing a Tn4001 transposon conferring tetracycline resistance through the tetM 
gene. This transposon and its derivatives have been useful in mycoplasmas and 
another group was successful in using a Tn4001 derivative transposon to transform 
several UPA clinical isolates [146-151]. This transposon, however, failed to 




We carried out multiple optimizations to the PEG mediated transformation 
procedure used for mycoplasmas. We tested different PEG concentrations, recovery 
times and conditions, different transposon systems, as well as different culture stages 
[253, 254]. Our starting point was the transformation protocol developed by Lartigue 
et al for Mycoplasma capricolum [249, 254, 255] 
5.4.4.1 Growth Media Composition 
Several growth media compositions can be found in the literature for 
cultivation of Ureaplasmas. In general the media used for culturing ureaplasmas is 
called 10B. The base of the 10B broth can be Pleuro pneumonia-Like Organisms 
(PPLO) broth base, Tryptic Soy Broth (TSB) base, or Mycoplasma Broth Base 
(MBB) [155, 256]. Urea is always present in the broth as ureaplasmas hydrolyze urea 
for the generation of ATP. Ureaplasmas require serum in the growth media. The 
serum type can be horse, fetal bovine, or porcine. Different concentrations of serum 
are found through the literature. Another component of the media is yeast extract. For 
the initial culturing of clinical isolates fresh yeast extract is preferred (verbal 
communication with Ken Waites), however, for established laboratory strains 
commercially prepared yeast extract can be used. The concentration of yeast extract 
can be varied as well. Optionally, Isovitalex supplements can be added to the media. 
Since transformation procedures are stressful to the cells being transformed, we chose 
to add the higher concentration of serum and yeast extract published and add 
Isovitalex to make the growth media rich in nutrients for the cells to recover after the 
shock of transformation. We varied the media compositions by using either horse or 




as base, since PPLO and TSB interfered with plasmid recovery in the nuclease assay. 
We determined that ureaplasmas were growing fastest in 10B media with porcine 
serum and fresh yeast extract. A major difference was seen when porcine serum was 
used instead of horse serum. Ureaplasma was growing faster in porcine serum. In 
media with fresh yeast extract the cells were growing slightly faster than in media 
with commercial yeast extract. Due to the laborious and long process of preparing 
fresh yeast extract and the minimal effect on growth, we decided to use 10B media 
prepared with MBB, porcine serum, commercial yeast extract and Isovitalex.    
5.4.4.2 PEG toxicity 
To test for PEG toxicity ureaplasmas were pelleted and washed wit PBS, then 
re-suspended in 1ml of PEG 8000 dissolved in PBS in concentrations varying from 
5%-60% in 5% increments. The cells were incubated with PEG for 1 minute at room 
temperature then spun down and washed in PBS. CCU assays were performed to 
determine the viability of the cells after the treatment. Under these conditions 35% 
PEG was tolerated best. Cells that were treated with PBS only or 35% PEG had 108 
CCUs; 5%, 15%, 25%, 30% had 107 CCU; 10%, 20%, 40%, 45%, 55%, 70% had 106 
CCUs; 50% had 105 CCUs and 65% had 104 CCUs. Next, we tested the PEG toxicity 
by performing the transformation protocol with different PEG concentrations and no 
donor DNA (substituted by PBS). Under these conditions 5%-30% PEG 
concentration were the least toxic to the cells. 35%-40% PEG showed a reduction of 
viability by about 102 CCUs. Poor cell viability was observed in samples treated with 




5.4.4.3 Optimal PEG Concentration 
Previous experiments have shown that mycoplasma transformation efficiency 
is dependent on PEG concentration. The optimal PEG concentration varies among 
different mycoplasma species. Accordingly, we experimented to find the optimal 
PEG concentration for UPA3. With the ambition of achieving permanent and more 
efficient transformation, we tested PEG 8,000 re-suspended in 1X PBS buffer with 
varying concentrations. We used the pTF20 plasmid with Tn4001 transposon, 
following the transformation procedures previously described. As a control of the 
involvement of PEG in the transformation process, we substituted the PEG solution 
with 1X PBS buffer. All samples were tested in 10B growth medium containing 
antibiotic. We tested the 0% PEG 8,000 control in both 10B growth medium with 
antibiotic and in 10B growth medium without antibiotic. The antibiotic control tested 
whether the PEG aided the insertion of DNA into the cell and potentially into the 
genome. The no antibiotic control tested whether the cells being used were viable.  
After overnight growth, only the samples subjected to 50% PEG solution grew 
up to the 10-2 dilution factor in the presence of tetracycline. The other samples only 
grew in the 10-1 dilution. In the absence of PEG during the transformation procedure 
no growth was observed in the presence of antibiotic. Thus, subsequent experiments 
were performed with 50% PEG 8,000. Neither of the transformation samples could be 
maintained in tetracycline growth media, suggesting transient transformation with the 




5.4.4.4 Ureaplasma Culture pH Optimum before Transformation 
We evaluated the best ureaplasma culture growth stage for transformation. We 
inoculated 50ml media with 200 μl of frozen stock (1000X concentrated overnight 
culture; pH 7.5-8.0 at harvest time). The inoculated media (1X) was serially diluted to 
produce 1/2X, 1/4X, and 1/8X concentration of the cells, thus reaching different pHs 
and culture states at the time of harvest. The pH of the different cultures was as 
follows: 1X=pH 8.00, 1/2X= pH 7.74, 1/4X=7.54, and 1/8X=7.29. CCUs of these 
cultures at the time of harvest were:  1X=105, 1/2X= 106, 1/4X=108, and 1/8X=108. 
Transient tetracycline resistance was observed in the samples with pH 7.74 and 7.54 
at the time of harvest. Cultures of these cells could not be maintained in the presence 
of tetracycline in the growth media. The cells from these samples were harvested and 
PCR for the presence of the tn5 transposon was performed with positive results for 
the samples transformed with the tn5 transposomes and negative results for the frozen 
stock used and the no transposome control sample (Figure 5-4). One explanation is 
that the transposome is in the ureaplasma cell but did not integrate into the gDNA, 
thus conferring only a temporary resistance to tetracycline. Alternatively, this may be 
a false positive PCR result caused by detection of leftover tn5 transposon DNA from 
the transformation reaction, which did not wash away effectively. If the tn5 
transposon integrated into the ureaplasma genomic DNA then an inverse PCR, 
followed by sequencing should be able to show the tn5 location in the ureaplasma 
genomic DNA (experiments in progress). The UUR9 tuf promoter was amplified 
using PCR and assembled into the tn5 transposon. Potential errors in the amplicon or 






Figure 5-4. PCR for the presence of the Tn5_UUR9tuf_TetM after PEG 
transformation reaction. 
The PCRFP and PCRRP primers were used to check for the presence of the custom 
Tn5_UUR9tuf_TetM transposon in samples that showed transient tetracycline 
resistance. 1KB DNA ladder by Invitrogen was used on both sides of the gel. Blue 
arrows point to the 1000 bp and 2036 bp bands in the DNA ladder. The expected 
amplicon size of the transposon is 2319 bp. As a positive control two samples of the 
custom pMOD-2 plasmid containing the transposon in question were used with the 
PCRFP and PCRRP primers. As negative controls a sample of the frozen UPA3 stock 
used to start the UPA3 culture for transformation was used. The second negative 
control was the transformation reaction in which no transposomes were added. In 
both negative control samples an amplicon of about 1000 bp is evident, probably due 
to the primers amplifying an irrelevant gDNA section in the UPA3. All 3 UPA3 





5.4.4.5 Transformation results: 
Attempts to transform UUR9 and UPA3 with linear Tn5 transposomes 
containing puromycin resistance gene were unsuccessful. We next attempted to 
transform using a tn5 containing tetM and the mycoplasma tuf promoter. To verify 
that the template plasmid of the tn5 was eliminated and was not a competitor target 
for the tn5, the linear Tn5TetM PCR product was electroporated into E. coli and 
grown on 100 µg/ml ampicillin plates. No colonies were observed, indicating that 
there was no plasmid template. The Tn5TetM DNA concentration was 180 ng/µl. A 
sample of it was diluted to 100 ng/µl and samples of both concentrations were used to 
prepare transposomes. Transformation of UPA3 cells with these transposomes was 
unsuccessful. We hypothesized that the reason the transformation failed was due to 
the use of the mycoplasma tuf promoter to operate the tetM. Therefore, we are 
constucting plasmids with the UUR9 tuf promoter or the UUR9 promoter in front of 
the endogenous tetM driving the tetM expression in the Tn5TetM transposon. 
Multiple transformation experiments yielded only transient antibiotic resistance in 
10B liquid culture and on 10B agar plates. We have extracted gDNA from one of the 
samples with transient antibiotic resistance and performed PCR analysis for the 
presence of the tn5 transposon and tetM. Although the PCR was positive we are in the 
process of determining if the transposon is inserted in the gDNA.  We are also 
constructing a tn5 with UUR9 tetM and its upstream promoter as well as a tn5 with 
UUR9 tuf promoter and a kanamycin resistance gene (aphA). Alternatively, we will 
attempt to further modify the transformation protocol to allow a shorter time of 




50% PEG incubation instead of 10B media without serum, and pelleting the cells 
right away, then recover in 10B media with porcine serum without antibiotic 
overnight, then select successful transformants in 10B media with antibiotic. The 
reason for this modification is that when using a transposon that integrates into the 
gDNA of the recipient, the recipient is not likely to lose the transposon. Furthermore, 
since the antibiotic gene is under the control of a constitutive promoter, the cells 
would have enough time to recover in more favorable conditions and produce the 
resistance protein to be able to survive once transferred to the selective media.  
5.4.5 Isolation and analysis of intact genomic DNA  
The ultimate goal of the project is to achieve targeted mutations of the 
ureaplasma genomes. For that goal the ureaplasma genome of interest will be cloned 
and modified in yeast, and later transplanted into a recipient cell. In order to attempt 
genome transplantation among ureaplasmas we isolated intact ureaplasma genomic 
DNA in agarose plugs. Briefly, the cells are suspended in 1% agarose and casted into 
a mold to produce solid agarose plug, which are treated chemically and enzymatically 
to remove cell debris and proteins and leave intact, naked, circular, genomic DNA. 
We determined the proper concentration of cells per agarose plug by analyzing the 
quality and quantity of genomic DNA in plugs of different cell concentrations. We 
determined that 20 ml of an overnight culture grown to pH 7.5-8.0 or about 107 CCU 
was optimal. To determine DNA quality we used 3 restriction enzymes. SdaI and 
SmaI contain only 1 restriction site in the UUR9 genome and ApaI contains two 




intact, circular, genomic DNA. Intact, circular, genomic DNA has a very faint, if any, 
band of linear genomic DNA or any other bands. However, when the DNA in the 
agarose plug is digested with single-cutting restriction enzyme, a single, thick band of 
linear, full genome size DNA band should appear on the analytical gel.      
5.5 Conclusions 
The dearth of genetic tools to work with ureaplasmas plays a major role in the 
lack of understanding of ureaplasmas as an sexually transmitted disease agents and 
therefore its pathogenicity. Although we are yet to successfully transform and 
maintain ureaplasma mutants, we have greatly advanced our understanding about the 
conditions needed to transform ureaplasmas. We suspect that the Tn5 transposons 
containing the UUR9 endogenous promoter and tetM will be succesful. The use of 
transposon mutagenesis to create a library of mutants would generate information 
about the genes present in ureaplasmas and would enable investigation of ureaplasma 
pathogenicity. 
 Recent and previous studies have identified potential pathogenicity factors in 
Ureaplasma by sequencing and annotation of the  ATCC type strains for each of the 
14 serovars of Ureaplasma, observing enzymatic activities [154, 155, 171, 172, 188], 
and comparative genome microarray study of Ureaplasma isolates [134]. Such 
putative pathogenicity factors will remain speculations unless their involvement in 
pathogenicity is tested by knock-out and subsequent complementation studies. 
Molecular tools allowing the creation of mutants and their subsequent 




differential pathogenicity of Ureaplasma strains and to the development of better 
screening methods, drug targets and vaccines to mitigate the adverse outcomes of 
ureaplasmal infections.   
Our observation of transient antibiotic resistance after transformation with a 
transposon indicates that UPA3 has the capability to read and express the tetM gene 
on the pTF20 and tn5 constructs. Because the pTF20 does not have an origin of 
replication compatible with the replication machinery of ureaplasmas and the tn5 is 
only a linear piece of DNA, if the transposon does not integrate into the genome, the 
daughter cells will not obtain a copy of the plasmid or linear tn5 transposon, causing 
death. Therefore, even though we saw an initial resistance to tetracycline in our 
cultures, the cultures were incapable of sustained growth. We suspect that the 
transposase gene on the pTF20 was not expressed. Because the Tn4001 transposon 
was ineffective, we chose to use the transposon Tn5 in a pre-made complex with the 
Tn5 transposase protein as an alternative, to ensure that the transposase is available 
for integration of the transposon into the genome. This relieved the cell of some 
duties and severed reliance on host cell transcriptional and translational machinery.  
We worked with five different Tn5 transposon designs with varying promoters 
and antibiotic resistance genes. As stated above, we have the Tn5 with puromycin and 
mycoplasma tuf promoter, Tn5 with TetM and mycoplasma tuf promoter , Tn5 
containing the UPA3 tuf promoter and tetM from the pTF20, and Tn5 containing the 
UUR9 endogenous tetM with either the upstream tetM promoter or the UUR9 tuf 
promoter. The ineffectiveness of the transformations with Tn5 containing 




differences in codon usage among different bacteria. In pTF20, the tetM gene 
promoter was cloned from Mycoplasma pulmonis, and the tetM gene was originally 
from Enterococcus faecalis [257].  Although genetically similar to mycoplasmas, 
ureaplasmas might not be recognizing mycoplasma promoters. Therefore, we 
designed Tn5 with the endogenous UUR9 tetM because we think it may have a higher 
expression level in ureaplasmas due to the differences in the sequences of the two 
homologous genes. If needed, we will also create a ureaplasma codon-optimized tetM 
gene.  
Alternatively, ureaplasma OriC plasmids are being constructed and tested as 
well. It has been show in mycoplasmas that after multiple passages, OriC plasmids 
may integrate into the genome of the host cell [258] or be lost. The capacity of the 
plasmid to be replicated and segregated may provide enough time for a transposon to 
integrate into ureaplasma genomic DNA or for the entire plasmid to integrate.  I am 
designing primers for the putative origin replication of several serovars and will clone 
OriC PCR amplicons to make ureaplasma specific OriC plasmids. 
Alternative Transformation Methods 
Electroporation will be explored as an alternative method to transform 
ureaplasma cells. A starting point for electroporation experiments will be the current 
protocols in use for mycoplasma electroporation in our lab. Although electroporation 
can be a convenient way to transform ureaplasma, electroporation has not worked to 




method may be the harsh conditions and procedures during the experiment which 
may fragment the genome, therefore making it not viable.  
Although conjugation has been reported [259-261], its mechanism is not well 
understood and it has worked only in limited number of mycoplasmas. The presence 
of the conjugal transposon Tn916 in U. urealyticum serovar 9, and some genes that 
are known to facilitate conjugation and integration of conjugal DNA material into the 
host chromosome (manuscript in preparation) could mean that Ureaplasma may be 
capable to acquire DNA through conjugation. A possible explanation for the presence 
of the Tn916 transposon of streptococcal origin [262] in the genome of U. 
urealyticum serovar 9 could be that it was acquired through conjugation from another 
urogenital bacteria containing this transposon [262], it may have been maintained on 
a plasmid for a short period of time, based on the isolated report of a tetM containing 
plasmid in a ureaplasma isolate [263] and it was integrated into its genome. Attempts 
to mate Ureaplasma with an enterococcal donor of Tn916 have failed to produce 
transconjugants (Dybvig, K., unpublished), however only some ureaplasma serovars 
have genes that may be involved in conjugation [237], and this information was not 
available at the time of these experiments. Furthermore, a different donor for mating 
and conjugal transfer may be required for successful transconjugation.  
Viral-based vectors have been used in Spiroplasma citri for transformation, 
and have been shown to achieve higher transformations frequencies [264]. Although 
some viruses have been identified that infect mycoplasmas, they have not been used 
extensively as tools for genome modification [265-272]. Our comparative genome 




insertion that seems to have occurred due to a chromosomal integration of a phage 
[237]. This insertion fragment has been shown to be present in some clinical isolates 
of the same serovar and absent in other clinical isolates of the same serovar. This 
phage fragment contains genes of unknown function with transmembrane domains, 
and lipoprotein attachment sites, because of which it is hypothesized that this may be 
a potential pathogenicity island [134] (manuscript in preparation). Some mycoplasma 
phages have been shown to be involved in the virulence and pathogenicity of the 
infected mycoplasma strain [273]. No phages have been isolated yetfrom ureaplasma 
cultures, the phage present in the 9 of the 14 serovars’ genomes might have been 
trapped in the host chromosome, not be able to excise, and its genome may have been 
changed by its host.   
Other reagents that could be tried for ureaplasma transformation are: 
Lipofectin, DMRIE-C reagent, and Lipofectamine 2000 by Invitrogen, and FuGENE 
6, and DOSPER by Roche. 
5.6 Future Directions 
5.6.1 Adapt synthetic biology tools to create desired Ureaplasma mutants 
After the first reported transformation in 1987 of Acholeplasma laidlawii and 
Mycoplasma pulmonis with Tn916 [274], there have been numerous studies to 
develop tools for genome manipulation [270, 275-281]. Even though tools like 
transposon mutagenesis and OriC plasmids have been developed for genetic 




mollicutes is often difficult, laborious, time consuming and sometimes with limited 
success [282, 283]. Furthermore, many passages of the transformants are required 
before chromosome integration [282, 284, 285]. Some mycoplasma species have 
proven completely recalcitrant to these methods. Although the method developed by 
Allam et al., to enhance targeted homologous recombination in M. mycoides [282] 
holds a great promise as a tool in other mollicutes, the synthetic biology-based 
approach of cloning genomes of organisms with such limited or no toolset in yeast 
[286] can open the door to the use of the powerful genetic tools of yeast (including 
new tools developed at JCVI for manipulation of bacterial genomes cloned as yeast 
centromeric plasmids [287]) to produce desired mutants. This approach has been used 
to create a M. mycoides strain that lacks its type III restriction gene, which would be 
impossible by using the previously existing genetic tools for this organism [249]. 
Developing a protocol to clone ureaplasmal genomes in yeast for genetic 
manipulation, and transplanting them into a host cell will contribute significantly to 
the ability of scientists to conduct research that may not be possible by using 
traditional tools. Examples include the creation of strains with multiple gene 
deletions, which may be necessary for completely abolishing virulence and better 
understanding of host-pathogen interactions. Also an attenuated ureaplasma strain 
could be useful for development of vaccines. Vaccine strains could also be 





5.6.2 Transplantation of UUR9 into UPA or U. diversum recipient 
We will use UUR9 as donor, because it contains a naturally integrated Tn916 
transposon with the tetM gene, which will serve as our marker to select transformants. 
If we achieve transformation, we can attempt to use a different donor serovar by 
transforming it with a marker of choice (like a puromycin resistance cassette, lacZ, or 
green fluorescent protein (GFP)). In the case of a resistance marker use, we can 
express the marker at different levels through the use of different promoters as 
mentioned earlier. The recipient cell needs to be different enough to allow 
discriminating between the donor and the recipient genome, as well as to minimize 
the opportunity for homologous recombination. The recipient cell still needs to be 
similar enough to allow for the recognition and booting up of the donor genome. 
Therefore, we will use as recipient the farthest phylogenetically removed UPA1. One 
of the potential problems during transplantation is recombination between the donor 
and recipient genomes, resulting in a chimeric genome molecule. Such recombination 
was observed in attempts to transplant M. genitalium strain G37 to M. genitalium 
strain 1019. Although we observed recombination among serovars in our serotyping 
study, chimeras containing markers from a UPA and UUR were less frequent (8%) 
than intra-species recombination (92%). Furthermore, recombination among UPA 
serovars appears to be less frequent (13%) than recombination among UUR serovars 
(79%); see Figure 5-5. This suggests lower recombination capacity of UPA serovars, 
thus we should observe a lower recombination frequency, if any, when UPA is used 















Figure 5-5. Inter- and Intra-species Distribution of 75 Chimeric Ureaplasma Isolates 
The majority of recombination is among strains of the same species. Only 8% of the 
chimeric strains contained markers from both species. Furthermore, of the intra-





Another option for a recipient cell is the UPA3. Its genome sequence is 
complete and it appears to potentially have only type I and type III RMS. However, 
the restriction subunit of the type I and both subunits of the type III RMS contain 
unverified frameshifts. This may mean that UPA3 does not have a functional RMS, 
which will have to be tested by our restriction assay. Should this be the case, UPA3 
will present a better choice for a recipient cell. Alternatively, we can use Ureaplasma 
diversum as a recipient, in which case we will sequence its genome. Since this 
ureaplasma is a bovine pathogen, and is more divergent, it may prove to be a better 
recipient for the transplantation experiments. Due to its greater divergence we expect 
it to facilitate the differentiation between the donor and recipient genome and 
minimize the possibility of homologous recombination resulting in the insertion of 
only the antibiotic resistance marker into the recipient genome. Furthermore, U. 
diversum is a recognized cause of bovine urogenital infections, including granular 
vulvitis, endometritis, salpingitis, spontaneous abortion, and infertility [88, 201] and 
may also be involved in bovine respiratory infections [201]. Therefore, sequencing, 
cloning to engineer, and transplanting U. diversum could provide an animal model 
system for studying ureaplasma induced diseases through observing phenotypic 
changes of a mutant strain in vivo.  
For the transplantation procedure we will isolate the donor genome by 
preparing plugs using CHEF Mammalian Genomic DNA Plug Kit from Bio-Rad 
[249, 254]. Treating the donor cells briefly with chloramphenicol, prior to cell 
collection may increase the quantity of whole genomes by synchronizing ongoing 




nucleoids [249, 291, 292]. The transplantation protocol will follow the transformation 
protocol that we will develop for Ureaplasma. Since serovar 9 already has a tetM 
marker in its genome, we may attempt transplantation at the same time as 
transformation, in which case we will follow and adjust the 
transformation/transplantation protocol used previously described for M. mycoides 
[249, 254]. Since at this step we will be transplanting a natural genome isolated from 
ureaplasma cells, methylation may not be necessary. Should transplantation be 
unsuccessful, we can use the crude cellular extracts restriction assay to determine 
whether restriction enzymes present in the recipient cell are the reason for 
unsuccessful transplantation. If this is the case we can use the crude cellular extract 
methylation assay to attempt to protect the donor genome before transplantation.  
Ureaplasmas can be visualized using a microscope on agar plates 24-48 hours 
after plating and incubation at 37°C. Their colonies are of approximately 15–60 μm in 
diameter. When grown on 10B agar, they form colorless colonies. One option would 
be to integrate the lacZ gene or another fluorescent marker into the genome. We 
could use an E. coli RecA expressing plasmid vector to enhance homologous 
recombination [282]. The positive transformants now have blue colonies on 10B agar, 
which should make them easier to visualize.   
Transplantation usually requires large quantity of DNA, which may be 
problematic with ureaplasma cell cultures. Ureaplasmas create an alkaline shift in the 
growth media, due to their production of ammonia as a result of urea hydrolysis. This 
alkaline shift prevents the cells to grow to a high cell density, which results in lower 




this problem is to pool the DNA from multiple cultures. An alternative is also to use 
ureaplasma genomes isolated from yeast, which should easily allow higher DNA 
yield for use in transplantation experiments.  
5.6.3 Clone the tetracycline resistant UUR9 genome in yeast 
An overview of the process of creating bacterial strains from genomes that 
have been cloned and engineered in yeast is represented in Figure 5-6 [249]. In order 
to clone an ureaplasma genome in yeast the integration of a yeast centromere, an 
autonomously replicating origin sequence and a yeast selection marker for 
maintenance of the genome in yeast is required. These sequences can be integrated 
into the ureaplasma genome using a plasmid. The plasmid will also contain a 
selectable marker like tetM (if not present naturally as in serovar 9) and optionally the 
lacZ gene or GFP, which will be used to select for transformants. The latter sequences 
will also be useful in subsequent genome transplantation from yeast.  The advantage 
of integrating the yeast sequences into the ureaplasma genome prior to yeast cloning 
is that only viable cells that tolerate the yeast sequences are selected. Transformants 
will be screened to determine the exact integration sites in the genome by direct 
genomic sequencing using primers specific for the integrated DNA to sequence into 
the genome.  Clones with insertions at suitable locations will be selected for cloning 
in yeast. These genomes will be transformed into yeast as described by Lartigue et 
al.[249]. To verify that the complete ureaplasma genome was cloned in yeast, we will 
use multiplex PCR with primer pairs that recognize sequences distributed around the 





Figure 5-6. Moving a bacterial genome into yeast, engineering it, and transplanting it 
back into a bacterium. 
The figure depicts 3 strategies to clone a bacterial genome in yeast: 1) The yeast 
centromere vector can be inserted in the bacterial DNA through bacterial 
transformation (preferred, as only viable insertions will be propagated to be cloned in 
yeast); 2) overlapping DNA fragments of the bacterial genome are co-transformed 
into yeast with the yeast centromere vector and the yeast recombination system 
assembles the bacterial genome as a YAC; 3) the intact bacterial genome is extracted 
and linearized; the linearized genome is co-transformed into yeast with the yeast 
centromere vector that has homologous sequences to the bacterial genome on both 
ends. Once the bacterial genome is in yeast, it can be engineered using yeast tools. 
The engineered genome is extracted and transplanted into suitable recipient cell to 
create engineered bacterial strains. 




In case we were unable to develop a traditional tool for the integration of the 
yeast maintenance sequences, or in order to clone the genome concurrently with the 
transformation experiments, we will use the alternative methods for cloning the 
genome into yeast (Figure 5-5).  One such method, transformation associated 
recombination (TAR) cloning, was used to clone the synthetic and natural M. 
genitalium and Mycoplasma mycoides subsp. capri (Mmc) genomes into yeast [255, 
286, 293, 294].  To use this method we will cut the Ureaplasma genome into several 
fragments.  The fragments can then be transformed into yeast with a yeast centromere 
plasmid (YCp) that contains homology arms to bridge two of the fragments and other 
DNA pieces that contain overlapping ends to bridge the remaining fragments.  
Alternatively, a whole linear genome can be transformed into yeast with an YCp that 
contains arms homologous to either side of the linear genome. Transformants will be 
tested as described earlier for clones containing an intact genome. By using these 
methods there is a possibility that a non-viable genome is created. Should this turn 
out to be the case, it is possible to use the genetic tools of yeast to change the location 
of the yeast maintenance sequences. Cloning the ureaplasma genome in yeast gives us 
an additional opportunity to clone 100-kb genomic fragments as was done to clone 
the natural 100-kb fragments of Mmc [255]. Using these fragments, we can generate 
more easily mutant Ureaplasma strains by modifying the fragments and then 
assembling the genome by combining natural and modified fragments for co-
transformation in yeast. 
We do not anticipate difficulties in cloning the ureaplasma genome in yeast. 




is not likely that ureaplasma genes may cause toxicity to the yeast cell. Furthermore, 
our experience of cloning genomes into yeast using the standard genetic code, shows 
that yeast can leave out fragments containing toxic genes. This leads to relatively easy 
identification of problematic genes, which could be mutated to enable cloning of the 
full genome. To date in addition to the four mycoplasma species whose genomes we 
have already reported being cloned in yeast [286], we have now cloned three other 
bacterial genomes as YACs. This suggests this step will not be difficult.  
5.6.4 Delete a gene of interest and transplant the deletion mutant to a 
recipient cell 
Once we have successfully cloned the ureaplasma genome in yeast, we will 
use the method developed for synthetic biology to delete a gene of interest. Figure 5-6 
illustrates the general strategy for knockout construction using  the Tandem Repeat 
Coupled with Endonuclease Cleavage (TREC) method [287]. The first step is to 
generate a core cassette that contains the endonuclease SceI under the control of a 
galactose responsive promoter, a URA3 gene for selection, and a SceI recognition site 
(asterisk). On one side of these sequences is a 50 bp of DNA identical to DNA 
adjacent to the 5′ end of the target gene and on the other side is a stretch of DNA 
homologous to DNA on the 5′ end of the target gene (red line). This will result in a 
tandem repeat (TR) upon integration.  The core cassette is then transformed into yeast 
containing the ureaplasma genome. After growth on selective medium, colonies are 
screened for positives that contain the replacement of the core cassette at the target 





Figure 5-7. TREC method for seamless deletions of target genes in genomes cloned 
and maintained in yeast 
Through homologous recombination, target gene is replaced with a mutagenesis 
cassette that consists of a knock-out CORE (an18-bp I-SceI recognition site (*), the 
SCEI gene under the control of a GAL1 promoter, and the URA3 marker) and a DNA 
fragment (shown as TR in green and red line) identical to a region upstream of the 
target site. The replacement generates tandem repeat sequences flanking the CORE 
(red lines). Galactose induces the expression of SceI, which generates a double-strand 
break (DSB) at the SceI site near the target locus. The DSB promotes an intra-
molecular homologous recombination between the repeat sequences, leading to an 





expression of SceI which cleaves its recognition site resulting in loss of the core 
cassette by recombination between the DNA adjacent to the 5′ end of the target gene 
and the tandem repeat. The cells are plated on medium containing 5-fluoroorotic acid 
(5-FOA) to select only those cells that have lost the core cassette resulting in the 
seamless deletion of the target gene. This method was used to remove a M. mycoides 
restriction enzyme gene in an earlier work [249]. The TREC method is needed to 
manipulate bacterial genomes in yeast because the traditional yeast genetic method of 
replacement of a gene with only a URA3 marker and subsequent counter selection 
with 5-FOA has led to instability of the bacterial genome resulting in unwanted and 
unpredictable deletions of genomic areas [287]. Once the changes are made to the 
ureaplasma genome in yeast, the next step is to transplant the altered genomes into 
the recipient cells to generate the mutant ureaplasma strain.  These strains can then be 
tested for loss of function or gain of function, depending on the nature of the deleted 
or inserted gene. 
5.6.5 Suggested modifications to the ureaplasma genome 
As mentioned earlier new experimental ureaplasma strains can be created by 
the deletion or insertion of genes. We are considering several initial modifications of 
the ureaplasma genome. One of them is introducing GFP, which can act as an 
additional marker to aid in the screening for transplants. A fluorescent ureaplasma 
strain can be useful in following the dissemination of the colonizing strain in tissues. 
When choosing genes to delete as a proof of concept, one should choose a target that 




potential target genes for deletion. RMS are rarely essential for survival in controlled 
laboratory conditions. Furthermore, the creation of an ureaplasma strain lacking RMS 
can ease the transplantation process by permanently removing a barrier. Another 
potential target for deletion is the major surface antigen of ureaplasma – the multiple 
banded antigen (MBA). Based on our comparative genome analysis of the 14 ATCC 
serovars we now know that the MBA is part of a large phase variable family. Most 
serovars contain multiple variable, surface exposed domains which are expressed one 
at a time by recombining the promoter and the 5` area of the gene (the conserved 
domain) with a variable domain [237]. One strategy to make a strain that does not 
express MBA is to delete the currently active mba gene (promoter, conserved domain, 
and variable domain), which will leave the rest of the variable domains silent. 
Another strategy is to delete the full MBA locus which may be up to 10 Kb long and 
may include genes that are expressed independently from the mba promoter and/or 
are not part of the MBA phase variable system. Because monoclonal antibodies 
recognizing different variable domains have been produced, we can confirm the 
deletion of the active mba gene and the silencing of the rest of the variable domains 
or their deletion by immunoblotting. A strain lacking MBA can be used in a future 
study to be compared to the wild-type in an animal model system for difference in 
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Chapter 6. Selecting against Recombination Events during Genome 
Transplantation by Crosslinking the Genome of the Recipient Cell 
with Mitomycin C 
6.1 Introduction 
6.1.1 Genome transplantation 
In 2007 the first genome transplantation was reported [254]. During genome 
transplantation a naked bacterial chromosome is installed into a suitable recipient cell, 
so that the recipient cell is reprogrammed to have only the attributes encoded by the 
new genome [254, 295]. This process was used to install a chemically synthesized 
genome version of Mycoplasma mycoides into Mycoplasma capricolum recipient 
cells in 2010 [255]. So long as genome transplantation is only possible between 
different members of the mycoides group of mycoplasmas, much of the potential of 
the synthetic cell will be unrealized. For instance, the DNA foundry SGI-DNA is 
advertising that they can synthesize whole bacterial genomes for customers, but in the 
absence of generalized genome transplantation, there is no use for such synthetic 
genomes. If we can develop genome transplantation technology, scientists will be 
able to design, build and test bacteria with synthetic genomes to solve human 
problems, such as bio-renewable fuels, new pharmaceuticals, and new vaccines. 
Furthermore, genome transplantation coupled with the modification of bacterial 
genomes in yeast [286, 287, 294] can expand our understanding of some pathogens 




many totally intractable pathogens, for which we have no genetic tools. Similarly, 
there are genetically intractable bacteria with unrealized pharmaceutical or industrial 
potentials because scientists cannot remodel their genomes. 
To realize the potential of this new technology we need to expand it to other 
pairs of organisms. The first reported genome transplantation used a genome donor 
and recipient pair of closely related bacteria of the mycoides group of mycoplasmas. 
Carole Lartigue has been able to transplant the genomes of 2 different mycoplasmas 
within the mycoides group and one mycoplasma species outside of the group, from 
the next closest related clade into M. capricolum recipient cells (manuscript in 
preparation). However, extending genome transplantation to donor-recipient 
organism pairs outside of the mycoides group has proven to be a difficult task. During 
our efforts to develop genome transplantation much of our research was aimed at 
transplanting genomes from Mycoplasma genitalium into either a very closely related 
species called Mycoplasma pneumonia or into different strains of M. genitalium. All 
of these efforts were unsuccessful. Often we obtained false positive transplants as a 
result of recombination events between the donor and recipient genomes, resulting in 
the acquisition of selective marker genes by the recipient’s genome and thus false 
positive results. This may potentially hamper the transplantation of ureaplasma 
genomes as well. We have already reported an extensive horizontal gene transfer 
among ureaplasmas and even though mosaic strains of UPA and UUR genes were 
rare, such were observed [104].  As we seek to apply the process to a large variety of 




transiently disable the recombination machinery that is virtually ubiquitous in 
bacteria.   
This problem can be solved by making the recipient genome unavailable for 
recombination. For this purpose we are exploring the use of the DNA alkylating agent 
Mitomycin C (MMC) to covalently crosslink the recipient genome right before we 
introduce the donor genomes to the recipient cells. The covalent crosslinking of the 
recipient genomes will eventually kill the recipient cells. We believe that the cell 
transcription and translation machinery are still intact shortly after the MMC 
treatment. Therefore, if a “healthy” intact donor genome is supplied to the still intact 
recipient cell, its machinery can now read and copy the “healthy” genome allowing 
the cell to survive.   
6.1.2 Mitomycin C 
MMC is an antibiotic isolated from Streptomyces caespitosus in 1958 [296]. It is an 
alkylating agent used in antitumor therapy [297, 298]. Three potentially active groups 
are recognized in MMC: a quinone, a urethane and an aziridine group. MMC requires 
activation by reduction by host enzymes (discussed later) of the quinone and 
subsequent loss of the methoxy group[299]. MMC can form different DNA adducts 
(Figure 6-1; discussed in details elsewhere [300, 301]), however its capacity to 
crosslink the complementary strands of the DNA molecule is most lethal: a single 





Figure 6-1. Adducts of MMC and DNA formed by reductive activation. 
Activation of only one of the alkylating functions gives monoadduct (6), whereas 
activation of both alkylating functions can give products (7-9). MMC is highlighted 





MMC can have different effects on the cell depending on concentration, 
genetic context and environmental conditions. Crosslinking of the host DNA can 
result in inhibition of DNA synthesis, degradation of DNA, nuclear lysis and 
formation of giant cells, and mosaicism [299, 302]. At very high concentrations, 30-
100 times more that the concentration needed to inhibit DNA synthesis, it has been 
shown to inhibit RNA synthesis [303]. 
The action of MMC is relatively specific to double stranded DNA in a 
sequence dependent manner: 3`-CpG-5`. MMC was shown to have no effect on DNA 
polymerase isolated from HeLa cells [304]. However, MMC can react with RNA, and 
can bind to some extent to proteins [305]. DNA repair mechanisms are not inhibited 
by MMC, as the use of DNA repair inhibitors greatly enhances the sensitivity of the 
cells to MMC [306]. DNA damage is observed when MMC is administered at any 
time in the cell cycle; however, mitosis and DNA synthesis are significantly more 
affected with application during late G1 and early S phase. G2 phase is the least 
sensitive phase, during which the drug inhibits mitosis by reducing the RNA 
synthesis [299, 307]. 
The crosslinking efficiency is different for eukaryotic and prokaryotic cells. 
About a third of the DNA in human tissues shows crosslinking after treatment with 
large amounts of MMC [308]. In bacteria 10-20% of all MMC has been observed to 





MMC in its original form is not reactive with DNA. In order for the 
crosslinking to occur bio-reduction of MMC is required within the cell. At least 5 
different enzymes have been described to activate MMC: 1) NADPH:cytochrome C 
(P-450) reductase; 2) NADH: cytochrome b5 reductase; 3) Xantine oxidase; 4) 
Xantine dehydrogenase; 5) DT-diaphorase. The reaction of MMC with these enzymes 
under different pH conditions results in different reactive MMC species and thus 
different MMC:DNA adducts are observed. Detailed description of the different 
reactive MMC species and the conditions under which they occur can be found in the 
MMC reviews by Sartorelli et al from 1994 [310]  and Cummings et al from 1998 
[311]. 
6.2 Materials and Methods 
6.2.1 MMC Solutions and Storage 
MMC crystalline powder was dissolved in DMSO to make a stock solution of 
1 mg/ml. The MMC stock solution was split in 1ml aliquots and stored at -20°C. 
Individual tubes were wrapped in aluminum foil to protect the solution from light. 
6.2.2 Minimum Inhibitory Concentration 
MIC assays were prepared in 96 well plates [248]. MMC was added to SP4 
media to make the highest desired concentration for testing in the MIC assay. We 
started with 16μg/ml as the highest concentration and 360 μlof 16 μg/ml MMC SP4 
were added to wells A12-H12. The rest of the wells of the 96 well plate were filled 




H12 and add in A11-H11, etc, stop at A2-H2, mix and discard 180μl). Wells A1-H1 
were left as no antibiotic control. We added 20 μl of 1X overnight culture (about 1010 
CCUs/ml) in A1-A12. Next we serially diluted 1:10 in each row (take 20 μl from A1-
A12 and add to B1-B12 with a multichannel until all rows are done). The plates were 
incubated at 37°C until no further color change was observed (48-72 hours). The 
inhibitory concentration was determined by recording the concentration at which no 
color change was observed in the 10-1 dilution (first well of dilution). 
6.2.3 Determining the MMC concentration and conditions to inactivate a 
grown culture 
Based on the MICs we tested the MMC concentration needed to inactivate an 
overnight culture if MMC is added to the culture directly, as well as the optimal 
incubation time and temperature. We tested 6 concentrations (0 μg/ml – control, 0.25 
μg/ml, 1 μg/ml, 2.5 μg/ml, 5 μg/ml, and 10 μg/ml), 3 time points (1, 2, and 4 hours of 
incubation) and 3 temperatures (4°C, 30°C and 37°C). An overnight culture was split 
into multiple samples to test all conditions. MMC was added directly to the culture 
samples to achieve the corresponding concentrations. Samples were incubates at the 
above temperatures and time periods. To determine the inhibitory effect of MMC in 
these conditions, CCU assays were performed on the above samples before (control 
without MMC) and after incubation (all samples) in triplicates in 96 well plates. The 
wells of the 96 well plates were filled with 180 μl of SP4 without MMC. Twenty μl 
of the corresponding sample were added to the first row (A1-A12) and 1:10 dilutions 




change was observed (48-72 hours) and CCU readings were performed to establish 
the most effective treatment for an overnight culture before transplantation.   
6.2.4 Preparation of intact circular genomes in agarose plugs  
The buffers, enzymes, and agarose in the following procedure are provided in 
the CHEF Mammalian Genomic DNA Plug Kit (BioRad catalog number 170-3591). 
To make 50 plugs with intact circular genomic DNA (gDNA) 1 ml mycoplasma 
culture (pH 6.5-7.0) per plug was harvested by centrifugation at 4575g for 15 min at 
10°C and washed in 20 ml of  TRIS-Sucrose Buffer [10 mM Tris (pH 6.5) plus 0.5 M 
sucrose] then spun as before. A cell suspension was prepared in 2.5 ml of TRIS-
Sucrose Buffer. The 50 well plug mold makes 5 ml of agarose plugs. A 2% low melt 
agarose solution in sterile water was prepared and melted using a microwave. The cell 
suspension solution and the 2% low melt agarose solution were equilibrated to 50 °C 
in a water bath. Next the cell suspension was combined with an equal volume of 2% 
CleanCut agarose and mixed gently but thoroughly. This results in a final 
concentration of 1% agarose. The cell/agarose mixture was kept at 50 °C, and 
transferred to plug molds. The agarose was allowed to solidify. This step can be 
expedited by placing the molds at 4 °C for 10–15 minutes. This also adds strength to 
the agarose for removal from the mold. 25 ml of Proteinase K Reaction Buffer was 
added in a 50 ml conical centrifuge tube. The solidified agarose plugs were pushed 
into the 50 ml centrifuge tube containing the Proteinase K solution by using the snap 
off tool provided on the plug mold. The plugs were incubated overnight at 50 °C 




30 minutes to 1 hour each at room temperature with gentle agitation. 1 mM PMSF 
was added during the second or third wash to inactivate any residual Proteinase K 
activity. The plugs were stored at 4 °C for 3 months to 1 year. The recipes of the 
buffers that come with this kit can be found in the manufacturer’s manual. 
6.2.5  Digests of genomes treated with MMC 
The plugs to be restricted were washed for 30 minutes in 0.1x wash buffer or 
TE. One plug per digest was placed in a sterile 1.5 ml microcentrifuge tube. The plug 
was incubated with 1 ml of the appropriate 1x restriction enzyme buffer for about 1 
hour with gentle agitation at room temperature. The buffer was removed and 0.3 ml 
of fresh 1x restriction enzyme buffer was added. 30-50 U per 100 μl plug restriction 
enzyme, in this case 50U of PspXI to linearize the M. mycoides genome, was added 
and incubated overnight at the appropriate temperature. After overnight digestion, the 
buffer was removed and 1 ml of wash buffer was added. 1⁄4 of a plug per sample was 
loaded on an agarose gel per well on a 1% agarose gel along with a lambda DNA 
ladder. The gel was electrophoresed in the CHEF Gel III system with the following 
parameters: Buffer: 0.5x TBE; Temperature: 14°C; Switch Time: 50-90 seconds; Run 
Time: 22 hours; Angle: 120°; Voltage Gradient: 6 V/cm. The gel was stained with 
SYBR Gold (Molecular Probes) and scanned. 
6.2.6  Genome Transplantation 
Restriction system free M. capricolum cells were grown overnight at 30°C to 




streptomycin and glucose). If MMC treatment was used, MMC was added to a final 
concentration of 2.5 μg/ml from a 1 mg/ml stock directly to the culture and the 
culture was incubated for 2 hours at 30°C. 3 ml of cell culture was used per 
transplantation reaction. A 100μl sample was obtained from the culture before 
processing (and before MMC) for CCU and CFU analysis. Remaining culture was 
centrifuged in bulk for 15 min at 4575 g at 10°C. The media was discarded and the 
pellet was re-suspended in 1 ml Tris-Sucrose Buffer [10 mM Tris (pH 6.5) plus 0.5 M 
sucrose], then additional 19 ml of Tris-Sucrose Buffer were added. Cells were 
pelleted for 15 min at 4575 g at 10°C. The Buffer was discarded and the remains were 
removed with a Kimwipe. The pellet was re-suspended in 200 μlof 0.1M CaCl2 per 
transplantation sample and incubated on ice for 30-45 minutes. In a 10ml Falcon tube 
for each sample was added: 410μlof SP4 growth media without serum; 20μlof melted 
gDNA plug (using wide bored tips for genomic manipulations); 20 μg of Yeast tRNA 
(10 μl). After the 30 minutes incubation on ice was done, 200 μl of cells was added in 
the 10 ml tubes per sample, followed by 650 μl of 10% PEG 6000 dissolved in 2X 
Tris/NaCl2/MgCl2 and gently mixed well by horizontally inverting and rolling the 
tubes. The transplantation reactions were incubated for 90 minutes at 30°C, then 5ml 
of warm SP4 growth media were added to each sample and samples were centrifuged 
immediately for 15 min at 4575 g. The media was decanted and remaining media was 
removed by aspiration. Cells were re-suspended in 1.2 ml of warm SP4 media per 
sample and each sample was platted on two SP4 agar plates with 4μg/ml tetracycline 
(600 μl of transplantation reaction per plate). Plates were incubated at 37°C for 3-5 




6.3 Results and Discussion  
6.3.1 Susceptibility of different mycoplasmas to MMC 
MMC is a powerful antibiotic. There are organisms that are highly sensitive to 
MMC and some that are very resistant. We tested the susceptibility to MMC of 
several mycoplasma species and two ureaplasma species available in our laboratory 
(Table 6-1). Bacillus subtilis growth is inhibited at 0.025 μg/ml, while most Gram 
positive and Gram negative bacteria are inhibited at 1μg/ml. Many viruses are also 
sensitive to MMC, however toxoplasma organisms, influenza A, Newcastle disease 
and Japanese encephalitis viruses are not resistant to MMC [299].  
 
Organism MMC MIC (μg/ml) 
Mycoplasma mycoides subspecies capri 1 μg/ml 
Mycoplasma capricolum  subspecies capricolum  1 μg/ml 
Mycoplasma pneumoniae  <0.5 μg/ml 
Mycoplasma gallisepticum 1 μg/ml 
Mycoplasma genitalium <0.5 μg/ml 
Mycoplasma penetrans 4 μg/ml 
Mycoplasma imitans 0.063 μg/ml 
Mycoplasma alligatoris 2 μg/ml 
Mycoplasma crocodyli <0.25 μg/ml 
Ureaplasma urealyticum Serovar 9 ATCC 33175 >80 μg/ml 
Ureaplasma parvum serovar 3 ATCC 27815 >80 μg/ml 
Table 6-1. Susceptibility of Different Mycoplasmas and Ureaplasmas to MMC 
We determined and summarized in this table the lowest concentration of MMC that 
inhibits the visible growth (color change in the CCU assay) of the microorganisms 




Several reasons for difference in susceptibility levels and resistance to MMC 
have been pointed out throughout the literature. The host may be deficient or express 
different levels of enzymes that can bio-reduce MMC, thus MMC remains non-
reactive with DNA or is activated at low levels. None of the bio-reductive enzymes 
shown to activate MMC seem to be present in the annotated mycoplasma genome 
sequences, there may be other reductases present in the mycoplasmas capable of 
activating MMC, as all tested mycoplasma species were sensitive to MMC. The 
different reduced states of MMC are very unstable and can be re-oxidized to 
inactivate MMC. In the biosynthetic gene cluster of MMC from Streptomyces 
lavendulae, the mcrA gene encodes a MMC oxidase capable of re-oxidizing the 
activated MMC. This is one of 3 self-protection mechanisms of Streptomyces 
caespitosus [312]. The other two mechanisms are 1:1 binding of MMC to the Mrd 
resistance protein and an MMC translocase that pumps the antibiotic out of the cell 
[312]. Effective DNA repair mechanisms have also been suggested to increase 
resistance to MMC. Micrococcus radiodurans, which is extremely effective and 
accurate in repairing its DNA is four times more resistant to MMC than the E. coli 
B/r [313]. Furthermore, the use of inhibitors of or mutants deficient in the DNA repair 
pathways, lead to increased susceptibility to MMC [302]. Additionally, four genes in 
E. coli have been linked to MMC resistance when these genes have been 
overexpressed: the multidrug resistance locus mdfA; gyrI, which inhibits the gyrase 
activity in vitro; rob, which activates the transcription of efflux pumps, and sdiA, 




We confirmed the stability of MMC in SP4 and SSG media with serum by 
pre-incubating MMC in the media at a 2.5 μg/ml final concentration for 2 hours or 
overnight at 30°C and 37°C. The test was done in a 96 well plate format to perform 
CCUs. Two hundred μl of overnight culture per column were spun down and the 
pellet was re-suspended in 200 μl per column pre-incubated MMC media. The 
cultures were deposited in the first well of each column and 1:10 CCU dilutions were 
performed. Only the cultures in the first row turned the color of the media to yellow. 
These wells had a large amount cells, which metabolism or death can change the pH 
of the media and shift the color. The rest of the dilutions did not change color, 
indicating that MMC was still available for activation and DNA crosslinking. Our 
experiments show that MMC does not lose its DNA crosslinking potential when 
incubated at 30°C or 37°C with growth media for at least 18 hours. An extensive 
review of MMC stability and storage condition is available elsewhere [314].    
6.3.2 Inactivation of the recipient cells genomic DNA with MMC 
We explored different conditions and concentrations for the inactivation of 
recipient cell genomes. Because we want to inactivate the recipient genomes just 
before the transplantation procedure, MMC was added directly to cultures grown 
overnight. Because an overnight culture is much more cell dense than the cultures in 
the MIC assays, we explored different concentrations of MMC by using the MIC 
concentration as a starting point. We explored 1 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml, 
and 20 μg/ml final concentrations when adding MMC to the overnight cultures. We 




and prepared to undergo genome transplantation: 1 hour, 2 hours and 4 hours. The 
temperature during the incubation period also was varied: 4°C and 30°C (recipient 
cells are grown at 30°C before transplantation) (Table 6-2 and Table 6-3). We 
explored these conditions only with M. capricolum, the recipient organism for the M. 
mycoides subspecies capri donor genomes. This recipient cell—donor genome 
combination is the only genome transplantation system currently used in our 
laboratory. As other recipient cell—donor genome transplantation systems are 
developed the parameters would need to be explored for each recipient species 
separately. This is due to the difference in metabolism and response to MMC in 
different species (Table 6-1). We found that if the cells were incubated at 4°C with 
MMC, there was very slight inhibition of cell growth and in order to achieve 
moderate inhibition of cell growth much higher concentrations of MMC were needed. 
Based on the results of these assays and the maximum number of hours that we could 
extend the transplantation protocol, we chose to use two hours incubation at 30°C for 





Table 6-2. Efficiency of Genome Transplantation with MMC Treated Cells  
M. capricolum recipient cells, which restriction modification system has been 
inactivated through a transposon insertion, were treated with different concentrations 
of MMC or not treated with MMC as control. The M. mycoides tetR, lacZ genome 
was used as donor; The pMyc01 plasmid (tetR, lacZ) was used to transform the a 
separate set of samples in the same conditions. The number of successful transplants 
resulting from cells that were not treated with MMC was used as 100% efficiency in 
order to compare the efficiency of transplantation when MMC treated cells are 
used.The number of viable cells in each sample was determined through a CCU assay 
performed before the transplantation.  
 
Description 
M. capricolum ΔRe 












2h 30°C non-treated 23 100% 2.83 x109 657 
2h 30°C 2.5μg/ml  22 96% 4.44 x102 0 
2h 30°C 5μg/ml  10 43% 1.67 x 102 0 
1h 30°C non-treated 23 100% 2.58 x 109 230 




Table 6-3. Efficiency of Genome Transplantation with MMC Treated Cells under 
different conditions 
Comparison of genome transplantation effectiveness between recipient cells treated 
or not treated with MMC under different conditions (temperature, incubation time, 
MMC concentration). Condition groups are highlighted for easier comparison. The 
number of transplants resulting from recipient cells not treated with MMC is used as 
100% efficiency in order to compare the efficiency of genome transplantation with 
MMC treated cell. The total remaining viable recipient cells (M. capricolum) after 
each experiment is given in the last column. 
 
Description 





Total viable  
M. capricolum cells 
Original culture before MMC  treatment 
(30°C)   9.8 x10
8 
2h 30°C Tris-NaCl Buffer 
No MMC 83 100% 3.0 x 10
9 
2h 30°C Tris-NaCl Buffer  
2.5μg/ml MMC 34 41% 1.2 x 10
2 
2h 4°C Tris-NaCl Buffer  
No MMC 82 100% 1.5 x 10
9 
2h 4°C Tris-NaCl Buffer  
2.5μg/ml MMC 36 44% Not counted 
4h 4°C Tris-NaCl Buffer  
No MMC 110 100% 9.5 x10
8 
4h 4°C Tris-NaCl Buffer 
5μg/ml MMC 58 52% 9.6 x 10
3 
4h 30°C Tris-NaCl Buffer 
No MMC 157 100% 2.3 x10
9 
4h 30°C Tris-NaCl Buffer  
2.5μg/ml MMC 49 31% 1.2 x 10
3 
2h 30°C Tris-Sucrose Buffer  
No MMC 15 100% 6.2 x 10
8  
2h 30°C Tris-Sucrose Buffer 
2.5μg/ml MMC 7 49% Not counted
 
4h 30°C Tris-Sucrose Buffer  
No MMC 3 100% 7.7 x 10
8  
4h 30°C Tris-Sucrose Buffer  
2.5μg/ml MMC 2 50% Not Counted 
Culture before overnight incubation at 4°C   2.7 x 10
9  
18h 4°C No MMC 65 100% 4.0 x 109  




Next we attempted genome transplantation with MMC treated recipient cells 
where we varied the final concentration of MMC: 2.5 μg/ml, 5μg/ml, and 10 μg/ml. 
As a comparison of the efficiency of the transplantation, a transplantation experiment 
was carried out with recipients that were not treated with MMC. We observed that the 
higher the MMC concentration and the closer we get to zero surviving recipient cells 
the lower the efficiency of the transplantation procedure became (Table 6-2). MMC is 
capable of reacting with RNA and to some extent with proteins [309], although 
double stranded DNA is the primary and preferred target of MMC. We believe that at 
higher concentrations, the transcription and translation machinery of the recipient 
cells may undergo damage and thus be unable to “read” the new intact genome in 
order to survive, thus reducing the transplantation reaction efficiency to undetectable 
levels.  
For the M. capricolum—M. mycoides subspecies capri recipient—donor pair 
of organisms we found that 2.5 μg/ml was the optimal MMC treatment concentration 
at which we achieved enough reduction of viable recipient cells and minimum 
reduction of transplantation efficiency (Table 6-2). Our transplantation efficiency 
with 2.5 μg/ml MMC treated recipient cells for 2 hours at 30°C, compared to non-
treated cells, varied between 40-96% with donor genomes extracted from bacteria. 
One potential contribution to this variability is the variable quantity and quality of the 
gDNA in individual plugs within the same batch of prepared plugs, due to the 
clumping nature of mycoplasma cells. Transplanting bacterial genomes that were 
cloned and modified in yeast is in general much less efficient than genomes extracted 




bacterial genomes extracted from yeast was less efficient than using untreated cells 
(about 5 colonies on average). We are currently working on improving the 
transplantation efficiency with MMC treated recipient cells for both sources of 
gDNA.  
To determine the effect of MMC on the gDNA and confirm that the genomes 
were inactivated we extracted gDNA in agarose plugs from MMC treated M. 
mycoides cells and examined the quality of the DNA by restriction digestion and gel 
electrophoresis (Figure 6-2). The majority of the gDNA appeared intact. The samples 
that were not digested with a single cutter restriction enzymehad a similar quantity of 
linearized gDNA across all MMC concentrations tested compared to the untreated 
gDNA. This linear fraction of the gDNA results primarily from the mechanical 
manipulations of the samples. Furthermore, no significant difference was observed in 
the background smearing in the lanes, suggesting the gDNA is not significantly 
degraded by MMC treatment. It is interesting to note that the restriction enzyme used 
in this experiment, PspXI, has a VC^TCGA_GB recognition site. It is reasonable to 
expect that if the complementary strands were cross-linked by MMC, PspXI will 
produce only nicks in the strands around the cross-linked CpG, which will hold the 
strands together, not allowing the linearization of the circular genome. We observed 
that digesting the plug with gDNA that was not treated with MMC produced a much 
larger linear gDNA band compared to the same undigested plug. However, digesting 
the samples treated with MMC, did not produce a significantly larger linearized 
gDNA band compared to the same undigested plugs. This is expected and indicative 




Figure 6-2. Restriction Digest of gDNA from MMC Treated Cells.  
Genomic DNA of MMC treated cells was embedded in agarose plugs and digested 







MMC treated genomes were also used as donor genomes in transplantation 
experiments with recipient cells that were not treated with MMC. As expected these 
donor genomes failed to produce viable transplants. Further studies are needed to 
explore the potential of these cross-linked genomes to participate in recombination 
events. Alternatively, recombination may still be possible between the genomes as the 
primary target of MMC is DNA and the enzymes in the recipient cells are still 
functional, as evidenced by the capability to obtain transplants. Therefore, it is likely 
that the enzymes participating in recombination are still active and recombination still 
occurs. We believe that if this is the case, virtually all recombination events will 
result in non-viable genomes, because even one gDNA crosslink may be enough to 
result in the death of the cell. 
It is interesting to note that after MMC treatment of the recipient cells, the 
remaining surviving recipient cells that we observe are a miniscule fraction of the 
total number of cells that we generally need to use in order to obtain a decent number 
of transplants. Only approximately 0.000016% of the cells were viable after MMC 
treatment. Although the surviving recipient cells are about 20 times more than the 
obtained transplants, we know from previous experiments that on average we need 3 
x 107 recipient cells to observe one transplantation event. Therefore, we believe that 
at least some of the transplants we obtained from our MMC treated recipient cells, 
result from donor genomes, entering recipient cells with cross-linked genomes, thus 
rescuing them from death, making them so called “zombie cells”. However, further 
studies will need to be completed to explore the validity of this hypothesis and 




6.3.3 Transplanting genomes without antibiotic selection markers 
Antibiotic treatment almost always results in decreased growth rates for 
resistant mutants. This is especially true for protein translation inhibitors like 
tetracycline. Therefore, antibiotic selection presents an additional challenge for the 
cells that already need to recover from the PEG treatment during genome 
transplantation, which may be contributing to the low efficiency of genome 
transplantation. We explored the use of MMC treated recipient cells to obtain 
transplants of genomes without antibiotic selection. Because our M. mycoides donor 
genomes contain a lacZ gene, we can still use a visual screening method to identify 
the transplants. Inclusion of Xgal in the SP4 agar results in the M. mycoides 
transplants being blue and easily distinguishable from surviving M. capricolum 
recipient cells, which are white. In the absence of MMC treatment, detecting blue 
transplants among recipient cells, when the transplantation reaction was plated on 
agar plates without antibiotic, was impossible, because less than one colony in 
100,000 was blue. Due to the high number of recipient cells needed for the 
transplantation, the plates grow a lawn of recipient cells and the agar turns yellow 
from red due to the pH shift resulting from the lactic acid produced during cell 
metabolism detected by the pH indicator phenol red. As a result no blue colonies can 
be detected. Plating a dilution of the transplantation reaction allowed observing 
separate recipient cell colonies, but no blue transplants. We used M. capricolum 
restriction free recipient cells treated with 2.5μg/ml MMC for 2 hours at 30°C and 
transplanted the same M. mycoides donor genomes that have been used in previous 




plated the transplantation reactions on plates without tetracycline. Using MMC 
treated recipient cells was the only condition that allowed us to observe blue 
transplants without selecting on plates with antibiotic (Figure 6-3). Next, we repeated 
the transplantation experiment with a M. mycoides donor genomes with (Figure 6-4) 
and without tetracycline resistance marker extracted from yeast or bacterial clones. 
Once again we were able to obtain blue transplants without antibiotic selection for 
both gDNA sources only when the recipient cells were treated with MMC. 
Figure 6-3. Transplanting Genomes Extracted from a Tetracycline Resistant M. 
mycoides strain without tetracycline selection. 
Recipient cells: M. capricolum restriction system free; gDNA donor: M. mycoides 
tetR, lacZ extracted from the bacterial strain. The first row of plates demonstrates that 
if the recipient cells are not treated with MMC, transplants (blue colonies) are 
obtained only if the transplantation reaction is plated on SP4 agar plates containing 
X-gal and tetracycline (no blue colonies on SP4 agar plates with X-gal only). The 
second row of plates, demonstrates that when the recipient cells are treated with 
MMC, transplants (blue colonies) can be obtained on SP4 plates with X-gal and no 
tetracycline. Next to the plates is a close up of the transplants (blue colonies) and 





Figure 6-4. Transplanting a Tetracycline Resistant M. mycoides Strain Genome 
Extracted from Yeast without tetracycline selection. 
Recipient cells: M. capricolum restriction system free; gDNA donor: M. mycoides 
tetR, lacZ extracted from yeast. The first row of plates demonstrates that if the 
recipient cells are not treated wih MMC, transplants (blue colonies) are obtained only 
if the transplantation reaction is plated on SP4 agar plates containing X-gal and 
tetracycline (no blue colonies on SP4 agar plates with X-gal only). The second row of 
plates, demonstrates that when the recipient cells are treated with MMC, transplants 
(blue colonies) can be obtained on SP4 plates with X-gal and no tetracycline. Next to 







The selection of antibiotic markers for mycoplasmas is limited to tetracycline 
puromycin and gentamycin. Tetracycline is the preferred marker in our laboratory as 
it has the lowest rate of spontaneous resistance. This marker, however, was reserved 
for genome transplantation in our laboratory. Genome transplantation is being used to 
iteratively delete segments of the M. mycoides genome, in order to find the minimum 
set of genes needed for growth in the laboratory [295]. Iterative probing of the 
resulting minimized M. mycoides strains with transposons to find out what other 
segments may be deleted has been difficult due to the need to “recycle” the antibiotic 
resistance markers. This means that once a change to the genome is made and a clone 
is established, we need to remove the antibiotic resistance marker from the modified 
genome, in order to use it along with the next transposon bombardment of the same 
genome. Currently, there are no methods developed for antibiotic resistance marker 
recycling in mycoplasmas. The current approach is to grow and passage the desired 
strain in media without antibiotic selection and wait until the strain becomes 
susceptible by losing the resistance gene (marker). This process is tedious and time 
consuming. The use of MMC to treat recipient cells and obtain transplants without 
antibiotic selection frees the tetracycline resistance marker and allows for iterative 
transposon probing by using up to tree antibiotic resistance markers, without the need 
to recycle selective markers. This in itself is an unexpected but useful application of 






As synthetic biologists, one of our goals is to create technologies that enable 
biological research by accelerating the rate of and expanding the scope of cycles of 
design, build and test experimentation as applied to biological systems.  Our Venter 
Institute team demonstrated this by booting up a bacterial cell programmed with a 
chemically synthesized genome in 2010 [255]. We developed technologies that 
enabled us to design and build a 1.1 Mb genome and then to test that genome by 
installing it in a suitable recipient cell using a process called genome transplantation.  
Four years later, the capacity to design and build whole genomes has greatly 
expanded. Our Venter Institute team designs and builds new bacterial genomes in 
weeks instead of months, commercial DNA foundries offer to synthesize 2 Mb 
genomes, and a team composed mostly of undergraduate students at Johns Hopkins 
University has redesigned and synthesized an entire yeast chromosome (unpublished 
data, [255], [315]). However scientists’ ability to test synthetic bacterial genomes 
extends no farther than genome transplantation amongst a few species of bacteria that 
comprise the mycoides cluster of mycoplasmas. One reason we believe that current 
genome transplantation methods work in those mycoplasmas is they have very 
inefficient enzymatic machinery for homologous recombination. Our efforts to 
transplant genomes between other bacterial species have been thwarted by 
recombination of the selectable markers in donor genomes into the genomes of 
recipient cells. This work lays the foundation of an approach that we hope will 




We have shown that treatment of cells to be used as genome recipients in 
genome transplantation reactions with the DNA alkylating agent MMC can inactivate 
the recipient cell genome leaving the cell intact and needing a new, i.e. donor 
chromosome to remain viable. Using our M. capricolum—M. mycoides recipient 
cell—donor genome system as a test bed, we demonstrated that MMC treatment of 
the M. capricolum recipient cells prior to genome transplantation inactivates the 
recipient cell genome and actually eliminates the need for antibiotic selection to 
isolate genome transplants.  
We now need to extend this method to enable genome transplantation of 
genomes not from members of the mycoides cluster of mycoplasmas. Because our 
data here show that the efficiency of MMC genome inactivation varies among 
bacterial species, we will choose a recipient cell for our genome transplantation 
reaction that is efficiently inactivated by MMC. We are now planning to transplant a 
genome from Mycoplasma gallisepticum into a closely related species, Mycoplasma 
imitans. Our experiments (Table 6-1) showed M. imitans was more susceptible to 
MMC treatment than M. capricolum. Additionally, in terms of phylogenetic 
relatedness, which has been demonstrated by Carole Lartigue to be directly correlated 
to transplantation efficiency in her transplantation studies among members of the 
mycoides cluster of mycoplasmas (personal communication), Mycoplasma imitans is 
a logical recipient cell species for M. gallisepticum donor genomes. 
Assuming our efforts to transplant M. gallisepticum are successful (or perhaps 
even if they are not), the next steps after that will be to further expand genome 




conventional bacteria. For the ureaplasmas we may need to increase the efficiency of 
the MMC treatment by inclusion of DNA repair inhibitors, or possibly inclusion in 
the MMC reaction of a suicide plasmid encoding a gene for the expression of one of 
the 5 different enzymes described to activate MMC.  Hopefully we will find that the 
MMC method for recipient cell genome corruption will be the key to enabling 
generalized bacterial genome transplantation. 
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Chapter 7. Conclusions and Future Directions 
7.1 Ureaplasma clinical importance 
Ureaplasmas are considered opportunistic pathogens. As many as 8 in 10 
healthy adult women are ureaplasma carriers [3].  While most infections are 
asymptomatic, there is still a very large burden of ureaplasma disease due to the 
adverse pregnancy outcomes resulting from ureaplasma infection of the upper 
urogenital tract. Ureaplasmas have been implicated in infertility, spontaneous 
abortion, stillbirth, premature birth, low birth weight, and perinatal morbidity and 
mortality. We believe that our research has added further evidence for the need for 
new research and changed the discussion in the field away from old ideas about the 
static nature of serovars and their importance in developing diagnostics and 
therapeutics.   
7.2 Development of diagnostic tools 
Over the past 20 years research in the field of ureaplasmas has been focused 
on developing suitable diagnostic tests that can identify and characterize the two 
species and their respective serotypes that could account for differential pathogenesis. 
The development of our real-time PCR assay that can detect each serovar without 
cross-reactivity and its application to a collection of 1061 clinical isolates changed the 
trajectory of diagnostic development away from a focus on using DNA approaches to 
associate serovar with disease outcome. Our hope was to be able to correlate specific 




complexity of patient isolates, often consisting of multiple serovars or genetic mosaic 
ureaplasma strains, and even some strains for which the serovar belonging or species 
could not be determined. Our study revealed extensive horizontal gene transfer 
among ureaplasmas, which lead us to question the utility of assays seeking to 
determine ureaplasma clinical isolate serovars.  
7.3 What is a serovar? 
Ureaplasma serovars were defined based on the reaction of different patient’s 
sera with different ureaplasma patient isolates Fourteen unique reaction groups were 
established, and thus the ureaplasma isolates were classified as serovars 1 thorough 
14  [5, 186]. No additional patient sera have been collected to determine if more 
serovars exists; although more likely could be found (several of the 1061 we analyzed 
using or serovar specific real time PCR assays could not be associates with any of the 
14 serovars). Some of the reactive antibodies in the sera were defined and determined 
to bind the MBA. Monoclonal antibodies were later developed for serotyping of 
ureaplasma isolates. Serotyping assays were used to attempt to determine serovar 
association with different clinical outcomes. However, cross-reactivity of the 
antibodies with different serovars hampered these attempts [222]. As the molecular 
biology technology advanced, multiple PCR assays were developed to address the 
question of differential pathogenicity of the serovars [3]. The mba gene is frequently 
used in these assays to determine species and/or serovar. The general assumption was 
that the UU serovar genomes are static and not capable of recombination, therefore 




7.4 Changing how we understand serovars 
MBA has been considered to be serovar specific [90, 181, 202, 204], and has 
been predominantly used in developing assays to determine the ureaplasma serovar of 
clinical isolates [3, 89]. Our comparative genome analysis (Chapter 2) showed that 
the MBA was part of a very large phase variable protein family. Furthermore, many 
serovars contained the MBA TRUs of other serovars (Figure 2-9 and Figure 2-10). 
We believe that serovars can switch from expressing one MBA TRU to expressing a 
different MBA TRU. For example UUR4 and UUR12 have an identical set of TRUs 
(Figure 2-11). A UUR4 strain may switch the expression of the TRU that is believed 
to be UUR4 specific to the TRU believed to be UUR12 specific. Such a strain will 
now test positive for UUR12 in assays that utilize the mba gene or the MBA protein 
as a target. It is also interesting to note that these two serovars have virtually identical 
genomes, with a notable genome rearrangement only in the mba locus, resulting in 
the expression of a different TRU (Figure 2-11).   
Our RT-PCR assay described in chapter 3 was applied to 1061 clinical isolates 
(Chapter 4). We observed ureaplasma clinical isolates with genomes containing RT-
PCR targets specific for more than one ATCC serovar. Closer examination of these 
isolates, through carefully designed molecular sequencing assays, reviled horizontal 
gene transfer (HGT) among ureaplasmas. Especially interesting was the case of one 
patient sample that tested positive for UPA1 and UPA6. We determined that this 
sample contained two hybrid strains. One strain had the MBA sequence of UPA1, but 




of UPA6, but the rest of the genomic DNA was UPA1.  Therefore, HGT represents an 
additional mechanism that ureaplasmas can utilize to vary their repertoire of MBA 
TRUs. These observations lead us to believe that due to the plastic nature of the 
ureaplasma genomes the genotype of an ureaplasma isolate is not important in 
developing diagnostics and therapeutics. Instead we need to first re-evaluate the 
relationship between the strain’s serovar designation (or serotype) and its genotype. 
Only then, we can develop effective diagnostic molecular assays for these organisms. 
Following are some questions demonstrating the need to re-evaluate the serotype to 
genotype relationship of ureaplasmas:   
1. What would be the serovar designation of the clinical strain that contains the 
UPA6 MBA but its remaining genome is identical to the ATCC UPA1 genome 
and vice versa? 
2. What would be the serovar designation of a UUR4 strain, which MBA TRU 
was switched to the UUR12’s TRU?  
3. What would be the serovar designation of a UUR10 strain, which MBA’s TRU 
was switched to a TRU that has not been observed to be active before? 
4. How do we determine the serovar designation of ureaplasma isolates that are 
negative for all serovars of all currently available serotyping and genotyping 
assays? 
5. If serovar designation is described using only the mba, is it significant and 
should we continue to strive to develop assays to differentiate the separate 




Should we expand the serovars to 22 instead of 14, and add more as we find 
novel TRUs? 
There is a need to clarify the definition of the ureaplasma serovars, especially 
if we want to attribute the differences among the serovars to different clinical 
outcomes. The extensive HGT we observed in the 1061 clinical samples suggests that 
ureaplasmas have plastic genomes that are prone to exchanging genetic material most 
likely during co-infections. HGT and MBA TRU switching can explain previously 
observed cross-reactivity of serotyping and genotyping assays [5, 86, 222]. MBA is 
the most widely used target to determine the serovar designation and some of the 
original sera used to develop the serotyping scheme contained antibodies targeting the 
MBA. Traditional serotyping techniques are being substituted by molecular 
techniques like PCR and the genomes of all 14 ATCC serovars have been sequenced. 
Therefore, even though not all antibody targets have been determined in the original 
serotyping method, we suggest the adaptation of the MBA as the serovar specific and 
determining factor. However, it should be made clear that the serovar number 
describes only the type of actively expressed mba at the time of testing. Based on our 
comparative genome analysis of 19 ureaplasma strains, each stain is capable of 
expressing only one mba gene with a single active TRU. The conserved domain of 
the mba gene contains its lipoprotein anchor and transmembrane domain. All 
analyzed ureaplasma genomes contain only one conserved domain attached to one 
TRU and surrounded by alternative TRUs in this locus that do not contain a start 
codon and thus are not recognized as open reading frames. In chapter 2 we have 




conserved domain, involving inverted repeats on both sides of each alternative TRU 
and a recombinase. It is conceivable that a second mba conserved domain may be 
acquired through HGT. We have not observed this in the tested clinical isolate 
collection or the sequenced ureaplasma genomes. However, we observed isolates 
which had exchanged at least the MBA TRU, if not the whole mba gene (the mba 
conserved domain sequence is conserved among strains of the same species). If the 
active MBA determins the serovar designation, then the serovar designation would no 
longer be strictly associated with a specific genotype of the organism due to the 
capability of the mba TRU to be switched for another TRU in the mba locus or to be 
transferred horizontally as well as the overall high HGT frequency among 
ureaplasmas. We observed genetic mosaic strains of UPA and UUR, although at a 
much lower rate. Thus, the serovar designation based entirely on the mba would no 
longer be indicative of the species designation, like it is currently: serovars 1,3,6, and 
14 are UPA and serovars 2,4,5,7-13 are UUR. Species would continue to be 
determined based on the urease PCR assays [316] and genome size [2].  
Preserving the serovar designation for ureaplasmas may be beneficial as the 
mba gene gets increasing attention, and accumulates evidence to be recognized as an 
immunogenic factor leading to the presentation of different severity of pathologies 
[127, 128, 317]. MBA size variation (the variation of the number of repeats of the 
TRU) believed to allow the organism to evade the host immune response. 
Furthermore, the difference in the number of repeats of the same MBA was 
associated with different pathology.  It is conceivable that different TRUs and the 




pathogenicity.  In this case genotyping based on the mba gene will be of importance, 
if the goal is to determine differential pathogenicity outcome based on the MBA 
variant and size. The MBA target should be carefully selected to account for the 
phase variability of the gene. Also two formats of the assay can be developed. One 
assay should determine the currently expressed TRU. This is the TRU attached to the 
conserved domain of the mba. Once specific pathologies have been associated with 
specific TRUs, a second assay should be developed to detect any TRU of pathogenic 
potential in the clinical isolate (including those that are not connected to the mba 
conserved domain as ureaplasmas are capable of switching to their use). To determine 
which TRU is currently active, primers should be designed to anneal to the conserved 
domain and the TRU. To determine that the TRU is attached to the mba conserved 
domain, and thus it is active, probes spanning the junction between the two should be 
used in a real-time PCR.     
7.5 Shift in literature to host-pathogen studies with animal models and 
cell lines 
We are pleased to see that our comparative genome analysis of all 14 ATCC 
serovars and 5 clinical isolates, along with our study revealing extensive horizontal 
gene transfer have provided a pivot point for research in the field of ureaplasma 
pathogenesis. A clear shift is noticeable in the published literature after our 
publications. Before our publications, the ureaplasma literature was describing 
development of assays to genotype the ureaplasmas to the serovar level for the 




outcomes was common. A summary of the majority of this literature is represented in 
a review by Waites et al [3]. Based on the observations of our studies, we suggested 
that differential clinical outcome is based on the presence or absence of potential 
pathogenicity genes in the ureaplasma strain infecting the patient and/or patient to 
patient differences in terms of autoimmunity and microbiome [9, 104]. The published 
studies after our publications and suggestions are dominated more by host-pathogen 
interaction studies in animal models and cell lines. These studies focus on the role of 
the host immune response [14, 35, 45, 47, 49, 51, 125, 127, 318-323] and the 
difference in host alleles for key immune system components [125] in the 
development of the pathologies associated with ureaplasmas. The interactions of the 
host immune system and the MBA have also received more attention and studies 
show that the severity of disease is associated with the size of the MBA (number of 
repeats of the TRU) [123, 127, 128]. Furthermore, a gene annotated as a putative 
tyrosine recombinase XerC in ureaplasmas was shown to be functional in a recent 
study and its suggested involvement in the recombination events responsible for the 
phase variation of the mba locus in UPA3 was confirmed [324]. Although not directly 
related to our studies and observations, it is worth noting that novel antibiotic 
treatment plans were developed showing that the administration of certain antibiotics 
before birth may be beneficial for the infant by preventing the development or 




7.6 Need to develop genome manipulation tools to support the 
understanding of pathogenicity and increase the power of using animal 
models. 
The ureaplasma research community is at a point where their work could be 
greatly enhanced by the development of genetic tools for the creation of designed 
mutant ureaplasmas. New molecular diagnostics methods show that ureaplasmas have 
a large impact on society due to their roles in adverse pregnancy outcomes and 
infection of neonates. Although we do not understand the nature of ureaplasma 
pathology, we have a number of hypotheses about specific genes products and 
antigenic variation that may result in inflammation and disease that cannot be tested 
at present. We have murine, ovine, and baboon models for ureaplasma pathology [27, 
56, 121, 247].  
The capacity to create deletion mutants has been a prerequisite in 
understanding host-pathogen interaction and factors involved in pathogenicity in 
many well studied pathogens. If we had the ability to manipulate ureaplasma 
genomes, we would make a series of gene knockouts to evaluate whether any of a set 
of predicted surface associated proteases contribute to pathogenicity. We would look 
carefully at the role of the phase variable MBA protein on ureaplasma pathogenesis. 
MBA is the dominant ureaplasma antigen based on assays using patient serum. Can 
the disease outcome be affected by eliminating MBA phase variation so that it is 
always on or always off?  There are many similar questions that could be addressed. 




development of better screening methods, drug targets and vaccines to decrease the 
morbidity associated with ureaplasmal infections. 
In chapter 5 we have laid a foundation for the effort to create ureaplasma 
mutants. We carefully studied the different growth conditions and transformation 
conditions for ureaplasmas, and believe that we able to insert foreign DNA in the 
ureaplasma cells, due to the transient antibiotic resistance we observe after 
transformation reactions. We are on the verge of successfully inserting a transposon 
into the UPA3 ATCC strain genome. Another group has already been able to 
transform ureaplasma strains with a tn4001 based transposon and a gentamycin 
resistance marker using protocols designed by John Glass (manuscript in 
preparation). However, their transformation success was limited only to UPA clinical 
isolate strains. We hope that our careful evaluation of transformation conditions and 
recovery of the transformed cells will allow is to expand the transformation method to 
all ureaplasma strains, including the ATCC strains. Furthermore, we are utilizing a 
different transposon system, the tn5, with an already purified transposase, to aid in the 
insertion of the transposon. We are also using tetM as a resistance marker gene, which 
if successful, will expand the choice of resistance markers to use for the creation of 
mutants. Once we have successful transformations, we can create a library of 
transposon mutants for the use of the ureaplasma scientific community. However, our 
ultimate goal is to make fast and specific alterations of the ureaplasma genome by 
utilizing the tools developed for synthetic biology at the J. Craig Venter Institute: 
genome cloning and modification in yeast and subsequent transplantation of the 




To achieve this goal our team is going to continue to work on cloning the 
UUR9 genome as yeast centromeric plasmids (YCPs). There are several approaches 
that can be utilized to achieve this goal. The UUR9 intact linearized genome can be 
co-transformed with the pRS313 plasmid we have constructed. The plasmid contains 
a YCP vector sequence comprised of yeast centromeric sequences and autonomous 
replication sequences flanked by two arms of homology to the UUR9 genome. Once 
the UUR9 linear genome and linear plasmid are in yeast, yeast can recombine the two 
to create a circular chromosome of UUR9 that will be maintained as one of the yeast 
chromosomes. Alternatively, once we have achieved successful transformation of 
ureaplasmas, we can use a transposon to insert the YCP vector sequence in the 
ureaplasma genome before we attempt to clone it in yeast (Figure 5-5). Yet another 
alternative is to fuse the ureaplasma cells, that have been transformed and contain the 
YCP vector sequence, with yeast spheroplasts, which has been used to successfully 
clone some mycoplasma genomes in yeast [326].   
Once we have successfully cloned the ureaplasma genome in yeast, we will 
use a JCVI method developed to manipulate a bacterial genome cloned in yeast. The 
Tandem Repeat Coupled with Endonuclease Cleavage (TREC) method [287] allows 
for knockout construction in yeast. The first step is to generate a core cassette that 
contains the gene encoding the endonuclease SceI under the control of a galactose 
responsive promoter, a URA3 gene for selection, and a SceI recognition site. On one 
side of these sequences is a 50 bp of DNA identical to DNA adjacent to the 5′ end of 
the target gene and on the other side is a stretch of DNA homologous to DNA on the 




The core cassette is then transformed into yeast containing the ureaplasma genome. 
After growth on selective medium, colonies are screened for positives that contain the 
replacement of the core cassette at the target gene locus.  The positive clone is then 
grown on galactose medium to induce expression of SceI, which cleaves its 
recognition site resulting in loss of the core cassette by recombination between the 
DNA adjacent to the 5′ end of the target gene and the tandem repeat. The cells are 
plated on medium containing 5-fluoroorotic acid (5-FOA) to select only those cells 
that have lost the core cassette resulting in the seamless deletion of the target gene. 
This method was used to remove a M. mycoides restriction enzyme gene in an earlier 
work [249].  The TREC method is needed to manipulate bacterial genomes in yeast 
because the traditional yeast genetic method of replacement of a gene with only a 
URA3 marker and subsequent counter selection with 5-FOA has led to instability of 
the bacterial genome resulting in unwanted and unpredictable deletions of genomic 
areas [287].  
Once the changes are made to the ureaplasma genome in yeast, the next step is 
to transplant the altered genomes into recipient cells to generate mutant ureaplasma 
strains. These strains can then be tested for loss or gain of function or gain of, 
depending on the nature of the deleted or inserted gene. However, this task is not easy 
to achieve. It requires that we first optimize the transformation reaction conditions for 
ureaplasma. Additionally, we need to design assays to detect recombination of the 
selection markers into the host genome, instead of complete donor genome 
transplantation. Such recombination has hampered the genome transplantation among 




in ureaplasma clinical isolates, it is likely that recombination between the donor and 
host genome may thwart genome transplantation in ureaplasma donor-recipient pairs, 
including extending this technology to a wider variety of organisms. We are 
exploring the use of the DNA cross-linking drug Mitomycin C to prevent false 
positive genome transplantation results due to recombination between the donor and 
recipient genomes. We hypothesize that covalently crosslinking the recipient gDNA 
before the donor genome enters the cells will prevent recombination and thus increase 
the probability of a true genome transplantation event. Alternatively, recombination 
between the cross-linked recipient genome and the “healthy” donor genome will 
result in non-viable offspring cells, providing an additional selection mechanism for 
cells resulting from true genome transplantation. In chapter 6 we describe the current 
progress of this project and the use of Mitomycin C to enable marker-less genome 
transplantation. Should Mitomycin C prove effective in facilitating genome 
transplantation in recombination prone organisms, the expansion of transplantation to 
species other than M. mycoides & M. capricolum could be successful. This can be a 
springboard to generalized genome transplantation and making use of the capacity to 
build synthetic genomes in the commercial sector to satisfy human needs, such as 
development and production of novel drugs, bio-renewable energy, and better 
understanding of host-pathogen interactions of genetically intractable pathogens, to 
name a few. 
In the short term, the development of traditional molecular microbiology tools 
like transposon mutagenesis, plasmids for gene knockout and complementation, and 




insertions in ureaplasma genomes will allow better understanding of host-pathogen 
interaction and mechanisms of pathogenicity for ureaplasmas. We believe these 
technologies will catalyze the expansion of ureaplasma biology to enable 
development of better screening methods for pathogenic ureaplasma strains, new drug 
targets and eventual creation of vaccines to decrease the adverse outcomes of 
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